CURRICULUM VITAE

LYNN R. WEBSTER, M.D., F.A.C.P.M., F.A.S.A.M.
LRWebsterMD@gmail.com
Twitter: @LynnRWebsterMD
LinkedIn: https://www.linkedin.com/in/lynnwebster
BlueSky: @butchielyons.bsky.social

EDUCATION

1976	Doctorate of Medicine University of Nebraska (Medicine)
1976	Bachelor of Science University of Nebraska (Medicine)
1976 – 77	Internship University of Utah Medical Center
1977 – 78	Fellowship University of Utah Medical Center Division of Artificial Organs Department of Surgery
1978 – 1980	Residency University of Utah Medical Center Department of Anesthesiology

PROFESSIONAL EXPERIENCE:

2013 – 2021	Vice President Scientific Affairs PRA Health Sciences 1255 East 3900 South

2023 – 2025	Executive Vice President, Scientific Affairs Dr. Vince Clinical Research Overland Park, KS
2023 – Present	Chief Medical Officer PainScripts Washington, D.C.
2021 – Present	Consultant Salt Lake City, UT
2020 – Present	Senior Fellow Center for U.S. Policy Washington, D.C.
	Salt Lake City, Utah 84103
2011 – 2013	Senior Consultant Omega Interventional Pain Clinic 3838 South 700 East, Suite 200 Salt Lake City, UT 84106
2011 – 2013	Medical Director/Investigator CRI Lifetree 3838 South 700 East, Suite 202 Salt Lake City, UT 84106
2003 – 2010	Co-Founder/Medical Director Lifetree Clinical Research 3838 South 700 East, Suite 202 Salt Lake City, UT 84106
1990 – 2010	CEO/Medical Director Lifetree Pain Clinic 3838 South 700 East, Suite 200 Salt Lake City, UT 84106
1989 – 2009	Medical Director Salt Lake Surgical Center 617 East 3900 South Salt Lake City, UT 84107

1980 – Present	Staff Salt Lake Regional Medical Center (formerly Holy Cross Hospital) 1050 East South Temple Salt Lake City, UT 84102

LICENSE

Utah Medical License 161058-1205 – Physician & Surgeon
161058-8905 – Physician/Surgeon CS Schedule 2 – 5
Nebraska Physician License 14084
DEA Controlled Substance License BW8544442 - Practitioner-DW/100 Schedule 2-5
NPI number: 1164420246

INTERESTS

Pain and Pain Mechanisms
Substance Abuse & Addiction
Sleep and Pain
Politics and Medicine

SPECIALTY CERTIFICATIONS

1986	Diplomat of the American Board of Anesthesiologists
1993	American Board of Pain Medicine: Certified
1994	Added Qualifications in Pain Medicine American Board of Anesthesiology
1998	Certification in Addiction Medicine
1993	Fellow of the American College of Pain Medicine
2010	Fellow of the Mayday Fund
2021	Utah Medical Licensure Program

PROFESSIONAL ASSOCIATIONS

American Pain Society
American Medical Association
American Academy of Pain Medicine

Addison Award Task Force	Chair March 2014 – Present
President	April 2013 – March 2014
President-Elect	February 2012 – April 2013

Board of Directors	Director-at-large (2008-2010) Treasurer (2010-2011)
College on Problems of Drug Dependence	Member (2011-Present)
American Society of Anesthesiologists	
Utah Medical Association	
Salt Lake County Medical Association	
Utah Academy of Pain Medicine	
North American Neuromodulation Society	

MEDICAL ORGANIZATIONS

2007 – 2017	Board of Directors, American Academy of Pain Medicine
2008 – 2009	Board of Directors, National Pain Foundation
2004 – 2007	Founding Member/President, Utah Academy of Pain Medicine
1993 – 2009	Board of Directors, Utah Medical Insurance Association

EDITORIAL PRIVILEGES

Pain Medicine	Senior Editor (2013 – Present) Neuromodulation Section Co-Editor (2011 – 2013) Opioids, Substance Abuse & Addiction Section Co-Editor (2008 – 2011)
WebMD	Neurology Editorial Advisory Board (2011 – Present)
Journal of Opioid Management	Senior Editor (2015 – Present)
Drug and Alcohol Review	Reviewer 2019
NIH 2020, 2025	Grant Reviewer

PUBLICATIONS

Columnist for *Pain News Network*
Columnist for *The Hill*
Columnist and Editorial Board Member for *Pain Medical News*

H-Index 56
i10-Index 168
ORCID ID: 0000-0001-8609-9424

BOOKS & CHAPTERS

1. **Webster LR**, Dove B. *Avoiding Opioid Abuse While Managing Pain: A Guideline for Practitioners*. 1st Edition. North Branch, MN: Sunrise Press; 2007.

2. **Webster LR**. Screening for the risk of substance abuse in pain management. In: Smith HS, Passik SD, eds. *Pain and Chemical Dependency*. 1st Edition. New York, NY: Oxford University Press; 2008:Chapter 47;395-405.

3. Smith HS, **Webster LR**, Gallati C, Kushida CE. Chronic Pain: Noncancer Pain: Pain and Sleep. In: Smith HS, ed. *Current Therapy in Pain*. Philadelphia, PA: Saunders Elsevier; 2009:363-73.

4. **Webster LR**. The Prescription Drug Abuse Epidemic and Emerging Prescribing Guidelines. In Benzon HT, Raja S, Liu SS, Fishman SM, Cohen SP, eds. *Essentials of Pain Medicine*. 4th edition. Philadelphia: Saunders Elsevier, 2018:389-394.

5. **Webster LR**. Pharmacogenetics of pain: the future of personalized medicine. In: Moore R.J., ed. *Handbook of Pain and Palliative Care: Biobehavioral Approaches for the Life Course*. Springer Science+Business Media, LLC; 2012; Chapter 26: 431-8.

6. **Webster LR**, Smith HS. Identifying patients at risk for pain medication misuse. In: Smith HS, Portenoy RK, eds. *Opioid Therapy for the 21st Century*. 2nd Edition. New York, NY: Oxford University Press; 2013.

7. **Webster LR**, Gitlow S. Addictive disorders and pain. In: Deer TD, Leong MS, Buvanendran A, Gordin V, Kim PS, Panchal SJ, Ray AL, eds. *Comprehensive treatment of chronic pain by medical, interventional, and integrative approaches: The American Academy of Pain Medicine textbook on patient management*. 1st Edition. New York, NY: Springer; 2013; Chapter 73;787-794.

8. Tang NKY, Goodchild CE, **Webster LR**. Sleep and chronic pain. In: Deer TD, Leong MS, Buvanendran A, Gordin V, Kim PS, Panchal SJ, Ray AL, eds. *Comprehensive treatment of chronic pain by medical, interventional, and integrative approaches: The American Academy of Pain Medicine textbook on patient management*. 1st Edition. New York, NY: Springer;

2013; Chapter 85; 947-62.

9. **Webster LR**. The double effect: In theory and in practice. In: Deer TD, Leong MS, Buvanendran A, Gordin V, Kim PS, Panchal SJ, Ray AL, eds. *Comprehensive treatment of chronic pain by medical, interventional, and integrative approaches: The American Academy of Pain Medicine textbook on patient management*. 1st Edition. New York, NY: Springer; 2013; Chapter 93; 1045-1052.

10. **Webster LR**. Methadone side effects: constipation, respiratory depression, sedation, sleep-disordered breathing, and the endocrine system. In: Cruciani RA, Knotkova H, eds. *Handbook of methadone prescribing and buprenorphine therapy*. 1st Edition. New York, NY: Springer 2013; Chapter 4; 39-49.

11. **Webster LR.** Chronic Pain and the Opioid Conundrum. In: Fine P, Ashburn M, eds. *Pain Management, An Issue of Anesthesiology Clinics*. 1st Edition. New York, NY: Elsevier 2016; 341-355.

12. **Webster L**, Belfer I**.** Pharmacogenetics and Personalized Medicine in Pain Management. *Clinics in Laboratory Medicine* 36 (2016), pp. 493-506.

13. **Webster L.** Risk Mitigation Strategies. In: Staats P, Silverman S, eds. Controlled Substance Management in Chronic Pain. First Edition. Switzerland: Springer 2016; 163-180.

14. **Webster L.** Novel Opioid Formulations. In: Bajwa Z, Wooton R, Warfield C, eds. Principles and Practice of Pain Medicine. 3rd Edition. San Francisco: McGraw Hill 2016; 641-647.

15. **Webster, L. R.** 2016. *The Painful Truth: What Chronic Pain Is Really Like and Why It Matters to Each of Us*. New York: Oxford University Press. https://doi.org/10.1093/med/9780190659721.001.0001.

16. **Webster LR**. (2018) Pharmacogenetics of pain: the future of personalized medicine. In: Moore RJ (ed) Handbook of pain and palliative care. Springer: Cham

17. Attal, N. and Bouhassira, D. 2023. *Neuropathic Pain* (New York, 2023; online edition, Oxford Academic, 1 Feb. 2023), https://doi.org/10.1093/med/9780197616345.001.000

18. Project co-editor. What Do I Do Now series. New York: Oxford University Press.

Begasse De Dhaem, O. and Bernstein, C. 2023. *Headache*. (forthcoming)

Doleys, D. M. *Psychological and Psychiatric Issues in Patients with Chronic Pain* https://doi.org/10.1093/med/9780197544631.001.0001. 2021.

Doleys, Dan (ed), **Webster LR** (co-editor), *Psychological and Psychiatric Issues in Patients with Chronic Pain.* 2021.

Cuevas-Trisan, R. *Painful Conditions of the Upper Limb* https://doi.org/10.1093/med/9780190066376.001.0001. 2021.

Xu, J and Webster, L. *Complex Regional Pain Syndrome*. (forthcoming)

Begasse de Dhaem, O and Bernstein, C. *Headache.* (forthcoming)

Standaert, CJ and Friedly, J. *Low Back Pain.* (forthcoming)

Smith, WR and Lipato T. *Management of Sickle Cell Pain.* (forthcoming)

Attal, N and Bouhassira, D. *Neuropathic Pain*. (forthcoming)

Cuevas, R. *Painful Conditions of the Upper Limb*. (forthcoming)

Doley, DM. *Psychiatric and Psychological Issues in Patients with Chronic Pai*n. (forthcoming)

ARTICLES & MANUSCRIPTS

1. **Webster LR**, Stanley TH, Jarvik R, Philbin D, Kolff WJ. Plasma cortisol and antidiuretic hormone concentrations after artificial heart implantation. *Southern Medical Journal.* 1978;71(1):305-9.

2. **Webster LR**, Stanley TH, Jarvik R, Philbin D, Kolff WJ. Plasma cortisol and antidiuretic hormone concentrations after artificial heart implantation. *Transactions – American Society for Artificial Internal Organs. 1978;24(1):305-9.*

3. **Webster LR**, Piping R, Stanley TH, Razecca K, Kolff WJ. White blood cell phagocytosis after artificial heart implantation. *Southern Medical Journal*. 1978; 71(1):578-80.

4. Stanley TH, **Webster LR**. Anesthetic requirements and cardiovascular effects of fentanyl–oxygen and fentanyl–diazepam–oxygen anesthesia in man. *Anesthesia & Analgesia*.

1978;57(4):411-16.

5. Lunn JK, Stanley TH, **Webster LR**, Bidwai AV. Arterial blood pressure and pulse rate responses to pulmonary artery catheterization prior to cardiac and major vascular surgery. *Anesthesiology*. 1979;51(3):265-9.

6. Lunn JK Stanley TH, Eisele J, **Webster L**, Woodward A. High dose fentanyl anesthesia for coronary artery surgery: plasma fentanyl concentrations and influence of nitrous oxide on cardiovascular responses. *Anesthesia and Analgesia* 1979; 58(5):390-395.

7. Stanley TH, Liu WS, **Webster LR**, Johansen RK. Haemodynamic effects of intravenous methadone anesthesia in dogs. *Canadian Journal of Anesthesia* 1980; 27(1):52-57.

8. **Webster LR**, Andrews M, Stoddard G. Modafinil treatment of opioid-induced sedation. *Pain Medicine*. 2003;4(2): 135-140.

9. **Webster LR**. Assessing abuse potential in pain patients. *Medscape Neurology and Neurosurgery.* 2004;6(1).

10. Reynolds L, Rauck R, **Webster L**, Dupen S, Heinze E, Portenoy R, Katz N, Charapata S, Wallace M, Fisher D. Relative analgesic potency of fentanyl and sufentanil during intermediate-term infusions in patients after long-term opioid treatment for chronic pain. *Pain, 110*(12), 182-188. 2004.

11. **Webster LR**, Butera PG, Wu N, Moran LV, Burns LH, Friedmann N. Oxytrex: a new opioid analgesic with minimal physical dependence and better overall safety. *IAPCD Newsletter*. May 2005.

12. **Webster LR**, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid risk tool. *Pain Medicine* 2005;6(6):432-42.

13. **Webster LR**. Questionnaire helps screen patients at risk for opioid abuse. *Pain Medicine News*. 2005;3(6):23.

14. **Webster LR**. More data needed in methadone-related deaths. *ABMDI Newsletter*. 2005;6(4):2-3.

15. **Webster LR**. Methadone-related deaths. *Journal of Opioid Management*. 2005;1(4):211-17

16. **Webster LR**. Ziconotide in complex regional pain syndrome. *Reflex Sympathetic Dystrophy Syndrome Association Review*. 2005;18(3).

17. **Webster LR**, Fakata K. Ziconotide for chronic severe pain. *Practical Pain Management*. 2005;5(4):47-56.

18. Rauck RL, Wallace MS, Leong MS, MineHart M, **Webster LR**, Charapata SG, Abraham JE, Buffington DE, Ellis D, Kartzinel R. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. *Journal of Pain and Symptom Management*. 2005;31(5):393-406.

19. Taylor DR, **Webster LR**. The recognition and management of noncancer breakthrough pain. *Medscape Neurology*. October 31, 2005.

20. **Webster LR**. Fentanyl effervescent buccal tablets in patients with chronic pain. *Medscape Neurology and Neurosurgery*. 2006;8(1).

21. **Webster LR**, Fakata K. Ziconotide: promising new treatment for complex regional pain syndrome (CRPS). *The Pain Practitioner*. 2006;16(1):63-4.

22. **Webster LR**. Interventional therapies in the continuum of care. *Practical Pain Management*. 2006;6(5).

23. **Webster LR**. Treatment: Q & A about methadone. *Reflex Sympathetic Dystrophy Syndrome Association Review*. October 2006.

24. **Webster LR**. Fentanyl buccal tablets. *Expert Opinion On Investigational Drugs*. 2006;15(11):1469-73.

25. **Webster LR**. Interventional therapy: when should spinal cord stimulation (SCS) be considered? *Practical Pain Management*. 2006;6(6).

26. **Webster LR**, Walker MJ. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. *American Journal of Therapeutics*. 2006;13(4):300-5.

27. **Webster LR**, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. *Journal of Pain*. 2006;7(12):937-46.

28. **Webster LR**. Pharmaceutical management of cancer breakthrough pain. *US Oncological Disease*. 2006;1(2):102-3.

29. **Webster LR**. Fentanyl effervescent buccal tablets in patients with chronic pain. *Medscape Neurology*. March 18, 2006.

30. Taylor D, **Webster LR**, Chun SY, Reinking J, Stegman M, Shoemaker S, Fortner B. Impact of breakthrough pain on quality of life in patients with chronic, noncaner pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). *Pain Medicine* 2007;8(3): 281-8.

31. **Webster LR**. Safety first: prescribing methadone for pain. *Pain Management Today*. 2007;6(3):1-8.

32. **Webster LR**. Are intrathecal therapy trials necessary? *Practical Pain Management*. 2007;7(2):58-61.

33. **Webster LR**, Fakata K, Stuart W. Practical issues of reimbursement for IT drug delivery: the ziconotide model. *Practical Pain Management*. 2007;7(3):46-52.

34. **Webster LR**. Sedation levels for intraspinal injections. *Practical Pain Management*. 2007;7(4):52-3.

35. **Webster LR**. PTI-821: Sustained-release oxycodone using gel-cap technology. *Expert Opinion on Investigational Drugs*. 2007;16(3):359-66.

36. **Webster LR**. Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation. *Expert Opinion on Investigational Drugs*. 2007;16(8):1277-83.

37. **Webster LR**. Opioid and nonopioid therapies for the management of pain. *Medscape Neurology*. March 23, 2007.

38. **Webster LR**, Dove B, Leavitt SB. Maximizing safety with methadone and other opioids. *Pain Treatment Topics*. July 7, 2007.

39. **Webster LR**, Dove B. Optimizing opioid treatment for breakthrough pain. *Medscape Neurology*. September 28, 2007.

40. **Webster LR**. Occipital nerve stimulation for migraine. *US Neurological Disease: Touch Briefings*. 2008;1(1):33-34.

41. **Webster LR**, Fakata K, Charapata S, Fisher R, MineHart M. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain. *Pain Medicine*. 2008;9(3):282-90.

42. **Webster L**, Jansen J, Peppin JB Lasko B, Irving B, Morlion B, Snidow J, Pierce A, Mortensen E, Kleoudis C, Carter E. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain. *Pain* 2008;137(2):428-40.

43. **Webster LR**, Fisher R, Charapata S, Wallace MS. Long-term intrathecal ziconotide for chronic pain: an open-label study. *Journal of Pain and Symptom Management.* 2008;37(3):363-72.

44. **Webster LR**. Breakthrough pain in the management of chronic persistent pain syndromes. *The American Journal of Managed Care*. 2008;14(5 suppl 1):S116-22.

45. Passik SD, **Webster LR**. Pain and addiction interface. *Pain Medicine*. 2008;9(6):631-3.

46. **Webster LR**. Pharmacogentics in pain management: the clinical need. *Clinics in Laboratory Medicine*. 2008;28(4):569-79.

47. **Webster LR**, Choi Y, Desai H, Grant BJB. Sleep-disordered breathing and chronic opioid therapy. *Pain Medicine.* 2008;9(4):425-32.

48. **Webster LR**. Current and future pharmacologic therapies: opioid analgesics. *University of Tennessee Advanced Studies in Pharmacy*. 2008; 5(1):8-15.

49. **Webster LR**. Appropriate candidates for opioid therapy. *Emerging Solutions in Pain*. September 2, 2008.

50. **Webster LR**. Exploring the relationship between sleep and pain. *Medscape Neurology*. November 14, 2008.

51. **Webster LR**. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations. *Pain Medicine*. 2009; 10(S2):S124-S133.

52. Mogri M, Desai H, **Webster L**, Grand BJB, Mador MJ. Hypoxemia in patients on chronic opioid therapy with and without sleep apnea. *Sleep & Breathing*. 2009;13:49-57.

53. Leonard K, Lokey K, Leong MS, Fiekowsky S, Stanton-Hicks M, Sapienza-Crawford AJ, **Webster LR**. Intrathecal Ziconotide for complex regional pain syndrome: seven case reports.

Pain Practice. 2009; 9(4):296-303.

54. **Webster LR**, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? *Expert Opinion on Investigational Drugs*. 2009;18(3):255-63.

55. Fishman SM, **Webster LR**. Unintended harm from opioid prescribing guidelines. *Pain Medicine*. 2009;10(2):285-6.

56. Couto JE, **Webster LR**, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an oxycontin regimen. *Journal of Opioid Management*. 2009;5(6):359-64.

57. **Webster LR**. Pain management in the high-risk patient. *Medscape Neurology.* March 6, 2009.

58. **Webster LR**. The question of opioid euphoria. *Drug Discovery and Development*. July 30, 2009.

59. Chapman CR, Lipschitz DL, Angst MS, Chou R, Denisco RC, Donaldson GW, Fine PG, Foley KM, Gallagher RM, Gilson AM, Haddox JD, Horn SD, Inturrisi CE, Jick SS, Lipman AG, Loeser JD, Noble M, Porter L, Rowbotham MC, Schoellas KM, Turk DC, Volinn E, Von Korff MR, **Webster LR**, Weisner CM. Opioid pharmacotherapy for chronic non-cancer pain in the United States: a research guideline for developing an evidence-base. *Journal of Pain*. 2010;11(9):807-29.

60. **Webster LR**, Fine PG. Approaches to improve pain relief while minimizing opioid abuse liability. *Journal of Pain*. 2010;11(7):602-11.

61. **Webster LR**, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Vanhove GF. A multicenter, randomized, double-blind, controlled dose finding study of NGX-4010, a high-concentration capsaicin patch for the treatment of postherpetic neuralgia. *Journal of Pain*. 2010;11(10):972-82.

62. **Webster LR**. Addressing the pain management paradox. *Pain Practitioner*. 2010;20(3):37-9.

63. **Webster LR**, Richards P, Stern W, Kelen R. A double-blind, placebo-controlled study of dual-opioid treatment with the combination of morphine plus oxycodone in patients with acute postoperative pain. *Journal of Opioid Management*. 2010;6(5):329-40.

64. Simpson DM, Gazda S, Brown S, **Webster LR**, Lu SP, Tobias JK, Vanhove GF. Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral

neuropathic pain. *Journal of Pain and Symptom Management*. 2010;39(6):1053-64.

65. **Webster LR**. Current state of chronic pain management: current and emerging long-acting opioids. *University of Tennessee Advanced Studies in Pharmacy.* 2010;7(2):36-40.

66. **Webster LR**, Tark M, Rauck R, Tobias JK, Vanhove GF. Effect of duration of postherpetic neuralgia on efficacy analyses in a multicenter, randomized, controlled study of NGX-4010, an 8% capsaicin patch evaluated for the treatment of postherpetic neuralgia. *BMC Neurology*. 2010;10:92.

67. **Webster LR**, Brewer R, Wang C, Sekora D, Johnson FK, Morris D, Stauffer J. Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain. *Journal of Pain and Symptom Management.* November 2010;40(5):734-746.

68. Wang H, Gargano C, Lukac S, Jackson A, Beals C, Smiley P, Drexel M, Ruddy M, Herman G, Johnson-Levonas AO, Medve R, **Webster L**, Reicin A. An enhanced bunionectomy model as a potential tool for early decision-making in the development of new analgesics. *Advances in Therapy*. 2010;27(12):963-80.

69. **Webster LR**. Considering the risks of benzodiazepines and opioids together. *Pain Medicine*. 2010;11(6):801-2.

70. Deer TR, Smith HS, Cousins M, Doleys DM, Levy RM, Rathmell JP, Staats PS, Wallace M, **Webster LR**. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. *Pain Physician.* 2010;13(3):175-213.

71. **Webster LR**. Letter to the Editor in response to Opioids and deaths. *New England Journal of Medicine*. 2011; 364:686-87.

72. **Webster LR**. Informed consent and management plans to optimize opioid therapy for chronic pain. *Pain Management Today*. 2011;1(2).

73. Setnik B, Roland CL, Cleveland JM, **Webster L**. The abuse potential of Remoxy, an extended-release formulation of oxycodone, compared with intermediate- and extended-release oxycodone. *Pain Medicine*. April 2011; 12(4):618-31.

74. Couto JE, **Webster L**, Romney MC, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to a hydrocodone regimen. *Journal of Clinical*

Pharmacy and Therapeutics. April 2011;36(2):200-07.

75. Friedmann N, Klutzaritz V, **Webster LR**. Long-term safety of Remoxy (extended-release oxycodone) in patients with moderate to severe chronic osteoarthritis or low back pain. *Pain Medicine.* 2011;12(5):755-760.

76. Peppin JF, **Webster LR**. Letter to the Editor in response to "The evidence for pharmacological treatment of neuropathic pain" by Finnerup et al. *PAIN*. 2011; 152(6):1440.

77. Friedmann N, Klutzaritz V, **Webster LR**. Efficacy and safety of an extended-release oxycodone (Remoxy) formulation in patients with moderate to severe osteoarthritic pain. *Journal of Opioid Management*. 2011;7(3):193-202.

78. **Wesbter LR**. Ending unnecessary opioid-related deaths: a national priority. *Pain Medicine*. 2011;12(S2):S13-15.

79. **Webster LR**, Cochella S, Dasgupta N, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson EM, Lee LK, Passik SD, Peppin J, Porucznik CA, Ray A, Schnoll SH, Stieg RL, Wakeland W. An analysis of the root causes for opioid-related deaths in the United States. *Pain Medicine.* 2011;12(S2):S26-35.

80. Wakeland W, Schmidt T, Gilson AM, Haddox JD, **Webster LR**. System dynamics modeling as a potentially useful tool in analyzing mitigation strategies to reduce overdose deaths associated with pharmaceutical opioid treatment of chronic pain. *Pain Medicine*. 2011;12(S2):S49-58.

81. Rich BA, **Webster LR**. A review of forensic implications of opioid prescribing with examples from malpractice cases involving opioid-related overdose. *Pain Medicine.* 2011;12(S2):S59-65.

82. **Webster LR**, Dasgupta N. Obtaining adequate data to determine causes of opioid-related overdose deaths. *Pain Medicine*. 2011;12(S2):S86-92.

83. **Webster LR**, Peppin JF, Murphy FT, Lu B, Tobias JK, Vanhove GF. Efficacy, safety and tolerability of NGX-4010, capsaicin 8% patch, in an open-label study of patients with peripheral neuropathic pain. *Diabetes Research & Clinical Practice*. 2011;93(2):187-97.

84. Passik SD, Kirsh KL, **Webster LR**. Pseudoaddiction revisited: a commentary on clinical and historical considerations. *Pain Management*. 2011;1(3):239-48.

85. **Webster LR**. Striving toward quality pain management. *Physician's Weekly.* 2011;15.

86. **Webster LR**, Messina J, Xie F, Nalamachu S. Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. *Journal of Opioid Management*. July/August 2011;7(4):297-308.

87. **Webster LR**, Fine PG. Reply to Universal precautions: it's not about the molecule! by Gourlay and Heit. *Journal of Pain*. 2011;12(6):723-24.

88. **Webster L**, St. Marie B, McCarberg B, Passik SD, Panchal SJ, Voth E. Current status and evolving role of abuse deterrent opioids in managing patients with chronic pain. *Journal of Opioid Management*. 2011;7(3):235-45.

89. **Webster LR**, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. *Drugs in R&D*. 2011;11(3):259-275.

90. **Webster LR**, Brewer R, Morris D, Cleveland JM, Setnik B. Opioid titration and conversion in patients receiving morphine sulfate and naltrexone hydrochloride extended release capsules. *Postgraduate Medicine*. 2011;123(5):155-64.

91. Deer TR, Smith HS, Burton AW, Pope JE, Doleys DM, Levy RM, Staats PS, Wallace M, **Webster LR**, Rauck R, Cousins M. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain guidelines. *Pain Physician.* 2011;14(3):283-312.

92. **Webster LR**. Oxycodone extended-release using gel-cap technology to resist alteration and abuse for the treatment of moderate-to-severe pain. *Pain Management*. 2011;1(5):417-425.

93. Brown J, Setnik B, Lee K, Cleveland JM, Roland CL, Wase L, **Webster LR**. Effectiveness and safety of morphine sulfate extended-release capsules in patients with chronic, moderate-to-severe pain in a primary care setting. *Journal of Pain Research.* 2011;4:373-384.

94. Peppin JF, Majors K, **Webster LR**, Simpson DM, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% patch for peripheral neuropathic pain. *Journal of Pain Research*. 2011;4:385-392.

95. Yancey-Wrona J, Dallaire B, Bilsky E, Bath B, Burkart J, **Webster LR**, Maqiera D, Yang X, Phelps M, Sadee W. 6β-Naltrexol, a peripherally selective opioid antagonist that inhibits against morphine-induced slowing of gastrointestinal transit: an exploratory study. *Pain Medicine*. 2011;12(12):1727-1737.

96. **Webster LR**, Nunez M, Tark MD, Dunteman ED, Lu B, Tobias JK, Vanhove GF. Tolerability of NGX-4010, a capsaicin 8% dermal patch, following pretreatment with lidocaine 2.5%/prilocaine 2.5% cream in patients with post-herpetic neuralgia. *BMC Anesthesiology*. 2011;11:25.

97. **Webster LR**. Butrans (buprenorphine) transdermal system: clinical study, initiation, and dose titration in opioid-naïve patients. *Pain Medicine News.* 2011;9(12):1-4.

98. Walker MJ, **Webster LR**. Opioid-induced hyperalgesia and monotherapy intrathecal ziconotide: experience with four cases. *Journal of Pain Management*. 2012;5(3):10.

99. Irving GA, Backonja M, Rauck R, **Webster LR**, Tobias JK, Vanhove GF. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. *Clinical Journal of Pain.* 2012;28(2):101-107.

100. **Webster LR**, Peppin JF, Murphy F, Tobias JK, Vanhove GF. Tolerability of NGX-4010, capsaicin 8% patch, in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. *Journal of Pain Research*. 2012;1(5):7-13.

101. Schultz DM, **Webster LR**, Kosek P, Dar U, Tan Y, Sun M. Sensor-driven position-adaptive spinal cord stimulation for chronic pain. *Pain Physician*. 2012;15(1):1-12.

102. **Webster LR**. Efficacy and safety of dual-opioid therapy in acute pain. *Pain Medicine.* 2012;13(Suppl 1):S12-20.

103. **Webster LR**, Fine PG. Review and critique of opioid rotation practices and associated risks of toxicity. *Pain Medicine*. 2012;13(4):562-570.

104. **Webster LR**, Fine PG. Overdose deaths demand a new paradigm for opioid rotation. *Pain Medicine*. 2012;13(4):571-574.

105. **Webster LR**, Bath B, Medve RA, Marmon T, Stoddard GJ. Randomized, double-blind, placebo-controlled study of the abuse liability of different formulations of oral oxycodone. *Pain Medicine*. 2012;13(6):790-801.

106. Brushwood DB, Rich BA, **Webster LR**, Coleman JJ, Passik SD, Brennan MJ. Balance and the adoption of abuse-deterrent opioid formulations in pain management practice. *University of the Incarnate Word Pharmacy Review.* 2012;1(1).

107. Goli V, **Webster LR**, Lamson MJ, Cleveland JM, Sommerville KW, Carter E. Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxide. *Harm Reduction Journal.* 2012;9(1):13.

108. **Webster LR**. Industry-Supported CME and Firewalls. *Pain Medicine News*. 2012;10(7):16,22.

109. **Webster LR**, Rolleri RL, Pixton GC, Sommerville KW. Randomized, double-blind, placebo-controlled and active-controlled study to assess the relative abuse potential of oxycodone HCl-niacin tablets compared to oxycodone alone in nondependent recreational opioid users. *Substance Abuse & Rehabilitation*. 2012;3(1):101-13.

110. Turk DC, O'Connor AB, Dworkin RH, Chaudhry A, Katz NP, Adams EH, Brownstein JS, Comer SD, Dard R, Dasgupta N, Denisco RA, Klein M, Leiderman DB, Lubran R, Rappaport BA, Zacny JP, Ahdieh H, Burke LB, Cowan P, Jacobs P, Malamut R, Markman J, Michna E, Palmer P, Peirce-Sandner S, Potter JS, Raja SN, Rauschkolb C, Roland CL, **Webster LR**, Weiss RD, Wolf K. Research design considerations for clinical studies of abuse-deterrent opioid analgesics: IMPACT recommendations. *Pain*. 2012;153(1):1997-2008.

111. Brennan MJ, Rhiner MI, Simpson DM, **Webster LR**, Koh-Knox CP. Persistent and breakthrough pain: opioid-based therapy for fluctuating pain profiles. *Practical Pain Management*. 2012;Supplement.

112. **Webster LR**. Ten things you need to know about conducting a human abuse liability study. *Clinical Leader*. October 10, 2012.

113. Fine PG, **Webster LR**, Argoff C. American Academy of Pain Medicine response to PROP petition to the FDA that seeks to limit pain medications for legitimate noncancer pain sufferers. *Pain Medicine*. 2012;13(10):1259-64.

114. **Webster LR**. The role of urine drug monitoring in pain management. *Pain Medicine News*. 2012;10:43-8.

115. Walker MJ, **Webster LR**. Risk factors for drug diversion in a pain clinic patient population. *Journal of Opioid Management.* 2012;8(6):351-62.

116. **Webster LR**. Industry-Supported CME and Firewalls. *Anesthesiology News*. 2012;38:10.

117. Grabois M, **Webster LR**. Continuing education in opioid prescribing. *Journal of the American Medical Association*. 2012;308(20):2082.

118. Setnik B, Roland CL, **Webster LR**. Response to letter by Dr. Ruan. *Pain Medicine*. 2013;14(1):161-2.

119. Kalliomaki J, Segerdahl M, **Webster L**, Reimfelt A, Huizar K, Annas P, Karlsten R, Quiding H. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. *Scandinavian Journal of Pain*. 2013;4(1):17-22.

120. Setnik B, Roland C, Goli V, Sommerville K, **Webster L**. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients. *Journal of Opioid Management*. 2013;9(2):139-50.

121. **Webster LR**. A Responsible Way to Treat Patients and Pain. *Pain Medicine*. 2013;14(5):615-6.

122. Quiding H, Jonzon B, Svensson O, **Webster L**, Reimfelt A, Karin A, Karlsten R, Segerdahl M. TRPV1 antagonistic analgesic effect: a study of AZD1386 in pain following third molar extraction. *PAIN*. 2013;154(6):808-12.

123. **Webster LR**. Eight Principles for Safer Opioid Prescribing. *Pain Medicine*. 2013;14(7):959-61.

124. Rauck R, Coffey RJ, Schultz DM, Wallace MS, **Webster LR**, McCarville SE, Grigsby EJ, Page LM. Intrathecal gabapentin to treat chronic intractable non-cancer pain. *Anesthesiology*. 2013;119(3):675-86.

125. Setnik B, Sommerville K, Goli V, Han L, **Webster LR**. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tablets and placebo in nondependent recreational opioid users. *Pain Medicine*. 2013;14(8):1173-86.

126. **Webster LR**, Slevin KA, Narayana A, Ear CQ, Yang R. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes. *Pain Medicine*. 2013;14(9):1332-45.

127. **Webster LR**. Pills, policies and predicaments: the unintended consequences of a health care system's policy toward opioids. *Pain Medicine*. 2013;14(10):1439-40.

128. **Webster LR**, Dhar S, Eldon M, Masuoka L, Lappalainen J, Sostek M. A Phase 2, double-blind, randomized, placebo-controlled, dose-escalation study to evaluate the efficacy, safety, and tolerability of naloxegol in patients with opioid-induced constipation. *PAIN.* 2013;154(9):1542-50.

129. Reisfield G, **Webster L**. Benzodiazepines in long-term opioid therapy. *Pain Medicine.* 2013;14(10):1441-6.

130. Wakeland W, Nielsen A, Schmidt TD, McCarty D, **Webster LR**, Fitzgerald J, Haddox JD. Modeling the impact stimulated educational interventions on the use and abuse of pharmaceutical opioids in the United States. *Health Education & Behavior*. 2013;40(1S):74S-86S.

131. **Webster LR**. New policing role for pharmacists undermines partnership with prescribers. *Pain Medicine*. 2013; 14(11):1619-20.

132. **Webster LR**, Harden RN. Why we need narratives of healing and qualitative pain research. *Pain Medicine*. 2013;14(12):1811-12.

133. **Webster LR**. It takes many true leaders to become a top-tier pain organization. *Pain Medicine*. 2014;15(1):3.

134. **Webster LR**. Pain and suicide: the other side of the opioid story. *Pain Medicine*. 2014;15(3):345-6.

135. Chey WD, **Webster L**, Sostek M, Lappalainen J, Barker PN, Tak J. Naloxegol for opioid-induced constipation in patients with noncancer pain. *New England Journal of Medicine*. 2014;370(25):2387-96.

136. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, **Webster LR**. Biased agonism of the mu opioid receptor by TRV130 inceases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled crossover study in healthy volunteers. *PAIN*. 2014;155(9):1829-35.

137. **Webster L**, Chey WD, Tack J, Lappalainen J, Diva U, Sostek M. Randomised clinical trial: long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation. *Alimentary Pharmacology & Therapeutics;* 2014;41(7):771-9.

138. Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, **Webster L**. Comparison of subjective effects of extended-release versus immediate-release oxycodone/acetaminophen tablets: a randomized trial. *Postgraduate Medicine*. 2014;

126(4):20-32.

139. Zhou XJ, Vince B, Hill JM, Lawitz EJ, O'Riordan W, **Webster LR**, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bolyai JZ, Mayers D. A randomized, double-blind, multiple-dose study of the pain-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. *Journal of Hepatology*. 2014 May; 60(5):920-7.

140. Zhou XJ, Vince B, Hill JM, Lawitz EJ, O'Riordan W, **Webster LR**, Gruener DM, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bolyai JZ, Mayers D. A randomized, double-blind, multiple-dose study of the pain-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. *Journal of Hepatology*. 2014 May; 60(5):920-7.

141. Radnovich R, Chapman CR, Gudin JA, Panchal SJ, **Webster LR**, Pergolizzi JV. Acute pain: effective management requires comprehensive assessment. *Postgraduate Medicine.* 2014;126(4):59-72.

142. **Webster LR**, Smith MD, Mackin S, Iverson M. Comparative effects of morning vs evening doses of extended-release hydromorphone on sleep physiology in patients with low back pain: a pilot study. *Pain Medicine*. 2014; doi: 10.1111/pme.12577.

143. Passik SD, **Webster LR**. Opioid analgesics: does potency matter? *The Journal of Opioid Management*. 2014;10(4):263-76.

144. **Webster LR**, Markman J. Medical management of chronic low back pain: efficacy and outcomes. *Neuromodulation: Technology at the Neural Interface.* 2014;17(S2):S18-23.

145. Camilleri M, Drossman DA, Becker G, **Webster LR**, Davies AN, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. *Neurogastroenterology & Motility*. 2014;26(10);1386-95.

146. **Webster LR**. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and Ziconotide. *Pain Medicine*. 2014; DOI: 10.1111/pme.12666.

147. Lawitz E, Gruener D, Marbury T, Hill J, **Webster L**, Hassman D, Nguyen AH, Pflanz S, Mogalian E, Gaggar A, Massetto B, Subramanian GM, McHutchison JG, Jacobson IM, Freilich B, Rodriguez-Torres M. Safety, pharmacokinetcs, and pharmacodynamics of the oral toll-like receptor 7 agonist GS-9620 in treatment naive patients with chronic hepatitis C. *Antiviral Therapy* 2015;20(7):699-708. doi: 10.3851/IMP2845. Epub 2014 Aug 8.

148. Gaertner J, Siemens W, Camilleri M, Davies A, Drossman DR, Webster L, Becker G. Definitions and outcome measures of clinical trials regarding opioid-induced constipation: a systematic review. *Journal of Clinical Gastroenterology* 2015 Jan;49(1):9-16. doi: 10.1097/MCG.0000000000000246.

149. **Webster L**, Reisfield G, Dasgupta N. Eight principles for safer opioid prescribing and cautions with benzodiazepines. *Postgraduate Medicine*. 2015;127(1):27-32.

150. Devarakonda K, Kostenbader K, Zheng Y, Mongtomery JB, Barrett T, Young JL, **Webster LR**. Human abuse potential of immediate-release/extended-release versus immediate-release hydrocodone bitartrate/acetaminophen: a randomized controlled trial in recreational users of prescription opioids. *Postgraduate Medicine*. 2015;127(1):13-21.

151. Joseph D, Schobelock M, Risenberg R, Vince B, **Webster L**, Adeniji A, Elgadi M, Huang F. Effect of steady-state Faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine/naloxone in subjects on stable addiction management therapy. *Antimicrobal Agents & Chemotherapy.* 2015;59(1):498-504.

152. **Webster L**. APhA2015 abstracts of contributed papers. *The Journal of American Pharmacists Association*. 2015;55(2):113-263.

153. Schatman ME, **Webster LR**. The health insurance industry: perpetuating the opioid crisis through policies of cost-containment and profitability. *Journal of Pain Research*. 2015;2015(8):153-58.

154. **Webster LR**, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP. Analysis of opioid-mediated analgesia in phase 3 studies of methylnaltrexone for opioid-induced constipation in patients with chronic non-cancer pain. *Journal of Pain Research*. 2015:8 771-780.

155. Lipman A, **Webster L**. The economic impact of opioid use in the management of chronic non-malignant pain. *Journal of Managed Care & Specialty Pharmacy*. 2015 Oct;21(10):891-9.

156. Jamal MM, Adams AB, Jansen JP, **Webster LR**. A randomized, placebo-controlled trial of Lubiprostone for opioid-induced constipation in chronic noncancer pain. *American Journal of Gastroenterology*. 2015; Advance online publication April, 28 2015; doi: 10.1038/ajg.2015.106.

157. Morton T, Devarakonda K, Kostenbader K, Mongtomery J, Barrett T, **Webster L**. Correlation of subjective effects with sytematic opioid exposure from fixed-dose combinations of hydrocodone/acetaminophen in recreational users of prescription drugs: a randomized controlled trial. *Pain Medicine.* 2015; Advance online publication August 25, 2015;

doi:10.1111/pme.12884.

158. **Webster L**, M Brennan, L Kwong, R Levandowski, J Gudin. Opioid abuse-deterrent strategies: role of clinicians in acute pain management. *Postgraduate Medicine*. 3 Dec 2015, At: 12:26.

159. **Webster L**, Finn A, Kirby T, Xiang Q. Low-dose naloxone provides an abuse-deterrent effect to buprenorphine. *Journal of Pain Research*. 2015 Nov 4;8:791-798.

160. **Webster L**, Grabois M. Current Regulations Related to Opioid Prescribing. *PM&R Pain Supplement*. November 2015 Volume 7, Issue 11, Supplement, Pages S236-S247.

161. **Webster L**, Kopecky E, Smith M, Fleming A. A Randomized, Double-blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of Xtampza ER™, a Novel Extended-Release Abuse-Deterrent Formulation of Oxycodone. *Pain Medicine*. 2015; 0: 1-19; doi: 10.1093/pm/pnv020.

162. Setnik B, Pixton GC, **Webster LR**. Safety profile of extended-release morphine sulfate with sequestered naltrexone hydrochloride in older patients: pool analysis of three clinical trials. *Current Medical Research & Opinion*. 2015; doi: 10.1185/03007995.2015.1131153.

163. **Webster L**, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the tolerability of switching patients on chronic full μ -opioid agonist therapy to buccal buprenorphine. *Pain Medicine* 2016; 0: 1-9; doi 10.1093/pm/pnv110.

164. Viscusi ER, **Webster L**, Kuss M, Daniels S, Bolognese JA, Zuckerman S, Soergel DG, Subach RA, Cook E, Skobieranda F. A Randomized, Phase 2 Study Investigating TRV130, a Biased Ligand of the μ-opioid Receptor, for the Intravenous Treatment of Acute Pain. *PAIN* 2016 Jan;157(1):264-72. doi: 10.1097/j.pain.0000000000000363.

165. Hulskotte EGJ, Bruce RD, Feng HP, **Webster LR**, Xuan F, Lin WH, O'Mara E, Wagner JA, Butterton J. Pharmacokinetic interaction between HCV protease inhibitor Boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. *European Journal of Clinical Pharmacology* March 2015, Volume 71, Issue 3, pp 303–31.

166. Carlquist JF, Moody DE, Knight S, Johnson EG, Fang WB, Huntinghouse JA, Rollo JS, Neimann DF, Morgan M, **Webster LR**, Anderson JL. A Possible Mechanistic Link Between the CYP2C19 Genotype, the Methadone Metabolite Ethylidene-1,5-Dimethyl-3,3-Diphenylpyrrolidene (EDDP), and Methadone-Induced Corrected QT Interval Prolongation in a Pilot Study. *Molecular Diagnosis & Therapy* 2015 Apr;19(2):131-8.

167. Sullivan JG, **Webster L**, Warneke T, Finn A. Novel buccal film formulation of buprenorphine-naloxone for the maintenance treatment of opioid dependence: a 12-week conversion study. *Clinical Therapeutics.* 2015 May 1;37(5):1064-75.

168. Jassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, **Webster L**, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela DM, Gardiner DF. A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection. *Journal of Hepatology* 2015 May;62(5): 1204-6.

169. **Webster LR**. Opioid-induced constipation. *Pain Medicine*. 2015 Oct;16 Suppl 1: S16-21.

170. Setnik B, Roland CL, Goli V, Pixton GC, Levy-Cooperman N, Smith I, Webster L. Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city. *J Opioid Manag*. 2015;11(6):463-73.

171. Argoff CE, Brennan MJ, Camilleri M, Davies A, Fudin J, Galluzzi KE, Gudin J, Lembo A, Stanos SP, **Webster LR**. Consensus recommendations on initiating prescription therapies for opioid-induced constipation. *Pain Med*. 2015;16(12):2324-2337.

172. Cheatle M, **Webster L**. Opioid Therapy and Sleep Disorders: Risks and Mitigation Strategies. *Pain Medicine*. 2015 Oct; 16(0 1): S22–S26.

173. **Webster L**, Stauffer J, Spencer R, Menzaghi F, Abrouk N, Lewis M, Chalmers D. Subjective and Objective Evidence of Low Abuse Potential of the Peripherally-Acting Kappa Opioid CR845, Compared with Pentazocine. *Drug and Alcohol Dependence.* 2015; 156: e211. http://dx.doi.org/10.1016/j.drugalcdep.2015.07.570

174. Backonja M, **Webster LR**, Setnik B, Bass A, Sommerville KW, Matschke K, Malhotra BK, Wolfram G. Intravenous abuse potential study of oxycodone in combination with naltrexone, simulating crushed ALO-02, in comparison with oxycodone alone in nondependent, recreational users. *The American Journal of Drug and Alcohol Abuse*. 2016. Doi: 10.3109/00952990.2016.1167215.

175. **Webster L.** Opioid-induced constipation: rationale for the role of norbuprenorphine in buprenorphine-treated individuals. *Substance Abuse and Rehabilitation*. 2016:7 81-86.

176. Viscusi ER, **Webster L**, Kuss M, Daniels S, Bolonese JA, Zuckerman S, Soergel DG, Subach RA, Cook E, Skobieranda F. TRV130, a biased ligand at the μ-opioid receptor for the intravenous treatment of acute pain. *Pain*. 2016 Jan; 157(1):264-72.

177. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, **Webster L**, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF. Daclatasvir + Asunaprevir + Beclabuvir ± Ribavirin for chronic HCV genotype 1-infected treatment-naive patients. *Liver International.* 2016 Feb;36(2):189-97.

178. **Webster L**, Nagata T, Yamada T, Ferriera JCA. A phase 2a, randomized, double-blind, placebo-controlled, single ascending-dose study to evaluate the safety and efficacy of naldemedine in patients with chronic non-cancer pain and opioid-induced bowel dysfunction. *The Journal of Pain*. 2016 Apr;17(4S):S94.

179. Smith M, **Webster L**, Lawler J, Lindhardt K, Dayno J. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (Morphine-ADER Injection-Molded Tablets) versus Extended-Release Morphine Administered Orally in Nondependent Recreational Opioid Users. *Pain Medicine* Vol 18 (9): 1695-1705. https://doi.org/10.1093/pm/pnw219

180. Chambers J, Gleason R, Kirsh K, Twillman R, **Webster L**, Berner J, Fudin J, Passik S. An Online Survey of Patient's Experiences Since the Rescheduling of Hydrocodone: The First 100 Days. *Pain Medicine* 2016; 17:1686-1693.

181. **Webster L**, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the tolerability of switching patients on chronic full μ -opioid agonist therapy to buccal buprenorphine. *Pain Medicine* 2016; 17: 899-907.

182. **Webster L**, Hjelmstrom P, Sumner M, Gunderson E. Efficacy and Safety of a Sublingual Buprenorphine/Naloxone Rapidly Dissolving Tablet for the Treatment of Adults With Opioid Dependence: A Randomized Trial. *Journal of Addictive Diseases* Volume 35, 2016 – Issue 4.

183. **Webster L**. Chronic Pain and the Opioid Conundrum. A*nesthesiology Clinics.* 2016 Jun; 34(2):341-55.

184. **Webster L,** Pantaleon C, Shah S, DiFalco R, Iverson M, Smith M, Kinzler E, Aigner S. A randomized, double-blind, double-dummy, placebo-controlled, intranasal drug liking study on a novel abuse-deterrent formulation of morphine ─ Morphine ARER. *Pain Medicine* (2017) 18 (7): 1303-1313.

185. Setnik B, Roland CL, Pixton G, **Webster L**. Measurement of drug liking in abuse potential studies: a comparison of unipolar and bipolar visual analog scales. *The Journal of Clinical Pharmacology* doi:10.1002/jph.801.

186. **Webster L**, Tummala R, Diva U, Lappalainen J. A 12-Week Extension Study to Assess the Safety and Tolerability of Naloxegol in Patients with Noncancer Pain and Opioid-Induced Constipation. *Journal of Opioid Management* 2016 Nov/Dec; 12(6):405-419.

187. **Webster L**, Markman J, Cone E, Niebler, G. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States. *Postgraduate Medicine*, 129:1, 102-110.

188. **Webster L**, Tummala R, Diva U, Lappalainen J. A 12-week extension study to assess the safety and tolerability of Naloxegol in patients with noncancer pain and opioid-induced constipation. *Journal of Opioid Management*. 12 (6), 405-419. Nov-Dec 2016.

189. Darwish M, Bond M, Yang R, **Webster LR.** Abuse potential with oral route of administration of a hydrocodone extended-release table formulated with-abuse-deterrence technology in nondependent, recreational opioid users. *Pain Medicine* (2017) 18 (1): 61-77.

190. **Webster L**, Heningfield J, Buchhalter A, Siddhanti S, Lu L, Odinecs A, Eldon M. Human Abuse Potential of the New Opioid Analgesic Molecule NKTR-181 Compared to Oxycodone. *Pain Medicine,* 2017 Mar 10. doi: 10.1093/pm/pnw344.

191. **Webster L**, Yamada T, Ferreira J. A phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. *Pain Medicine,* 2017 Mar 23. Doi: 10.1093/pm/pnw/325.

192. **Webster L**, Konrad P, McRoberts P, Poree L. Treatment Options for FBSS Patients with Refractory Chronic Pain. *Journal of Spine.* 2017 Apr 12. doi: 10.1097/ BRS.0000000000002217.

193. Bond M, Schoedel K, Rabinovich-Guilatt L, Gasior M, Malamut R, Ma Y, **Webster L**. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. *Pain Medicine* 2017; 0: 1-16 doi: 10.1093/pm/pnx133.

194. **Webster L**, Michna E, Khan A, Israel R, Harper J. Long-Term Safety and Efficacy of Subcutaneous Methylnaltrexone in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain: A Phase 3, Open-Label Trial. *Pain Medicine* Volume 18, Issue 8, 1 August 2017, Pages 1496-1504.

195. Cryer B, Drossman D, Chey W, **Webster L**, Habibi S, Wang M. Analysis of Nausea in Clinical Studies of Lubiprostone for the Treatment of Constipation Disorders. *Digestive*

Diseases and Sciences DOI 10.1007/s10620-017-4680-1.

196. **Webster L**, Brewer R, Lichtlen P, Losch-Beridon T, Shadreck M, Wang M. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class. *Pain Medicine*, pnx212, https://doi.org/10.1093/pm/pnx212.

197. **Webster L**, Katz N, Passik S. Abuse-Deterrent Opioids: Why Rush to Judgement? *Practical Pain Management,* October 5, 2017.

198. **Webster L**, Diva U, Tummala R, Sostek M. Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioid-Induced Constipation. *Pain Practice*, doi: 10.1111/papr.12640.

199. Argoff C, Alford D, Fudin J, Adler J, Bair M, Dart R, Gandolfi R, McCarberg B, Stanos S, Gudin J, Polomano R, **Webster L**. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations. *Pain Medicine* 2017; 0: 1-2. Doi 10.1093/pm/pnx285.

200. **Webster L**. Risk Factors for Opioid Use Disorder and Overdose. *Anesthesia & Analgesia*: November 2017 – Volume 125 – Issue 5 – p 1741-1748.

201. **Webster L**. Doctor driven problem or doctor driven solution? *Journal of Opioid Management – Abuse Deterrent Opioid Special Edition*, Vol 12, No 6 (2017) 351-352.

202. Miller C, Dart R, Katz N, **Webster L**. Insights and issues from FDA Advisory Committee meetings on abuse-deterrent opioids. *Journal of Opioid Management – Abuse Deterrent Opioid Special Edition*, Vol 12, No 6 (2017) 379-389.

203. **Webster L**. Interpreting labels of abuse-deterrent opioid analgesics. *Journal of Opioid Management – Abuse Deterrent Opioid Special Edition*, Vol 12, No 6 (2017) 415-423.

204. **Webster L**. Risk Factors for Opioid-Use Disorder and Overdosed. *Anesthesia and Analgesia*, Vol 125(5):1741-1748. DOI: 10.1213/ANE.0000000000002496

205. Rockett I, Caine E, Connery H, D'Onofrio G, Gunnell D, Miller T, Nolte K, Kaplan M, Kapusta N, Lilly C, Nelson L, Putman S, Stack S, Värnik P, **Webster L**, Jia H. Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history. PLoS ONE 13(1): e0190200. https://doi.org/10.1371/journal.pone.0190200.

206. **Webster L**, Viscusi E, Brown C, Dayno J. Human Abuse Potential Studies of Abuse-Deterrent Opioids: Lessons from Oral and Intranasal Studies with Morphine Abuse-Deterrent, Extended-

Release, Injection-Molded Tablets. *Current Medical Research and Opinion, Vol 34(2018)* 893-901. DOI: 10.1080/03007995.2018.1433144.

207. **Webster L**. Loss of Trust and Empathy Ends an Era of Opioid Self-Assessment. *Pain Medicine*, 2018; 0: 1-2, doi 10.1093/pm/pny010.

208. **Webster L**, Iverson M, Pantaleon C, Smith M, Kinzler E, Aigner S. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation. *Pain Medicine*, 2018; 0: 1-11 doi: 10.1093/pm/pny043.

209. **Webster L**, Pantaleon C, Iverson M, Smith MD, Kinzler E, Aigner S. Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-deterrent Formulation: Results from a Randomized, Double-blind, Four-way Crossover Study in Nondependent, Opioid-Experienced Subjects. *Pain Research and Management* Volume 2018, Article ID 7276021. https://doi.org/10.1155/2018/7276021

210. **Webster L.** Opioid Assessment Tools for High-Risk Patients. Accepted for publication in *Anesthesia & Analgesia* on August 18, 2017.

211. Mickle T, Guenther S, Barrett A, Roupe KA, Zhou J, Dickerson D, **Webster L**. Pharmacokinetics and Abuse Potential of Benzhydrocodone, a Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users. *Pain Medicine*, 2017 Oct 28. doi: 10.1093/pm/pnx247

212. Feng H, Guo Z, Caro L, Marshall W, Liu F, Panebianco D, Vadaddy P, Barbour A, Reitmann C, Jumes P, Gilmartin J, Wolford D, Valesky R, Martinho M, Butterton J, Iwamoto M, Fraser I, **Webster L**, Yeh W. No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy. *Clinical and Translational Science*, Vol 11, No 6(2018) 562-572. |https://doi.org/10.1111/cts.12565

213. Gharibo, C, Argoff C, Markenson J, **Webster L,** Nezzer J, Solorio D, Lauterio M, and Young C. Opioid-sparing Effects of SoluMatrix Indomethacin in a Phase 3 Study in Patients with Acute Postoperative Pain. *The Clinical Journal of Pain*, Vol 34, No 2(2018) 138-144(7). https://doi.org/10.1097/AJP.0000000000000525

214. **Webster L,** Nalamachu S, Yamada T, Reddy J, Baba Y, Ferreira J. Long-term Safety and Tolerability of Naldemedine for Opioid-induced Constipation in Subjects with Non-cancer Pain: A Randomized, Double-blind, Placebo-controlled, Phase III Trial. *Pain Medicine.* 18(8) 2017 1496-1504. DOI: 10.1093/pm/pnx148

215. Rockett I, Caine E, Connery H, D'Onofrio G, Gunnell D, Miller T, Nolte K, Kaplan M, Kapusta N, Lilly C, Nelson L, Putnam S, Stack S, Varnik P, **Webster L**, Jia H. Discerning suicide in drug intoxication deaths: Paucity and primacy of suicide notes and psychiatric history. *PLOS|ONE*, January 10,2018. https://doi.org/10.1371/journal.pone.0190200

216. **Webster L**. Abuse-Deterrent Formulations on the Frontlines of the Opioid Crisis. Submitted to *Anesthesia & Analgesia* on July 31, 2017.

217. Feng H, Guo Z, Caro L, Marshall W, Liu F, Panebianco D, Vadaddy P, Reitmann C, Jumes P, Gilmartin J, Wolford D, Fraser I, Butterton J, Iwamoto M, **Webster** L, Yeh W. No pharmacokinetic interactions between Elbasvir or Grazoprevir and methadone in participants receiving maintenance opioid agonist therapy. Submitted to *The European Journal of Clinical Phamacology* on August 30, 2017.

218. Bass A, **Webster L**, Matschke K, Malhotra B, Wolfram G. Effects of Intravenous Oxycodone Alone or in Combination with Naltrexone on Measures of Respiratory Depression: A Randomized, Controlled Study. Submitted to *Pain Practice* as on November 29, 2017.

219. **Webster L**. Interpreting Labels of Abuse-Deterrent Opioid Analgesics. *Journal of Opioid* Management [S.l.], v. 13, n. 6, p. 415-423, Dec. 2017 doi:http://dx.doi.org/10.5055/jom.2017.0418.

220. **Webster L,** Israel R. Oral Methylnaltrexone is Efficacious and Well Tolerated for the Treatment of Opioid-Induced Constipation in Patients with Chronic Noncancer Pain Taking Concomitant Methadone. *Journal of Pain Research, 2018*; 11: 2509-2516. https://doi.org/10.2147/JPR.S160625

221. **Webster L**, Nalamachu S, Morlion B, Reddy J, Babad Y, Yamadad T, Camilo J, Ferreirad A. Long-term use of Naldemedine in the treatment of opioid-induced constipation in patients with chronic non-cancer pain: a randomized, double-blind, placebo-controlled phase 3 study. *PAIN, 2018;159(5):987-994.* doi: 10.1097/j.pain.0000000000001174.

222. **Webster L**, Israel R. Oral Methylnaltrexone Does Not Negatively Impact Analgesia in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain. *Journal of Pain, 2018;11: 1503-1510.* https://doi.org/10.2147/JPR.S160488

223. Setnik B, Sommerville KW, Pixton GC, **Webster L**. Extended-release morphine sulfate and naltrexone hydrochloride (EMBEDA): naltrexone associated effects in patients with chronic pain and recreational opioid users. *Current Medical Research and Opinion,2018; 20: 1-10.*

doi: 10.1080/03007995.2018.1533457

224. Burns, L., Friedmann N, Marsman, M, Kater A, **Webster L**. A nasal abuse potential randomized clinical trial of REMOXY(R) ER, a high- viscosity extended-release oxycodone formulation. *Journal of Opioid Management*, 2018; 14(6): 437-443. DOI: http://dx.doi.org/10.5055/jom.2018.0476

225. Visvikis-siest S, Gorenjak V, Stathopoulou M, Petrelis A, Weryha G, Masson C, Hiegel B, Kumar S, Barouki R, Boerwinkle E, Dagher G, Deloukas P, Innocenti F, Lamont J, Marschler M, Meyer H, Meyer U, Nofziger C, Paulmichl M, Vacher C, **Webster L**. The 9th Santorini Conference: Systems Medicine, Personalized Health and Therapy. "The Odyssey from Hope to Practice", Santorini, Greece, 30 September–3 October 2018. *Journal of Personalized Medicine,2018, 8(43), 1-12.* doi:10.3390/jpm8040043

226. Bass A, **Webster** LR, Matschke KT, Malhotra B, Wolfram G. Effects of intravenous oxycodone alone or in combination with naltrexone on measures of respiratory depression: a randomized placebo-controlled study.*Therapeutic Advances in Drug Safety, 2019, 10, 01 January 2019.* https://doi.org/10.1177/2042098618821274

227. Cicero TJ, Mendoza M, Cattaneo M, Dart R, Mardekian J, Polson M, Roland CL, Schnoll S, **Webster LR** & Park PW. Real-world misuse, abuse, and dependence of abuse deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. *Postgraduate Medicine*, 22 Feb 2019. DOI: 10.1080/00325481.2019.1585688

228. Zebala J, Searle S, **Webster LR,** Johnson M, Schuler A, Maeda D, Kahn S. Desmetramadol has the Safety and Analgesic Profile of Tramadol Without Its Metabolic Liabilities: Consecutive Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Trials. *The Journal of Pain,* 18 Apr 2019. DOI: https://doi.org/10.1016/j.jpain.2019.04.005

229. **Webster, L.R**., Kinzler, E.R., Pantaleon, C. , Iverson M., Aigner S. Relative Oral Bioavailability of an Abuse-Deterrrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study. *Advances in Therapy,* 07 May 2019. https://doi.org/10.1007/s12325-019-00963-0

230. **Webster L,** Schmidt WK. Dilemma of Addiction and Respiratory Depression in the Treatment of Pain: A Prototypical Endomorphin as a New Approach. *Pain Medicine*, June 5, 2019. pii: pnz122. doi: 10.1093/pm/pnz122.

231. Zaho X, Shah D ,Gandhi K, Wei. W, Dwibedi N, **Webster L**, Sambamorrthi U. The association of pain interference and opioid use with healthcare utilization and costs, and wage

loss among adults with osteoarthritis in the United States. *Journal of Medical Economics,* 21 August 2019: 22(11). https://doi.org/10.1080/13696998.2019.1658590

232. Zaho X, Shah D ,Gandhi K, Wei. W, Dwibedi N, **Webster L**, Sambamorrthi U. Clinical, humanistic, and economic burden of osteoarthritis among non institutionalized adults in the United States. *Osteoarthritis and Cartilage*, November 2019: 27 (11), 1618-1626. https://doi.org/10.1016/j.joca.2019.07.002

233. **Webster L**, Gudin J, Raffa R, Kuchera J, Rauck R, Fudin J, Adler J, Mallick-Searle T. Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion. *Pain Medicine,* pnz356, January 09, 2020. https://doi.org/10.1093/pm/pnz356

234. Shah D, Zhao X, Wei W, Gandhi K, Dwibedi N, **Webster L** Sambamoorthi U. A Longitudinal Study of the Association of Opioid Use with Change in Pain Interference and Functional Limitations in a Nationally Representative Cohort of Adults with Osteoarthritis in the United States. *Advances in Therapy*, February 2020: 37(2), 819-832. https://doi.org/10.6084/m9.figshare.11353643.

235. **Webster L.** Strengths and Weakness of Atypical Opioids. *Doximity*, March 3, 2020, https://opmed.doximity.com/articles/strengths-and-weakness-of-atypical-opioids.

236. Wild J, **Webster LR**, Yamada T, Hale. M Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥ 65 Years of Age. *Drugs Aging*, February 21, 2020, https://link.springer.com/article/10.1007/s40266-020-00753-2#article-info

237. Wild J, **Webster LR**, Hale M, Yamada T, Wild J. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy, March 25, 2020, https://www.dovepress.com/a-renal-impairment-subgroup-analysis-of-the-safety-and-efficacy-of-nal-peer-reviewed-article-JPR

238. Webster, L.R., Hansen, E., Cater, J. *et al.* A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive. *Adv Ther* 37, 4685–4696 (2020). https://doi.org/10.1007/s12325-020-01481-0

239. **Webster L.** *Pain News Network*, May 2, 2020. Why Coronavirus Is the Modern-Day Titanic.

240. **Webster L.** *Pain News Network*, Chronic Pain vs. COVID-19: Why Is Treating One Disease More Noble Than the Other?, May 9, 2020.

241. Relistor reduces mortality in patients with opioid-induced constipation. *Healio Gastroenterology.* May 11, 2020.

242. **Webster L.** *Pain News Network*, Where Are You Most Likely to Contract COVID-19?, May 16, 2020.

243. **Webster L.** *Pain News Network*, Why We Need Connections, May 23, 2020.

244. **Webster L.** *Pain News Network*, A Tribute to My Father and the Greatest Generation, May 30, 2020.

245. **Webster L.** *Pain News Network*, Pain, Protests and Prejudice, June 6, 2020.

246. **Webster L.** *Pain News Network*, White Privilege and People in Pain, June 27, 2020.

247. **Webster L.** *Pain News Network*, New Podcast Discusses Pain and Politics, July 11, 2020.

248. **Webster L.** *Pain News Network*, Honoring Black Pioneers in Medicine, July 18, 2020.

249. **Webster L.** *Pain News Network*, New Podcast Discusses Pain and Politics, July 11, 2020.

250. **Webster L.** *Pain News Network*, 'First, Do No Harm' Doesn't Mean 'No Rx Opioids,' July 25, 2020.

251. **Webster L.** *Pain News Network*, Genetic Studies Could Pave the Way to New Pain Treatments, August 1, 2020.

252. **Webster L.** *Pain News Network*, How to Say Goodbye When Someone Is Dying, August 8, 2020.

253. **Webster L.** *Pain News Network*, What Is the Best Kind of Face Covering?, August 15, 2020.

254. **Webster L.** *Pain News Network*, Developing a Covid-19 Vaccine Requires Patience, August 22, 2020.

255. **Webster L.** *Pain News Network*, CDC Is Prioritizing Politics Over Science, August 29, 2020.

256. **Webster L.** *Pain News Network*, Election May Determine Whether Marijuana Will Be Decriminalized, September 5, 2020.

257. Pesic, Marija, Schippers, Frank, Saunders, Rob, **Webster, Lynn,** Donsbach, Martin, and Stoehr, Thomas, *European Journal of Clinical Pharmacology*, Pharmacokinetics and pharmacodynamics of intranasal remimazolam—a randomized controlled clinical trial, September 4, 2020.

258. Rauck, Richard L. and Webster, Lynn R. *Atypical Opioids and Their Effect on Respiratory Drive*. Submitted September 8, 2020.

259. **Webster L**. *Pain News Network*, Ironic Partners: Suicide Prevention and Pain Awareness Month, September 19, 2020.

260. Camilleri, Michael, Hale, Martin, Morlion, Bart, Tack, Jan, **Webster, Lynn**, Wild, James. Submitted September 17, 2020.

261. **Webster L**. *Pain News Network*, 6 Reasons to Participate in Clinical Trials, September 26, 2020.

262. Webster, Lynn R., Hansen, Erik, Cater, Jacqueline. A Phase I Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride Administration on Respiratory Drive, October 3, 2020.

263. **Webster L**. *Pain News Network*, 6 Reasons to Participate in Clinical Trials, September 26, 2020.

264. **Webster L**. *Pain News Network*, Pre-existing Conditions Deserve Affordable Treatment, September 26, 2020.

265. Schippers F, Pesic M, Saunders R, Borkett K, Searle S, **Webster L**, Stoehr T. Randomized Crossover Trial to Compare Abuse Liability of Intravenous Remimazolam Versus Intravenous Midazolam and Placebo in Recreational Central Nervous System Depressant Users, *The Journal of Clinical Pharmacology*, June 3, 2020.

266. **Webster, Lynn**, Suzanne, Karan. The Physiology and Maintenance of Respiration: A Narrative Review, *Pain and Therapy*, October 6, 2020.

267. Gudin J, **Webster LR**, Greuber E, Vought K, Patel K, Kuritzky L. Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches

5% and Lidocaine Medicated Plaster 5% in Healthy Subjects, *Journal of Pain Research*, February 23, 2021.

268. **Webster, L**, Track J, Camilleri, M, Hale, M, Morlion, B, Nalamachu, S, Wild, J. Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation, May 6, 2021.

269. **Webster, L**, Pergolizzi Jr, Joseph V, Vortsman, Eugene, LeQuang, Jo Ann, Raffa, Robert B. Wooden Chest syndrome: The atypical pharmacology of fentanyl overdose, July 8 2021.

270. **Webster, L**, Camilleri, M, Hale, M, Morlion, B, Tack, J, Wild. Naldemedine Improves Patient-Reported Outcomes of Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain in the COMPOSE Phase 3 Studies, *Journal of Pain Research,* July 16, 2021, https://doi.org/10.2147/JPR.S282738

271. **Webster, L**, Rauck, Richard L. Atypical opioids and their effect on respiratory drive, *Journal of Opioid Management*, Vol 17, No 7, 2021.

272. **Webster, L**. The Pain Community Should Support Voter Rights, *Chronicle*, Winter 2021.

273. Barret, Andrew, C, **Webster, L**. Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of dmethylphenidate, J*ournal of Child and Adolescent Psychopharmacology*, 2021.

274. Shram MJ, Spencer RH, Qian J, Munera CL, Lewis ME, Henningfield JE, **Webster, L**, Menzaghi, F. Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users, *Clinical and Translational Science*, October 29, 2021.

275. **Webster LR**, Hansen E, Stoddard G, Rynders A, Ostler D, Lennon H. Ventilatory Response to Hypercapnia as Experimental Model to Study Effects of Oxycodone on Respiratory Depression, *Current Reviews in Clinical and Experimental Pharmacology*, 2022.

276. **Webster L**, Cater J, Smith, T. Pharmacokinetics of Buprenorphine Buccal Film and Orally-administered Oxycodone in a Respiratory Study: An Analysis of Secondary Outcomes from a Randomized Controlled Trial. *Pain Therapy,* May 7, 2022.

277. **Webster L**, Cater J, Smith, T. Effects of buprenorphine buccal film and oral oxycodone on pupil diameter in a respiratory study. *Journal of Opioid Management*, 2022.

278. **Webster L**, Shram M, Setnik B, Guenther S, Mickle T, Braeckman R, Kanski J, Martin A, Kelsh D, Vince B, Barrett A. Oral, intranasal, and intravenous abuse potential of serdexmethylphenidate, a novel prodrug of d-methylphenidate. *Curr Med Res Opin*, June 3, 20022.

279. **Webster, L**. Mobile Health Technology and Pain Management. *The Research Post*. September 1, 2022.

280. **Webster LR**, Brenner D, Israel RJ, Stambler N, Slatkin, NE, Reductions in All-Cause Mortality Associated with the Use of Methylnaltrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis, *Pain Medicine*, Volume 24, Issue 3, March 2023, Pages 341–350, https://doi.org/10.1093/pm/pnac136

281. **Webster L,** Backhaus O, Bianco A. Three recent court decisions reframe what constitutes criminal conduct in prescribing controlled substances. J Opioid Mgmt. 2023; 19(7): 17-21. DOI: 10.5055/jom.2023.0795.

282. Ceko, M, Baeuerle, T, **Webster, L**, Wager, TD, Lumley, MA. The effects of virtual reality neuroscience-based therapy on clinical and neuroimaging outcomes in patients with chronic back pain: a randomized clinical trial. *Pain*. 2024; Preprint. https://pubmed.ncbi.nlm.nih.gov/37546872/.

283. **Webster L**, Gudin J. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access. *J Pain Res*. 2024;17:1989-2000. https://doi.org/10.2147/JPR.S457982

284. **Webster, Lynn R**. The Impact of Medication Adherence on Health Outcomes and Cost Reduction. *Journal of Opioid Management.* vol. 21, no. 3, June 2025, pp. 193-5, https://wmpllc.org/ojs/index.php/jom/article/view/3870/.

285. **Webster, Lynn**. Continued Blaming of Purdue Pharma Won't Solve the Opioid Crisis, *Pain News Network,* July 23, 2025. https://www.painnewsnetwork.org/stories/2025/7/23/continued-blaming-of-purdue-pharma-wont-solve-the-opioid-crisis

286. **Webster, Lynn R**. Postmarketing Research for Opioid Abuse-Deterrent Formulations: A Narrative Review, *Journal of Pain Research*, August 9, 2025. https://doi.org/10.2147/JPR.S519421

287. **Webster, Lynn R**. Beyond Financial Disclosure: Rethinking Conflicts of Interest in Science and Policy, *Pain Medicine News*, August 15, 2025.

https://www.painmedicinenews.com/Commentary/Article/08-25/Beyond-Financial-Disclosure-Rethinking-Conflicts-of-Interest-in-Science-and-Policy/77870

288. Webster LR. Long-Term Pain Therapy With Opioids. JAMA. Published online December 22, 2025. doi:10.1001/jama.2025.21043

289. Webster LR. From Purity to Proportionality: Managing Nonfinancial Conflicts of Interest in Pain Medicine, *Pain Medicine*, February 2, 2026. https://doi.org/10.1093/pm/pnag018

290. Webster LR. Why Cutting Opioid Prescriptions Didn't Stop the Overdose Crisis, *Psychreg*, June 16, 2026

291. Webster, L. Tailoring Technology for Pain Management: A Qualitative Comparison of Digital Health Platforms, *Pain Management Nursing*. Volume 26, Issue 2, April 2025, Page e221. https://www.sciencedirect.com/science/article/abs/pii/S1524904225000499

292. Enhancing Pain Management Through Mobile Health Technology: A Value-Driven Approach. *Pain Management Nursing.* Volume 27, Issue 2, April 2026, Pages e232-e233.

293. Fauci Senate Hearing: The Fifth, the Feud, and the Facts. American Council on Science and Health. July 31, 2026. https://www.acsh.org/news/2026/07/31/fauci-senate-hearing-fifth-feud-and-facts-50259

294. The Opioid Crisis Is Driven by Demand, Not Just Supply. The Good Men Project. July 13, 2026. https://goodmenproject.com/everyday-life-2/the-opioid-crisis-is-driven-by-demand-not-just-supply/

295. Opinion: Fewer overdoses don't signal end of Connecticut's opioid crisis.

***ABSTRACTS* & POSTERS**

1. **Webster LR**, Piping R, Stanley TH, Razecca K. White blood cell phagocytosis after artificial heart implantation. The 24th Annual Meeting of the American Society for Artificial Internal

Organs; April 27 – 29, 1978; Chicago, IL.

2. **Webster LR**, Stanley TH. Plasma corticol and ADH concentrations after artificial heath implantation. The 24th Annual Meeting of the American Society for Artificial Internal Organs; April 27 – 29, 1978; Chicago, IL.

3. **Webster LR**, Lunn J, Stanley TH. Arterial blood pressure and pulse rate responses to pulmonary artery catheterization prior to cardiac and major vascular surgery. Abstract in: 1978 ASA Annual Meeting proceedings. 1978; 7:577.

4. **Webster LR**, Stanley TH, Liu WS, Port D, Johansen R. Comparison of intravenous nitroglycerin and sodium nitroprusside on hypoxia pulmonary vasoconstriction. Abstract in: 1978 ASA Annual Meeting proceedings. 1978; 7:67-68.

5. **Webster LR,** Stanley TH, Razecca K, Port D. Comparison of cardiopulmonary bypass with membrane and bubble oxygenerators on leukocyte phagocytosis during halothane anesthesia. Abstract in: 1978 ASA Annual Meeting proceedings. 1978; 7:95-96.

6. **Webster LR**, Stanley TH, Woodward A. High dose fentanyl and anesthesia for open heart surgery: plasma fentanyl concentrations and influence of N20 on cardiovascular dynamics. Abstract in: 1978 ASA Annual Meeting proceedings. 1978; 7:583-584.

7. **Webster LR**, Liu WS, Stanley TH, Johansen R. Cardiovascular effects of anesthetic doses of intravenous methadone in dogs. Abstract in: 1978 ASA Annual Meeting proceedings. 1978; 7:37-38.

8. **Webster LR**, Stanley TH, Razecca K, Paping R, Jarvik R, Wolff WK. Electrical and pneumatic artificial hearts on phagocytosis. The 31st Annual Conference in Engineering and Biology; October 1978; Atlanta, GA.

9. Wong KC, Ohmura A, Roberts TH, **Webster LR**, Cook GL. Anesthetic Management for Separation of Craniopagus Twins. Anesthesia & Analgesia; November 1980; 59:11.

10. **Webster LR**. Radical prostatectomy. The 14th Annual Meeting of the American Pain Society (APS); November 10-13, 1995; Los Angeles, CA.

11. **Webster LR**, Liu WS, Stanley TH. Comparison of cardiovascular effects of nitroglycerin before and during morphine-nitrous oxide anesthesia. The 19th Annual Meeting of the American Pain Society (APS); November 2 – 5, 2000; San Diego, CA.

12. **Webster L**, Henderson R, Katz N, Ellis D. Characterization of confusion, an adverse event associated with intrathecal study medication infusion in chronic pain patients. Poster #233; The 19th Annual Meeting of the American Pain Society (APS); November 2 – 5, 2000; San Diego, CA.

13. **Webster LR**. Addiction liability assessment. The 4th Annual Conference on Pain Management and Chemical Dependency; December 7 – 9, 2000; Washington, DC.

14. **Webster LR**. Characterization of confusion: an adverse event associated with intrathecal zicontide infusion in chronic pain patients. The 17th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 14-18, 2001; Miami Beach, FL.

15. Leong M, **Webster L**, Ellis D, Gaeta R. Identification of an effective and well-tolerated dose range for Ziconotide, a novel non-opioid intrathecal analgesic for chronic pain. The 37th Annual Meeting of the American Society of Clinical Oncology; May 12 – 15, 2001; San Francisco, CA.

16. **Webster L**, Gaeta R, Leong M, Ellis D. Ziconotide efficacy in patients with chronic intractable pain of malignant origin: efficacy as a function of patient characteristics. Abstract #1550; The 37th Annual Meeting of the American Society of Clinical Oncology; May 12 – 15, 2001; San Francisco, CA.

17. **Webster LR**, Gaeta R, Leong MS, Ellis D. Study medication efficacy in patients with chronic intractable pain of malignant origin: efficacy as a function of patient characteristics. The 37th Annual Meeting of the American Society of Clinical Oncology; May 12 – 15, 2001; San Francisco, CA.

18. **Webster LR**, George K. Modafinil Treatment in patients with opiate-induced sedation. The 22nd Annual Scientific Meeting of the American Pain Society (APS); March 20 – 23, 2003; Chicago, IL.

19. **Webster LR**, Chun SY, Reinking J, Stegman M, Taylor D. Oral transmuscosal fentanyl citrate (OTFC) for the treatment of chronic noncancer pain: a retrospective survey of 100 patients. The 20th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 3 – 7, 2004; Orlando, FL.

20. **Webster LR**. Efficacy of intrathecal ziconotide for the treatment of severe chronic pain in adults. The 21st Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23 – 27, 2005; Palm Springs, CA.

21. **Webster LR**, Taylor DR, Peppin JF, Niebler G. Open-label study of fentanyl effervescent buccal tablets in patients with noncancer pain and breakthrough pain: patient reference assessment. The 22nd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 22 – 25, 2006; San Diego, CA.

22. **Webster LR**, Peppin Jf, Messina J, Martin H. Open-label study of fentanyl effervescent buccal tablets in patients with chronic pain and breakthrough pain: interim safety results. The 22nd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 22 – 25, 2006; San Diego, CA.

23. **Webster LR**, Fakata K, Grant BJB, Stoddard G. Patterns of sleep-disordered breathing in chronic pain patients on opioid therapy vs. primary care patients not on opioid therapy. The 22nd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 22 – 25, 2006; San Diego, CA.

24. **Webster LR**, Grant BJB, Youngmi C. Sleep apnea associated with methadone and benzodiazepine therapy. The 22nd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 22 – 25, 2006; San Diego, CA.

25. **Webster LR**, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex has minimal physical dependence and improved safety vs. Oxycodone in phase III clinical trial in low back pain. The 25th Annual Meeting of the American Pain Society (APS); May 3 – 6, 2006; San Antonio, TX.

26. **Webster LR**. Correlation of symptom relief with global improvement of opioid induced bowel dysfunction: results of a phase IIb study of the PAM0OR antagonist, Alvimopan in non-cancer pain. The 23rd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 7 – 10, 2007; New Orleans, LA.

27. **Webster LR**, Hale M, Peppin J, Xie F, Messina J. Fentanyl buccal tablet (FTB) in the management of opioid-tolerant patients with non-cancer related breakthrough pain: an interim analysis of a long-term safety and tolerability study. The 23rd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 7 – 10, 2007; New Orleans, LA.

28. **Webster LR**, Veeramachaneni S, Choi Y, et al. Titration and auto-adjusting CPAP in patients with obstructive sleep apnea. The 26th Annual Meeting of the American Pain Society (APS); May 5 – 7, 2007; Washington, DC.

29. **Webster LR**, Taylor D, Messina J, Xie F. Multi-study analysis of patients' preference for fentanyl buccal tablet (FBT) in the management of breakthrough pain. The 2007 Annual Meeting of the American Conference on Pain Medicine; June 15 – 16, 2007; New York City,

NY.

30. **Webster LR**, Medve R, Backer R. Evaluation of proprietary algorithm to provide a clinical adjunct to predicting dose compliance. The 7th International Conference on Pain and Chemical Dependency; June 21-24, 2007; New York City, NY.

31. **Webster LR**. A retrospective review of initial motives for seeking opioids as reported by patients being treated for opioid addiction. Poster 166; The 24th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 12-16, 2008; Orlando, FL.

32. **Webster LR**, Medve R, Berk B, Dick C, Behl C. A pilot study to select a dose of Naltrexone hydrochloride that will reduce subjective euphoric effects of Oxycodone hydrochloride in non-dependent, opioid-preferring subjects. Poster 158; The 24th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 12-16, 2008; Orlando, FL.

33. **Webster LR**. A retrospective review of initial motives for seeking opioids as reported by patients being treated for opioid addiction. The 24th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 12 – 16, 2008; Orlando, FL.

34. **Webster LR**, Gazda SK, Medoff Jr, Tobias J, VanHove GF. NGX-4010 in painful diabetic neuropathy. The 60th Annual Meeting of the American Academy of Neurology (AAN); April 12 – 19, 2008; Chicago, IL.

35. **Webster LR**, Nalamachu S, Messina J, Xie F. Long-term dosing, safety, and tolerability of fentanyl buccal tablet (FBT) in the management of breakthrough pain (BTP). The 12th World Congress on Pain; August 17 – 22, 2008; Glasgow, Scotland.

36. **Webster L**, Kelen R, Richards P, Stern W. Dual opioid treatment of acute postoperative pain: a double-blind, placebo-controlled study. The 2008 Annual Meeting of the American Society of Anesthesiologists (ASA); October 20, 2008; Orlando, FL.

37. **Webster LR**, Kelen R, Richards P, Stern W. Dual-opioid treatment of acute postoperative pain: a double-blind, placebo-controlled study. The 2008 Annual Meeting of the American College of Nurse Practitioners; October 29–November 2, 2008; Nashville, TN.

38. **Webster LR**. Prospective study to evaluate the opioid sparing effects of Prialt and hydromorphone in combination therapy v. intrathecal (IT) hydromorphone. The 8th International Conference on Pain and Chemical Dependency (ICPCD); October 29 – November 1, 2008; Philadelphia, PA.

39. **Webster LR**, Brewer RP, Sekora D, Morris D, Stauffer J. Long term safety of ALO-01 (Morphine sulfate extended release with sequestered Naltrexone Hydrochloride) capsules in patients with chronic, moderate to severe, non-malignant pain. The 19th Annual Conference of the National Association of Drug Diversion Investigators (NADDI); November 11 – 14, 2008; Nashville, TN.

40. **Webster LR**. Clinical implications of Ziconotide stability: a case report. The 12th Annual Meeting of the North American Neuromodulation Society (NANS); December 4 – 7, 2008; Las Vegas, NV.

41. **Webster LR**, Bath B, Medve RA, Jessing K, Mueller AL, Jackson A. The effect of different Cmax/Tmax ratios on euphoria following oral Oxycodone dosing in opioid experienced, non-dependent, recreational drug users. The 25th Annual Meeting of the American Academy of Pain Medicine (AAPM); January 27 – 31, 2009; Honolulu, HI.

42. **Webster LR**. A high concentration capsaicin patch, in painful diabetic neuropathy (PDN). The 25th Annual Meeting of the American Academy of Pain Medicine (AAPM); January 27 – 31, 2009; Honolulu, HI.

43. **Webster LR**, Schultz D, Bijwadia J, Bath B, Treacy M, Grant BJB. A prospective evaluation of the prevalence of sleep disordered breathing in patients on stable treatment for chronic pain. The 25th Annual Meeting of the American Academy of Pain Medicine (AAPM); January 27 – 31, 2009; Honolulu, HI.

44. **Webster L**, Kelen R, Richards P, Stern W. Dual-opioid treatment of acute postoperative pain: a double-blind, placebo-controlled study. The 25th Annual Meeting of the American Academy of Pain Medicine (AAPM); January 27 – 31, 2009; Honolulu, HI.

45. **Webster LR**, Richards P. Safety, tolerability and efficacy of dual opioids for acute postoperative bunionectomy pain. The 2009 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS); February 25 – 28, 2009; Las Vegas, NV.

46. **Webster LR**, Dhar S. NKTR-118 significantly reverses opioid-induced constipation. Poster 39; The 20th Annual Clinical Meeting of the American Academy of Pain Management; October 8 – 11, 2009; Phoenix, AZ.

47. **Webster LR**, Blonsky ER, Matz P, Levinsky D, Martz R, Dhar S, Neumann T, Eldon M, Patrick T. Efficacy, safety and pharmacokinetics of oral NKTR-118 in patients with opioid-induced constipation: results of a randomized, double-blind, placebo-controlled phase 2 study. The 2009 Annual Clinical Meeting of the American College of Gastroenterology (ACG);

October 23–28, 2009; San Diego, CA.

48. Bennett D, **Webster L**, Lampert BA, Lubenow TR, Sharan A, Whiten D, Jaax KN. Occipital nerve stimulation: surgical technique and outcomes from the PRISM study of ONS for drug-refractory migraine. Poster 1DA54; The 13th Annual Meeting of the North American Neuromodulation Society (NANS); December 3 – 6, 2009; Las Vegas, NV.

49. **Webster LR**, Blonsky ER, Matz P, Levinsky D, Martz III R, Dhar S, Neumann TA, Marcadis I, Masuoka L. Once daily oral NKTR-118 improves gastrointestinal function in patients with opioid-induced constipation without reversing analgesia: results of a randomized, double-blind, placebo-controlled phase 2 study. Poster #17; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

50. **Webster LR**, Dove B, Murphy AG. Select medical-legal reviews of unintentional overdose deaths. Poster #73; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

51. Cochella S, Rolfs R, Johnson E, Bateman K, Rose T, Dove B, Murphy AG, **Webster LR**. The effect of academic detailing on curbing opioid-related deaths in Utah. Poster #82; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

52. Jones B, Talbott AP, Murphy AG, **Webster LR**. Comparison of the theoretical cost of morphine and Prialt® IT therapies with oral brand or generic medication for chronic pain. Poster #102; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

53. Larsen CP, Murphy AG, **Webster LR**. Costs of oral pain medications pre-IT pump implantation compared to post-IT pump implantation: a retrospective analysis. Poster #103; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

54. Couto JE, Webster L, Romney M, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to an OxyContin regimen. Poster #117; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

55. **Webster LR**, Tran J, Wilson P, Lu B, Jang N, Tobias JK, Vanhove GF. Tolerability of treatment with NGX-4010 in conjunction with pre-patch topical application of a Lidocaine 2.5% / Prilocaine 2.5% anesthetic cream. Poster #118; The 26th Annual Meeting of the

American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

56. **Webster LR**, Peppin J, Murphy FT, Tobias JK, VanHove GF. Tolerability of NGX-4010 in conjunction with three topical anesthetic formulations for the treatment of neuropathic pain. Poster #119; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

57. Romney M, **Webster L**, Couto JE, Leider HL, Linden A. Use of an algorithm applied to urine drug screening to assess adherence to a Hydrocodone regimen. Poster #127; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

58. Bateman K, Cochella S, Dasgupta N, Dove B, Fakata KL, Fine PG, Fishman SM, Grey T, Johnson E, Lee LK, Murphy AG, Passik SD, Peppin J, Porucznik CA, Ray A, Rolfs R, Schnoll SH, Stieg R, **Webster L**. Root cause analysis for unintentional overdose deaths involving opioids in chronic pain patients reveals disproportionate methadone involvement. Poster #139; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

59. **Webster LR**. The effect of different PK parameters on euphoria and liking following different oral Hydromorphone formulations in opioid-experienced, non-dependent, recreational drug users. Poster #183; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

60. Lee KW, Brown J, **Webster L**, Siegel S, Roland C, Setnik B, Katz N. A clinical trial to assess, stratify and monitor the risk of prescription opioid abuse and misuse in the primary care setting. Poster #200; The 26th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 3 – 6, 2010; San Antonio, TX.

61. **Webster L**, Owen J, Darling I, Richards P, Kelen R, Stern W. Single-dose and steady-state pharmacokinetics of MoxDuo, a dual-opioid formulation containing a fixed ratio of morphine and oxycodone. Poster #298; The 29th Annual Scientific Meeting of the American Pain Society (APS); May 6-8, 2010; Baltimore, MD.

62. **Webster L**, Richards P, Kelen R, Warren S. Efficacy and tolerability of dual-opioid treatment with Morphine plus Oxycodone (MoxDuo) for acute postoperative pain. Poster #300; The 29th Annual Scientific Meeting of the American Pain Society (APS); May 6-8, 2010; Baltimore, MD.

63. **Webster LR**, Malan TP, Tuchman MM, Mollen MD, Tobias JK, Biao L, Vanhove GF. Duration of treatment response to Qutenza (NGX-4010), a high-concentration capsaicin patch,

in patients with post-herpetic neuralgia. The Third International Congress on Neuropathic Pain (NeuPSIG); May 27 – 30, 2010; Athens, Greece.

64. Lee LK, McCarty D, Haddox JD, J Fitzgerald, Wakeland W, **Webster** L. Non-prescribed use of Vicodin and OxyContin among U.S. youth. Poster #369; The 72nd Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 12 – 17, 2010; Scottsdale, AZ.

65. Wakeland W, Lee L, McCarty D, Haddox JD, Fitzgerald J, Gilson A, Homer J, Macovsky L, **Webster L**. Data gaps regarding diversion and abuse of prescription opioid analgesics. Poster #699; The 72nd Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 12 – 17, 2010; Scottsdale, AZ.

66. **Webster LR**, Irving G, Backonja MM, Tobias JK, Vanhove GF. Weekly response to NGX-4010, an 8% capsaicin patch, in patients with post-herpetic neuralgia: results of integrated analysis. Poster PH 094; The 13th Annual World Congress on Pain; August 29 – September 2, 2010; Montreal, Quebec, Canada.

67. Simpson DM, Backonja M, Irving G, **Webster LR**, Tobias JK, Vanhove GF. Efficacy of NGX-4010, an 8% capsaicin patch in patients with post-herpetic neuralgia, HIV-associated distal sensory polyneuropathy or painful diabetic neuropathy. Poster PW 104; The 13th Annual World Congress on Pain; August 29 – September 2, 2010; Montreal, Quebec, Canada.

68. Quiding H, **Webster L**, Jonzon B, Karin A, Karlsten R, Reimfelt A, Svensson O, Segerdahl M. Effects of the TRPV1 antagonist AZD1386 in patients with pain after third molar extraction. Poster #PN 373; The 13th Annual World Congress on Pain; August 29 – September 2, 2010; Montreal, Quebec, Canada.

69. **Webster LR**, Bath B, Medve R, Marmon T. The effect of pharmacokinetic parameters on euphoria and drug liking following different oral hydromorphone formulations in opioid-experienced, non-dependent, recreational drug users. Poster #182; PAINWeek 2010; September 8-11, 2010; Las Vegas, NV.

70. **Webster LR**, Rauck R, Rosenblum SM, Wallace MS. Long-term intrathecal ziconotide for severe chronic pain: an open-label, multicenter extension study. Poster #64; The 2010 Annual Pain Medicine Meeting & Workshops of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 18-21, 2010; Phoenix, AZ.

71. **Webster LR**, Brewer R, Morris D, Cleveland JM, Setnik B. Incidence and prevalence of adverse advents in an open-label, long-term safety study of morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic, moderate-to-severe pain. Poster #168; The 27th Annual Meeting of the American Academy of Pain Medicine (AAPM);

March 24-27, 2011; Washington, DC.

72. **Webster LR**, Brewer R, Morris D, Cleveland JM, Setnik B. Attainment of stable dose of morphine sulfate and naltrexone hydrochloride extended release capsules by patients with chronic, moderate to severe pain. Poster #169; The 27th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 24-27, 2011; Washington, DC.

73. **Webster LR**, Bath B, Medve R, Marmon T. The effect of pharmacokinetic parameters on euphoria and drug liking following different oral hydromorphone formulations in opioid-experienced, nondependent, recreational drug users. Poster #170; The 27th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 24-27, 2011; Washington, DC.

74. **Webster LR**, Freyer A, Rodzvilla J, Reeves R, Mack RJ. A double-blind, placebo-controlled, crossover evaluation of the analgesic effects of REC1100 in chronic low back pain patients. Poster #171; The 27th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 24-27, 2011; Washington, DC.

75. Johnson SC, Denna S, Fakata KL, **Webster LR**. Opioid induced hyperalgesia and monotherapy Intrathecal ziconotide (Prialt). Poster #172; The 27th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 24-27, 2011; Washington, DC.

76. Yancey-Wrona J, Dallaire B, **Webster LR**, Burkart JA, Magiera D, Bilsky E, Sadee W. 6β-Naltrexol: a peripherally selective, potent, and well-tolerated antagonist prevents opioid-induced gastrointestinal slowing in human subjects. Poster #275; The 27th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 24-27, 2011; Washington, DC.

77. Sommerville KW, **Webster LR**, Rolleri RL, Pixton GC. Relative abuse potential of oxycodone HCI and oxycodone HCI/niacin tablets in non-dependent recreational opioid users. Abstract #S59-004; The 63rd Annual Meeting of the American Academy of Neurology; April 9–16, 2011; Honolulu, HI.

78. **Webster LR**, Goli V, Lamson MJ, Carter E. Mitigation of $EtCO_2$, a surrogate measure of respiratory depression, after intravenous injection of morphine sulfate and naltrexone hydrochloride. The 73rd Annual Meeting of The College on Problems of Drug Dependence; June 18-23, 2011; Hollywood, Florida.

79. Vickery R, Yu-Ping L, Kohler R, **Webster L**, Singla N, Daniels O. TD-1211 demonstrates peripheral selectivity and constipation-relieving effects in patients with opioid-induced constipation. Poster #0215; PAINWeek 2011; September 7–10, 2011; Las Vegas, NV.

80. **Webster L**, Iverson M, Medve R, Odinecs A, Eldon MA. Pharmacokinetics and pharmacodynamics of Oral NKTR-181, a novel opioid analgesic: results of a single ascending dose phase 1 study. The 22nd Annual Meeting of the American Academy of Pain Management; September 20-23, 2011; Las Vegas, NV.

81. Tobias JK, **Webster LR**, Smith G, Bley K, Vanhove GF. Effect of application duration of a new topical capsaicin liquid on epidermal nerve fiber density and sensory function. The 7th Congress of the European Federation of IASP© Chapters (EFIC); September 21 – 24, 2011; Hamburg, Germany.

82. Vickery R, Li YP, Kohler R, **Webster L**, Singla N, Daniels O. TD-1211 demonstrates constipation-relieving effects, including decrease in rescue laxative use, in patients with opioid-induced constipation. The 2011 Annual Scientific Meeting of the American College of Gastroenterology (ACG); October 28–November 2, 2011; Washington, DC.

83. Setnik B, Roland CL, Cleveland JM, Veeraindar G, Sommerville K, **Webster L**. Evaluating the effects of single-dose administration of crushed and whole morphine sulfate extended-release with a sequestered core of naltrexone hydrochloride on the induction of clinical opiate withdrawal signs and symptoms in opioid-dependent patients with chronic, non-cancer pain. The 10th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia (ASRA); November 17-20, 2011; New Orleans, LA.

84. Setnik B, Roland CL, Cleveland JM, Veeraindar G, **Webster L**. Self-reports of prescription opioid misuse, abuse and diversion in a sample of non-dependent, recreational opioid users. The 10th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia (ASRA); November 17-20, 2011; New Orleans, LA.

85. Setnik B, Cleveland JM, Sommerville K, Goli V, **Webster L**. Assessing the abuse potential of crushed morphine sulfate extended-release with sequestered Naltrexone hydrochloride compared to crushed morphine sulfate controlled-release tablets and placebo in non-dependent, recreational opioid users following oral administration. The 10th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia (ASRA); November 17-20, 2011; New Orleans, LA.

86. Backonja M, Irving G, **Webster L**, Vanhove GF, Tobias JK. Efficacy of NGX-4010, a prescription strength capsaicin 8% patch for the treatment of postherpetic neuralgia, across a range of patient populations. The 10th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia (ASRA); November 17-20, 2011; New Orleans, LA.

87. Schultz DM, **Webster L**, Kosek P, Sun M, Tan Y, Robischon M. Efficacy and convenience of position-adaptive stimulation: results of the RestoreSensor Study. Poster #96; The 15th Annual

Meeting of the North American Neuromodulation Society (NANS); December 8–11, 2011; Las Vegas, NV.

88. **Webster L**, Schultz D, Roberts J, Basu S, Skelton D, Panken E, Sun M, Tan Y, Robischon M. Results of the RestoreSensor study: assessment of device programming for position-adaptive spinal cord stimulation. Poster #115; The 15th Annual Meeting of the North American Neuromodulation Society (NANS); December 8–11, 2011; Las Vegas, NV.

89. Schultz DM, **Webster L**, Tan Y, Skelton D, Panken E, Sun M. Spinal cord stimulation amplitude varies significantly with changes in body position: results of the RestoreSensor study. Poster #122; The 15th Annual Meeting of the North American Neuromodulation Society (NANS); December 8–11, 2011; Las Vegas, NV.

90. Schultz DM, **Webster L**, Tan Y, Skelton D, Sun M, Panken E. Results of the RestoreSensor study: spinal cord stimulation therapy impedance does not vary significantly with changes in body position. Poster #123; The 15th Annual Meeting of the North American Neuromodulation Society (NANS); December 8–11, 2011; Las Vegas, NV.

91. **Webster L**, Schultz D, Kosek P, Sun M, Tan Y. Assessment of device programming and other patient and physician-reported benefits of positive-adaptive spinal cord stimulation (SCS). Poster #PP666; The 6th World Congress on Pain of the World Institute of Pain; February 4-6, 2012; Miami Beach, FL.

92. Schultz D, **Webster L**, Sun M, Tan Y. Variations in spinal cord stimulation (SCS) amplitude and impedance: results of the Restore Sensor Study. Poster #PP667; The 6th World Congress on Pain of the World Institute of Pain; February 4-6, 2012; Miami Beach, FL.

93. Schultz D, **Webster L**, Kosek P, Sun M, Tan Y. Positive-adaptive spinal cord stimulation (SCS) for chronic pain: results of the Restore Sensor Study. Poster #PP668; The 6th World Congress on Pain of the World Institute of Pain; February 4-6, 2012; Miami Beach, FL.

94. Vickery R, Li YP, Beattie D, Kohler R, DeNoia E, Singla N, **Webster L**, Daniels O. TD-1211 relieves opioid-induced constipation without interfering with centrally-mediated opioid analgesia. Poster #PP721; The 6th World Congress on Pain of the World Institute of Pain; February 4-6, 2012; Miami Beach, FL.

95. Schultz DM, **Webster L**, Kosek P, Sun M, Tan Y, Robischon M. Efficacy and convenience of position-adaptive stimulation: results of the RestoreSensor study. Poster #118; The 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23-26, 2012; Palm Springs, CA.

96. Schultz DM, **Webster L**, Tan Y, Skelton D, Panken E, Sun M. Spinal cord stimulation amplitude varies significantly with changes in body position: results of the RestoreSensor study. Poster #120; The 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23-26, 2012; Palm Springs, CA.

97. Schultz DM, **Webster L**, Tan Y, Skelton D, Sun M, Panken E. Results of the RestoreSensor study: spinal cord stimulation therapy impedance does not vary significantly with changes in body position. Poster #121; The 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23-26, 2012; Palm Springs, CA.

98. **Webster L**, Schultz DM, Roberts J, Basu S, Skelton D, Panken E, Sun M, Tan Y, Robischon M. Results of the RestoreSensor study: assessment of device programming for position-adaptive spinal cord stimulation. Poster #153; The 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23-26, 2012; Palm Springs, CA.

99. **Webster LR**, Iverson M, Mackin S, Hollingsworth R. Comparison of morning and evening dosing of extended-release hydromorphone on sleep disordered breathing in patients with low back pain. Poster #282A; The 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23-26, 2012; Palm Springs, CA.

100. **Webster L**, Odinecs A, Herzog S, Eldon MA, Medve R. Multiple dose pharmacokinetics and pharmacodynamics of the new oral opioid analgesic NKTR-181. Poster #282B; The 28th Annual Meeting of the American Academy of Pain Medicine (AAPM); February 23-26, 2012; Palm Springs, CA.

101. Lawitz E, Hill J, Marbury T, Hazan L, Gruener D, **Webster L**, Majauskas R, Morrison R, DeMicco M, German P, Stefanidis D, Svaroskaia E, Arterburn S, Ray A, Rossi S, McHutchinson J, Rodriguez-Torres M. GS-6620, a liver-targeted nucleotide prodrug, exhibits antiviral activity and favorable safety profile over 5 days in treatment naive chronic HCV genotype 1 subjects. The 47th Annual Meeting of the European Association for the Study of the Liver (EASL); April 18-22, 2012; Barcelona, Spain.

102. Schnoll SH, Fant RV, Buchhalter AR, **Webster L**. Novel formulations and mechanisms of action for pain medications: new challenges to human abuse liability assessment and drug scheduling. Poster #200; The 31st Annual Meeting of the American Pain Society (APS); May 16–19, 2012; Honolulu, HI.

103. **Webster L**, Wallace M, Welles B, Tobias J, Babbar S, Bhattacharya S. Efficacy and safety of NGX-1998, a novel topical liquid formulation of capsaicin, in patients with postherpetic neuralgia: results of a multi-center, placebo-controlled study. Poster #386; The 31st Annual

Scientific Meeting of the American Pain Society (APS); May 16-19, 2012; Honolulu, HI.

104. **Webster L**, Smith M, Iverson M. Abuse liability of oral formulations of hydromorphone in opioid-experienced, recreational drug users: importance of onset of effect. Poster #422; The 31st Annual Scientific Meeting of the American Pain Society (APS); May 16-19, 2012; Honolulu, HI.

105. Narayana A, Hale ME, Yang R, **Webster LR**. Consistent efficacy with fentanyl buccal tablet in the treatment of breakthrough pain in patients receiving maintenance opioid therapy for chronic, persistent, noncancer-related pain. Poster #429; The 31st Annual Scientific Meeting of the American Pain Society (APS); May 16-19, 2012; Honolulu, HI.

106. **Webster LR**, Smith M, Iverson M. Abuse liability of oral formulations of hydromorphone in opioid-experienced, recreational drug users: importance of onset of effect. Poster #4; The International Conference on Opioids (ICOO); June 10-12, 2012; Boston, MA.

107. Schultz DM, **Webster L**, Kosek P, Sun M, Tan Y. Position-Adaptive Spinal Cord Stimulation (SCS) for Chronic Pain: Results of the RestoreSensor Study. The 14th Annual Meeting of the American Society of Interventional Pain Physicians (ASIPP); June 9 - 13, 2012; Arlington, VA.

108. **Webster LR**, Smith M, Iverson M. Abuse liability of oral formulations of hydromorphone in opioid-experienced, recreational drug users: importance of onset of effect. The 27th National Conference of the American Academy of Nurse Practitioners (AANP); June 20-24, 2012; Orlando, FL.

109. Narayana A, **Webster L**, Nalamachu S, Janka L. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain: a pooled analysis of patient preference in two studies. Poster # PW 401; The 14th World Congress on Pain; August 27–31, 2012; Milan, Italy.

110. Wallace M, **Webster L**, Narayana A, Janka L. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain: a subanalysis of patients with back pain in two studies. Poster # PW 407; The 14th World Congress on Pain; August 27 – 31, 2012; Milan, Italy.

111. **Webster L**, Wallace M, Narayana A, Janka L. A 12-week, randomized, double-blind, placebo-controlled study of fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant patients with chronic noncancer-related pain: a subanalysis of patients with back pain. Poster # PW 408; The 14th World Congress on Pain; August 27 – 31, 2012; Milan, Italy.

112. Setnik B, Roland CL, Goli V, Pixton GC, Levy-Cooperman N, Smith I, **Webster LR**. Self-reports of prescription opioid abuse and diversion in two samples of nondependent recreational opioid users. Poster #92; PAINWeek 2012; September 5–8, 2012; Las Vegas, NV.

113. Vickery R, Li YP, Schwertschlag U, Singla N, **Webster L**, Canafax D. TD-1211 demonstrates improvement in bowel movement frequency without impacting analgesia in a phase 2b study of patients with opioid-induced constipation. Poster #121; PAINWeek 2012; September 5–8, 2012; Las Vegas, NV.

114. Wallace M, **Webster L**, Narayana A, Janka L. Fentanyl buccal tablet compared with immediate-release Oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain. Poster #126; PAINWeek 2012; September 5–8, 2012; Las Vegas, NV.

115. **Webster L**, Wallace M, Narayana A, Janka L. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant patients with chronic noncancer-related Pain: A subanalysis of a 12-week, randomized, double-blind, placebo-controlled study in patients with back pain. Poster #127; PAINWeek 2012; September 5–8, 2012; Las Vegas, NV.

116. **Webster L**, Smith M, Iverson M. Abuse liability of oral formulations of hydromorphone in opioid-experienced, recreational drug users: importance of onset of effect. Poster #128; PAINWeek 2012; September 5–8, 2012; Las Vegas, NV.

117. Walker MJ, **Webster L**. Risk factors for drug diversion in a pain clinic patient population. Poster #2; The 23rd Annual Clinical Meeting of the American Academy of Pain Management; September 20–23, 2012; Phoenix, AZ.

118. Vickery R, Li YP, Schwertschlag U, Singla N, **Webster L**, Canafax D. Phase 2b evaluation of TD-1211 in opioid-induced constipation. Poster #23; The 23rd Annual Clinical Meeting of the American Academy of Pain Management; September 20–23, 2012; Phoenix, AZ.

119. **Webster L**, Smith M, Iverson M. Abuse liability of oral formulations of hydromorphone in opioid-experienced, recreational drug users: importance of onset of effect. Poster #26; The 23rd Annual Clinical Meeting of the American Academy of Pain Management; September 20–23, 2012; Phoenix, AZ.

120. Hulskotte EGJ, Feng HP, Bruce RD, **Webster LR**, Xuan F, Lin W, O'Mara E, Wagner JA, Butterton JR. Pharmacokinetic interaction between HCV protease inhibitor Boceprevir and methadone or buprenorphine/naloxone in subjects on stable maintenance therapy. Poster # 1417138; Australian Gastroenterology Week (AGW) 2012; October 16–19, 2012; Adelaide,

Australia.

121. Vickery R, Li Y, Schwertschlag U, Singla N, **Webster LR**, Canafax D. TD-1211 demonstrates improvement in bowel movement frequency and Bristol Stool Scores in a phase 2b study of patients with opioid-induced constipation. Abstract #OP242B; United European Gastroenterology Week (UEGW) 2012; October 20–24, 2012; Amsterdam, Netherlands.

122. Mayers D, Vince B, Hill J, Lawitz E, O'Riordan W, **Webster L**, Gruener D, Mofsen RS, Murillo A, Donovan E, Chen J, McCarville JF, Sullivan-Bolyai JZ, Zhou XJ. IDX719, HCV NS5A Inhibitor, demonstrates pan-genotypic activity after three days of monotherapy in genotype 1, 2, 3 or 4 HCV-infected subjects. Poster # 1774; The Liver Meeting 2012: The 63rd Annual Meeting of the American Association for the Study of the Liver (AASLD); November 9 – 13, 2012; Boston, MA.

123. Schultz DM, **Webster L**, Panken E, Sun M. Spinal cord stimulation amplitude varies significantly with changes in body position: results of the RestoreSensor Study. Abstract #A31; The 11th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 15–18, 2012; Miami, FL.

124. Schultz DM, **Webster L**, Sun M, Tan Y. Automatic position-adaptive spinal cord stimulation: advantages and clinical benefits reported in the RestoreSensor study. Abstract #A32; The 11th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 15–18, 2012; Miami, FL.

125. **Webster L**, Schultz DM, Panken E, Sun M. Results of the RestoreSensor Study: Assessment of Device Programming for Position-Adaptive Spinal Cord Stimulation. Abstract #A34; The 11th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 15–18, 2012; Miami, FL.

126. Schultz DM, **Webster L**, Sun M, Tan Y. Efficacy and Convenience of Position-Adaptive Stimulation: results of the RestoreSensor study. Abstract #A125; The 11th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 15–18, 2012; Miami, FL.

127. Schultz DM, **Webster L**, Sun M, Panken E, Tan Y. Results of the RestoreSensory study: spinal cord stimulation therapy impedance does not vary significantly with changes in body position. Abstract #A126; The 11th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 15–18, 2012; Miami, FL.

128. **Webster L**, Schultz D, Sun M, Tan Y. Effect of convenience in the assessment position-adaptive stimulation: results of the RestoreSensor study. The 16th Annual Meeting of the North

American Neuromodulation Society (NANS); December 6–9, 2012; Las Vegas, NV.

129. **Webster L**, Schultz D, Sun M, Tan Y. Position-adaptive stimulation and improved pain relief: results of the RestoreSensor study. The 16th Annual Meeting of the North American Neuromodulation Society (NANS); December 6–9, 2012; Las Vegas, NV.

130. Eldon MA, Odinecs A, Herzog S, Medve R, Abrouk N, **Webster L**. New oral opioid analgesic NKTR-181 demonstrates analgesic response in cold pressor test in healthy subjects. Poster # 115; The 29th Annual Meeting of the American Academy of Pain Medicine (AAPM); April 11–14, 2013; Fort Lauderdale, FL.

131. Setnik B, Sommerville K, Goli V, Pixton G, Levy-Cooperman N, Mills C, Shram M, Smith I, Han L, **Webster L**. Assessing the pharmacodynamic effects of oral and intranasal administration of crushed extended-release morphine/naltrexone capsules versus crushed controlled-release morphine tablets and placebo in nondependent recreational opioid users. Poster # 128; The 29th Annual Meeting of the American Academy of Pain Medicine (AAPM); April 11–14, 2013; Fort Lauderdale, FL.

132. **Webster L**, Schultz D, Tan Y, Sun M. The role of convenience in the efficacy of position-adaptive stimulation: results of the RestoreSensor study. Poster # 216; The 29th Annual Meeting of the American Academy of Pain Medicine (AAPM); April 11–14, 2013; Fort Lauderdale, FL.

133. **Webster L**, Schultz D, Tan Y, Sun M. Improved pain relief with position-adaptive stimulation: results of the RestoreSensor study. Poster # 217; The 29th Annual Meeting of the American Academy of Pain Medicine (AAPM); April 11–14, 2013; Fort Lauderdale, FL.

134. Lawitz E, Gruener D, Marbury T, Hill J, **Webster L**, Hassman D, Pflanz S, Massetto B, Subramanian M, McHutchison J, Jacobson IM, Freilich B, Rodriguez-Torres M. Pharmacodynamics of oral TLR-7 agonist GS-9620 in treatment-naïve chronic hepatitis C patients. The International Liver Congress 2013 (EASL); April 24 - 28, 2013; Amsterdam, The Netherlands.

135. **Webster LR**, Schultz DM, Sun M. Position-Adaptive Stimulation and Improved Pain Relief: Results of the RestoreSensor Study. 81st Annual Meeting of the American Association of Neurological Surgeons (AANS); April 27 - May 1, 2013; New Orleans, LA.

136. Patel SK, Toscani M, **Webster L**, Volino L, Neumann C, Barone JA. Opioid risk assessment among pharmacy students. Rutgers Pharmacy Research Day 2013; April 30, 2013; Piscataway, NJ.

137. Singla N, Canafax D, Kang A, Li YP, Schwertschlag U, **Webster L**, Vickery R. TD-1211 demonstrates tolerability and clinical activity following multiple treatment administration strategies in patients with opioid-induced constipation. Poster #376; The 32nd Annual Scientific Meeting of the American Pain Society (APS); May 8 - 11, 2013; New Orleans, LA.

138. Vickery R, Li Yp, Schwertschlag U, Singla N, **Webster L**, Canafax D. TD-1211 demonstrates a durable increase in bowel movement frequency and return toward normal bowel function in a 5-week Phase 2b opioid-induced constipation study. Poster #411; The 32nd Annual Scientific Meeting of the American Pain Society (APS); May 8 - 11, 2013; New Orleans, LA.

139. Vickery R, **Webster L**, Li YP, Schwertschlag U, Singla N, Canafax D. No evidence of analgesic interference of CNS opioid withdrawal for TD-1211 in a phase 2b study in opioid-induced constipation. Poster #421; The 32nd Annual Scientific Meeting of the American Pain Society (APS); May 8 - 11, 2013; New Orleans, LA.

140. Dart R, Severtson G, Patrick J, **Webster L**. Abuse, misuse, and diversion of Hydromorphone before and after the introduction of the extended-release formulation (Exalgo). Poster #419; The 32nd Annual Scientific Meeting of the American Pain Society (APS); May 8 - 11, 2013; New Orleans, LA.

141. Vickery R, Li YP, Schwertschlag U, Singla N, **Webster L**, Canafax D. TD-1211 phase 2b study demonstrates increased bowel movement frequency and constipation-related symptom improvement in patients with opioid induced constipation. Digestive Disease Week 2013 (DDW); May 19 - 21, 2013; Orlando, FL.

142. Chey WD, **Webster L**, Sostek M, Lappalainen J, Barker PN, Tack J. Efficacy and safety of Naloxegol in patients with opioid-induced constipation: Results from 2 prospective, randomized, controlled trials. Digestive Disease Week (DDW) 2013; May 19 - 21, 2013; Orlando, FL.

143. **Webster L**, Gursahani H, Ali C, Choi I, Riggs J, Gogas K, Iverson M, Medve R, Odinecs A, Eldon M, Evans J, Quach P, Trinchero P, Hennessey M, Harrison S. A role for novel, orally available mu-opioid agonists with both centrally and peripherally mediated analgesia in the treatment of neuropathic pain. The 4th International Congress on Neuropathic Pain; May 23 – 26, 2013; Toronto, Canada.

144. Zhou XJ, Vince B, Hill J, Lawitz E, O'Riordan WO, **Webster L**, Gruener D, Mofsen RS, Murillo A, Donovan E, Chen J, Sullivan-Bolyai JZ, Mayers D. Pharmacokinetics and pharmacodynamics of IDX719, a pan-genotypic HCV NS5A inhibitor, in genotype 1, 2, 3, or 4 HCV-infected subjects. The 2013 Annual Meeting of the Asian Pacific Association for the

Study of the Liver (APASL); June 6 - 10, 2013; Singapore, China.

145. Vickery R, **Webster L**, Li YP, Schwertschlag U, Singla N, Canafax D. TD-1211 demonstrates increased bowel movement frequency with no evidence of analgesic interference or CNS opioid withdrawal in a phase 2b study in opioid induced constipation. Poster #57; The International Conference on Opioids (ICOO); June 9 – 11, 2013; Boston, MA.

146. Patel SK, Toscani M, **Webster L**, Volino L, Neumann C, Barone J. Opioid risk assessment among pharmacy students. The 2013 International Conference on Opioids (ICOO); June 9 – 11, 2013; Boston, MA.

147. **Webster L**, Smith S, Silowsky J, Gogas K, Odinecs A, Eldon MA, Abrouk N, Medve R, Henningfiled JE, Buchhalter AR, Cone EJ, Fant RV, Schnoll SH. Abuse potential assessment of novel opioid analgesic NKTR-181: implications for labeling and scheduling. Poster #21; The 2013 Annual Meeting of The College on Problems of Drug Dependence (CPDD); June 15 - 20, 2013; San Diego, CA.

148. Roland CL, Setnik B, Pixton G, **Webster L**. Measurement of drug-liking in abuse potential studies: a comparison of bipolar and unipolar visual analog scales. Poster #79; The 2013 Annual Meeting of The College on Problems of Drug Dependence (CPDD); June 15 - 20, 2013; San Diego, CA.

149. Fraser L, Yeh WW, Reitmann C, Caro L Talaty J, Guo Z, **Webster LR**, Butterton JR. Lack of PK interaction between the HCV protease inhibitor MK-5172 and methadone and buprenorphine/naloxone in subjects on stable opiate maintenance therapy. Poster #0_16; The 8th International Workshop on Clinical Pharmacology of Hepatitis Therapy; June 26 - 27, 2013; Cambridge, MA.

150. Tack J, Gralla R, **Webster L**, Sostek M, Lappalainen J, Barker PN, Chey WD. Efficacy and safety of naloxegol in patients with opioid-induced constipation (OIC): results from 2 identical phase 3, prospective, randomized, multicenter, double-blind controlled trials. Poster # MASCC-0737; 2013 MASCC/ISOO International Symposium on Supportive Care In Cancer; June 27 - 29, 2013; Berlin, Germany.

151. Bond M, Yang R, Darwish M, **Webster LR**. Evaluation of the abuse potential of an extended-release hydrocodone bitartrate tablet formulated wtih OraGuard technology in non-dependent, recreational opioid users. Poster #6; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

152. Chang S, Onojighofia T, Zoleikhaeian M, Hua M, Hubbard J, Meshkin B, Smith G, Deer T, **Webster L**, Trescott A, Sinel M. Retrospective analysis of the clinical and economic results (R.A.C.E.R.) of genotyping chronic pain patients to guide medical detoxification of

prescription opioid analgesic abuse (RxO): 2-year study. Poster #10; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

153. Chang S, Onojighofia T, Zoleikhaeian M, Hua M, Hubbard J, Meshkin B, Deer T, **Webster L**, Prescott A, Smith G, Sinel M. Observational study to calculate addictive risk to narcotics due to genetic predisposition in chronic pain patients. Poster #11; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

154. Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, **Webster L**. Relationship between oxycodone pharmacokinetics and subjective drug effects following oral administration of an immediate-release combination of oxycodone and acetaminophen and MNK-795 controlled-release oxycodone/acetaminophen (CR OC/APAP) tablets. Poster #68; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

155. Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, **Webster L**. Comparison of subjective drug effects of orally administered MNK-795 controlled-release oxycodone/acetaminophen (CR OC/APAP) tablets versus immediate-release oxycodone/acetaminophen tablets in recreational users of prescription opioids. Poster #69; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

156. Patel SK, Toscani M, **Webster L**, Volino L, Neumann C, Barone J. Opioid risk assessment among pharmacy students. Poster #118; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

157. **Webster L**, Chey WD, Tack J, Lappalainen J, Barker PN, Tummala R, Sostek M. Efficacy and safety of naloxegol in patients with opioid-induced constipation: results from 2 identical phase 3, prospective, randomized, mutlicenter, double-blind, placbo-controlled trials. Poster #120; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

158. **Webster L**, Chey WD, Tack J, Lappalainen J, Barker PN, Tummala R, Sostek M. Naloxegol efficacy in subpopulations of patients with opioid-induced constipation: results from 2 prospective randomized controlled trials. Poster #121; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

159. Vickery R, **Webster L**, Li YP, Schwertschlag U, Singla N, Canafax D. No Evidence of Analgesic Interference or CNS Opioid Withdrawal for TD-1211 in a Phase 2b Study in Opioid-Induced Constipation. Poster #124; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

160. Vickery R, Li YP, Schwertschlag U, Singla N, **Webster** L, Canafax D. TD-1211 Demonstrates a Durable Increase in Bowel Movement Frequency and Return Toward Normal Bowel Function in a 5-Week Phase 2b Opioid-Induced Constipation Study. Poster #125; PAINWeek

2013; September 4-7, 2013; Las Vegas, NV.

161. Argoff C, Nalamachu S, **Webster L**, Young C. Diclofenac submicron particle capsules reduce opioid rescue medication use in a phase 3 study in patients with acute pain following elective surgery. Poster #139; PAINWeek 2013; September 4-7, 2013; Las Vegas, NV.

162. Odinecs A, Eldon MA, Herzog S, Harite S, Medve R, **Webster L**. No effect of gender and food on the pharmacokinetics of NKTR-181. Poster #22; The 24th Annual Clinical Meeting of the American Academy of Pain Management; September 26-29, 2013; Orlando, FL.

163. Eldon MA, Odinecs A, Herzog S, Medve R, Abrouk N, **Webster L**. NKTR-181 demonstrates analgesic response in cold pressor test. Poster #23; The 24th Annual Clinical Meeting of the American Academy of Pain Management; September 26-29, 2013; Orlando, FL.

164. Chang S, Onojighofia TG, Smith GA, Deer TR, **Webster L**, Trescott A, Sinel MS, Zoleikhaeian M, Hua M, Hubbard J, Meshkin B. Retrospective analysis of the clinical and economic results (R.A.C.E.R.) of genotyping chronic pain patients to guide medical detoxification of prescription opioid analgesic abuse (RxO): 2-year study. Poster #35; The 24th Annual Clinical Meeting of the American Academy of Pain Management; September 26-29, 2013; Orlando, FL.

165. Vickery R, **Webster L**, Li YP, Schwertschlag U, Singla N, Canafax D. TD-1211 phase 2b study demonstrates increased bowel movement frequency in patients with opioid-induced constipation (OIC) regardless of baseline opioid dose. Poster #120; EFIC - 8th "Pain in Europe" Conference; October 9 - 12, 2013; Florence, Italy.

166. **Webster L**, Chey WD, Tack J, Lappalainen J, Barker PN, Sostek M. Long-term safety and tolerability of naloxegol in patients with opioid-induced constipation. Poster #P494; The 2013 Annual Scientific Meeting of the American College of Gastroenterology (ACG); October 11 – 16, 2013; San Diego, CA.

167. **Webster LR**, Brenner D, Rolleri RL, Barrett AC, Bortey E, Paterson C, Forbes WP. All-cause mortality in placebo-controlled clinical trials of methylnaltrexone: a pooled analysis. Poster #P495; The 2013 Annual Scientific Meeting of the American College of Gastroenterology (ACG); October 11 – 16, 2013; San Diego, CA.

168. Chey WD, Tack J, **Webster LR**, Barker P, Lappalainen J, Sostek M. Efficacy of Naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from 2 prospective, randomized, controlled trials. Poster #P1690; The 2013 Annual Scientific Meeting of the American College of Gastroenterology (ACG);

October 11 – 16, 2013; San Diego, CA.

169. Tack J, Chey WD, **Webster L**, Lappalainen J, Barker PN, Sostek M. Naloxegol symptom responder rates in patients with opioid-induced constipation: results from 2 prospective randomized controlled trials. Poster #P1535; United European Gastroenterology Week's 21st Annual Conference (UEGW); October 12 - 16, 2013; Berlin, Germany.

170. Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, **Webster L**. Relationship between oxycodone pharmacokinetics and subjective drug effects following oral administration of an immediate-release combination of oxycodone and acetaminophen (OR OC/APA) and MNK-795 Oxycodone/Acetaminophen Extended-Release (OC/APAP ER) Tablets. The 37th Annual Scientific Session of the Midwest Pain Society; October 25 - 26, 2013; Chicago, IL.

171. Joseph D, Schobelock MJ, Riesenberg A, Vince B, **Webster LR**, Adeniji A, Elgadi M, Huang F. Effect of steady-state Faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine/naloxone in subjects on stable addiction management therapy. Poster #483; The Liver Meeting 2013: The 6^{4th} Annual Meeting of the American Association of the Study of Liver Diseases (AASLD); November 1 – 5, 2013; Washington, DC.

172. Marshall WL, Caro L, Jumes P, Ma J, Mangin E, Liu Y, Huang X, Dreyer D, **Webster LR**, Butterton J. Pharmacokinetic interaction between the HCV non-structural protein 5A inhibitor MK-8742 and methadone in subjects on stable maintenance therapy. Poster #59; HepDart 2013; December 8 – 12, 2013; Big Island, HI.

173. King J, Smollin M, Evans J, Smith M, **Webster LR**. Pharmacist's role in human abuse liability studies. Poster #110; The 30th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 6 – 9, 2014; Phoenix, AZ.

174. **Webster LR**, Morton T, Kostenbader K, Montgomery J, Devarkonda K, Barrett T. Relationship between oxycodone pharmacokinetics and subjective drug effects following oral administration of an immediate-release combination of oxycodone and acetaminophen and MNK-795 oxycodone/acetaminophen extended-release (XR OC/APAP) tablets. Poster #180; The 30th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 6 – 9, 2014; Phoenix, AZ.

175. Setnik B, Pixton GC, **Webster LR**. Safety profile of Embeda (morphine sulfate and sequestered Naltrexone hydrochloride) extended-release capsules in older patients: pooled analysis of 3 clinical trials. Poster #186; The 30th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 6 – 9, 2014; Phoenix, AZ.

176. **Webster L**, Morton T, Kostenbader K, Montgomery J, Devarkonda K, Barrett T. Abuse quotient of orally administered MNK-195 extended-release oxycodone/acetaminophen (ER OC/APAP) tablets versus immediate-release oxycodone/acetaminophen (IR OC/APAP) tablets in recreational users of prescription opioids. Poster #193; The 30th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 6 – 9, 2014; Phoenix, AZ.

177. Argoff C, Nalamachu S, **Webster L**, Young C. Diclofenac submicron particle capsules reduce opioid rescue medication usage in a phase 3 study in patients with acute pain following elective surgery. Poster #197; The 30th Annual Meeting of the American Academy of Pain Medicine (AAPM); March 6 – 9, 2014; Phoenix, AZ.

178. Smith M, **Webster LR**, Iverson M, Theisen T, Jenkins J, Smollin M. Preliminary report on effect of dose on ability to discriminate between active control and placebo. Poster #227; The 30th Annual Meeting of the American Academy of Pain Medicine; March 6 – 9, 2014; Phoenix, AZ.

179. Joseph D, Schobelock MJ, Risenberg RA, Vince B, **Webster L**, Adeniji A, Elgadi M, Huang F. Effect of steady-state faldaprevir on the pharmacokinetics of steady-state methadone and buprenorphine/naloxone in subjects on stable addiction management therapy. The 2014 Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL); March 12 - 15, 2014; Brisbane, Australia.

180. **Webster L**, Altman R, Nalamachu S, Markenson J, Solorio D, Young C. Lower Dose SoluMatrix Indomethacin Capsules Developed Using SoluMatrix Fine Particle TechnologyTM: Relationship of Pharmacokinetic Properties and Onset of Analgesia. The 39th Annual Regional Anesthesiology and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); April 3 – 6, 2014; Chicago, IL.

181. Solorio D, Gan TJ, **Webster L**, Gibofsky A, Young C. Lower Dose Diclofenac Capsules Provide Clinically Meaningful Reductions in Pain in a Phase 3 Study of Patients Following Bunionectomy. The 39th Annual Regional Anesthesiology and Acute Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); April 3 – 6, 2014; Chicago, IL.

182. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, **Webster L**, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela D, Gardiner DF. All-oral therapy with Daclatasvir in combination with Asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection. Poster #P1163; The 29th Annual Meeting of the European Association for the Study of the Liver (EASL); April 9 - 13, 2014; London, United Kingdom.

183. **Webster L**, Smith M, Unal C, Finn A. Low-dose naloxone provides an abuse deterrent effect to buprenorphine doses less than 1 mg. Poster #10; The 45th Annual Medical-Science Conference of the American Society of Addiction Medicine (ASAM); April 10 – 13, 2014; Orlando, FL.

184. Setnik B, Sommerville KW, Pixton GC, **Webster L**. Extended-release morphine sulfate and naltrexone hydrochloride (Embeda): Naltrexone associated effects in patients with chronic pain patients and recreational opioid users. Poster #121; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

185. Wallace M, **Webster L**, Rauck RL, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal Ziconotide in a long-term extension study. Poster #393; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

186. Vickery R, **Webster L**, Li YP, Singla N, Canafax D. Axelopran phase 2b study demonstrates a sustained increase in bowel movement frequency in patients regardless of duration of opioid-induced constipation. Poster #406; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

187. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Barrett T, Young JL, **Webster LR**. Comparison of subjective drug effects of orally administered MNK-155 extended-release hydrocodone bitartrate/acetaminophen (ER HB/APAP) tablets versus immediate-release hydrocodone bitartrate/acetaminophen tablets in recreational users of prescription opioids. Poster #421; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

188. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Barrett T, Young JL, **Webster LR**. Relationship between hydrocodone pharmacokinetics and subjective drug effects following oral administration of an immediate-release combination of hydrocodone bitartrate and acetaminophen and MNK-155 extended-release hydrocodone bitartrate/acetaminophen (ER HB/APAP) tablets. Poster #425; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

189. Tack J, Chey WD, Lappalainen J, Sostek M, Barker PN, **Webster L**. Symptom improvement following naloxegol treatment in noncancer pain patients with opioid-induced constipation. Poster #447; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

190. **Webster LR**, Popescu A, Brewer RP, Mareya S. Efficacy of Lubiprostone for the treatment of opioid-induced constipation according to opioid class. Poster #452; The 33rd Annual Scientific

Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

191. Soergel DG, Subach RA, Burnham N, Lark MW, James IE, Sadler BM, Skobieranda F, Violin JD, **Webster LR**. The biased ligand TRV130 increases analgesia and reduced on-target adverse effects versus morphine in healthy volunteers. Poster #478; The 33rd Annual Scientific Meeting of the American Pain Society (APS); April 30 - May 3, 2014; Tampa, FL.

192. Cryer B, **Webster LR**, Losch-Beridon T. Nausea reported by patients enrolled in clinical studies of Lubiprostone: analysis of well-controlled and long-term, open-label studies of chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. Poster #Sa2021; Digestive Disease Week (DDW) 2014; May 3 – 6, 2014; Chicago, IL.

193. **Webster L**, Kostenbader K, Montgomery J, Devarakonda K, Barrett T. Respiratory rates and O_2 saturation after administration of MNK-795 (oxycodone/acetaminophen extended-release tablets). Poster #252; The 61st Annual Meeting of the American College of Sports Medicine (ACSM); May 27 – 31, 2014; Orlando, FL.

194. Siemens W, Gartner J, Jors K, Camilleri M, Drossman DA, **Webster LR**, Becker G. Opioid-induced constipation definitions and outcome measures. Poster #P145; The 8th World Research Congress of the European Association for Palliative Care (EAPC); June 5 - 7, 2014; Lleida, Spain.

195. Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, **Webster L**. Relationship between oxycodone pharmacokinetics and subjective drug effects following oral administration of an immediate-release combination of oxycodone and acetaminophen (IR OC/APAP) and MNK-795 oxycodone/acetaminophen extended-release (OC/APAP ER) tablets. Poster #19; The 2014 International Conference on Opioids (ICOO); June 8 – 10, 2014; Boston, MA.

196. Vickery R, **Webster L**, Li YP, Singla N, Canafax D. Axelopran phase 2b study demonstrates a sustained increase in bowel movement frequency in patients regardless of duration of opioid-induced constipation. Poster #28; The 2014 International Conference on Opioids (ICOO); June 8 – 10, 2014; Boston, MA.

197. Smith M, Jenkins J, Iverson M, **Webster LR**. THC use does not affect liking discrimination of opioid versus placebo in HAP studies. Poster #131; The 76th Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 14 – 19, 2014; San Juan, Puerto Rico.

198. **Webster L**, Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T. Abuse quotient of orally administered MNK-795 extended-release oxycodone/acetaminophen tablets

versus immediate-release oxycodone/acetaminophen tablets in recreational users of prescription opioids. The 2014 National Conference of the American Association of Nurse Practitioners (AANP); June 18 - 22, 2014; Nashville, TN.

199. Rauck RL, **Webster L**, Wallace M, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal Ziconotide in a long-term extension study. Pain, 2014 (West Virginia Society of International Pain Physicians); June 19 - 22, 2014; San Juan, Puerto Rico.

200. Peppin J, Webster L, Morton T, Devarakonda K, Montgomery J, Kostenbader K, Barrett T. Correlation of pharmacodynamic and pharmacokinetc parameters to compare the abuse liability of orally administered extended-release oxycodone/acetaminophen tablets and immediate-release oxycodone acetaminophen tablets in recreational users of prescription opioids. The 68th Interallied Confederation of Reserve Medical Officers Congress; August 4 - 9, 2014; Fulda, Germany.

201. Webster LR, Kostenbader K, Montgomery J, Devarakonda K, Barrett T. Respiratory rates and oxygen saturation after administration of oxycodone/acetaminophen extended-release tablets. Poster #5; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

202. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Barrett T, Young JL, Webster LR. Comparison of subjective drug effects of orally administered MNK-155 extended-release hydrocodone bitartrate /acetaminophen tablets versus immediate-release hydrocodone bitartrate /acetaminophen tablets in recreational users of prescription opioids. Poster #27; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

203. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Young JL, Webster LR. Influence of Pharmacokinetic Differences on Pharmacodynamic Measures of Abuse Liability: Comparison of MNK-155 Extended-Release Hydrocodone Bitartrate/Acetaminophen Tablets and Immediate-Release Hydrocodone Bitartrate/Acetaminophen Tablets in Recreational Users of Prescription Opioids. Poster #28; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

204. **Webster L**, Pantaleon C, Shah MS, DiFalco R, Iverson M, Smith MD, Kinzler ER, Aigner S. Intranasal human abuse potential of a novel abuse-deterrent extended-release formulation of morphine. Poster #145; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

205. Argoff C, Nalamachu S, **Webster L**, Gudin J, Young C. SoluMatrix Diclofenac demonstrates sustained opioid-sparing effects in a phase 3 study of patients with acute pain following elective surgery. Poster #155; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

206. Rosenblum S, Wallace M, **Webster L**, Rauck RL, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study. The 21st Annual Napa Pain Conference; September 5 - 7, 2014; Napa, CA.

207. Hassanein T, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, **Webster L**, Younossi Z, Schwartz H, Thuluvath H, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela D, Gardiner D. All-oral therapy with Daclatasvir in combination with Asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection. Poster #37; The American Association for The Study of Liver Diseases (AASLD) / The European Association for the Study of the Liver (EASL) Special Conference on Hepatitis C; September 12 – 13, 2014; New York City, NY.

208. Darwish M, Bond M, Ma Y, **Webster LR**. Evaluation of the abuse potential of an extended-release hydrocodone bitrate tablet formulated with abuse-deterrent technology in non-dependent, recreational opioid users. The 25th Annual Clinical Meeting of the American Academy of Pain Management; September 18 - 21, 2014; Phoenix, AZ.

209. Darwish M, Bond B, Ma Y, **Webster LR**. Evaluation of the abuse potential of an extended-release hydrocodone bitrate tablet formulated with Teva abuse-deterrent technology in non-dependent, recreational opioid users. The 27th Annual U.S. Psychiatric & Mental Health Congress (USPMHC); September 20 - 23, 2014; Orlando, FL.

210. **Webster L**, Morton T, Kostenbader K, Devarakonda K, Barrett T, Patrick J. Correlation of pharmacodynamic and pharmacokinetic parameters to assess the abuse abuse liability of orally administered MNK-795 extended-release oxycodone/acetaminophen tablets vs immediate-release oxycodone/acetaminophen tablets in recreational users of prescription opioids. Poster #A2231; The 2014 World Congress on Pain; October 6 - 11, 2014; Buenos Aires, Argentina.

211. **Webster L**, Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T, Melikian D. Correlation of Pharmacodynamic and Pharmacokinetic Parameters to Assess the Abuse Liability of Orally Administered Extended-Release Oxycodone/Acetaminophen Tablets vs Immediate-Release Oxycodone/Acetaminophen Tablets in Recreational Users of Prescription Opioids. The 2014 Annual Meeting of the American Managed Care Pharmacy (AMCP); October 7 - 10, 2014; Boston, MA.

212. Rosenblum S, Wallace M, **Webster L**, Rauck RL, Hokett S, Alvarez-Horine MS, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events with intrathecal ziconotide. *Anesthesiology 2014*; October 11 – 15, 2014; New Orleans, LA.

213. Cryer B, **Webster LR**, Losch-Beridon T, Ueno R. Characterisation of nausea in well-controlled and long-term, open-label studies of lubiprostone for chronic idiopathic constipation, opioid-induced constipation, and irritable bowel syndrome with constipation. Poster # E007549; European Gastroenterology Week (UEGW) 2014; October 18 - 22, 2014; Vienna, Austria.

214. **Webster L**, Wallace M, Rauck RL, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of Concomitant Antidepressant and Anticonvulsant Use on Adverse Events in Patients Receiving Intrathecal Ziconotide in a Long-Term Extension Study. The 38th Scientific Session of the Midwest Pain Society (MPS); October 24 - 25, 2014; Chicago, IL.

215. **Webster L**, Hjelmstrom P, Sumner M, on behalf of the 007 study investigators. Treatment with an advanced formulation of sublingual buprenorphine/naloxone tablets improves quality-of-life measures in opioid-dependent adults. The 28th Annual National Conference of the Association for Medical Education and Research in Substance Abuse (AMERSA); November 6 - 8, 2014; San Francisco, CA.

216. Rauck RL, Wallace M, **Webster L**, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of Concomitant Antidepressant and Anticonvulsant Use on Adverse Events in Patients Receiving Intrathecal Ziconotide in a Long-Term Extension Study. The Pain Medicine Sympoisum 2014: Evolving Advanced Pain Therapies; November 6 - 9, 2014; Jersey City, NJ.

217. Everson G, Sims KD, Thuluvath PJ, Schwartz H, Hassanein T, Lawitz E, **Webster L**, Brau N, Desta T, Galati J, Ghalib R, Gitlin N, Han S, Hinestrosa F, Rodriguez-Torres M, Nahass R, Ruane P, Luo WL, McPhee F, Gardiner DF. Daclatsavir in combination with asunaprevir and BSM-791325 for prior null responders with chronic HCV genotype 1 infection. Poster #1943; The Liver Meeting 2014 - The 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD); November 7- 11, 2014; Boston, MA.

218. **Webster L**, Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T. Abuse quotient of orally administered MNK-795 extended-release oxycodone/acetaminophen tablets vs immediate-release oxycodone/acetaminophen tablets in recreational users of prescription opioids. Poster #526; The 2014 Annual Assembly of the American Academy of Physical Medicine & Rehabilitation (AAPM&R); November 13 – 16, 2014; San Diego, CA.

219. Rauck R, **Webster L**, Wallace M, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study. The 13th Annual Pain Medicine Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA); November 13 - 16, 2014; San Francisco, CA.

220. **Webster L**, Hjelmstrom P, Sumner M, on behalf of the 007 study investigators. Titrating to effective dose of Zubsolv, an advanced formulation of sublingual buprenorphine/naloxone, in adults with opioid dependence. The 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry (AAAP); December 4 - 7, 2014; Aventura, FL.

221. **Webster L**, Hjelmstrom P, Sumner M, on behalf of the 007 study investigators. Assessing buprenorphine/naloxone efficacy during induction therapy in opioid-dependent patients: what is the ideal measure? The 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry (AAAP); December 4 - 7, 2014; Aventura, FL.

222. **Webster L**, Hjelmstrom P, Sumner M, on behalf of the 007 study investigators. Efficacy of treatment with Zubsolv, an advanced formulation of sublingual buprenorphine/naloxone tablets, in adults with opioid dependence. The 25th Annual Meeting and Symposium of the American Academy of Addiction Psychiatry (AAAP); December 4 - 7, 2014; Aventura, FL.

223. Rauck RL, Wallace M, **Webster L**, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Concomitant Antidepressant and Anticonvulsant Use and Adverse Events with Intrathecal Ziconotide Therapy: Long-Term Extension Study. The 18th Annual Meeting of the North American Neuromodulation Society (NANS); December 11 - 14, 2014; Las Vegas, NV.

224. Rosenblum S, Wallace M, **Webster L**, Rauck RL, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of Concomitant Antidepressant and Anticonvulsant Use on Adverse Events In Patients Receiving Intrathecal Ziconotide In A Long-Term Extension Study. Poster #9146; The 68th Annual Postgraduate Assembly in Anesthesiology; December 12-16, 2014; New York, NY.

225. Smith MD, **Webster LR**, Levitt SB. An exploratory survey of opioid abuse: who are they? Which opioids are abused? Why? How? Submitted to the 11th Annual Meeting of the International Society for CNS Clinical Trial and Methodology (ISCTM); February 17-19, 2015; Washington, DC.

226. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Barrett T, Young JL, **Webster LR**. Comparison of Subjective Drug Effects of Orally Administered Immediate-Release/Extended-Release Hydrocodone Bitartrate/Acetaminophen Tablets Versus Immediate-Release Hydrocodone Bitartrate/Acetaminophen Tablets in Recreational Users of Prescription Opioids. Submitted to: The 2015 Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS); February 19 - 22, 2015; Phoenix, AZ.

227. Webster L, Morton T, Kostenbader K, Montgomery J, Barrett T, Devaraknda K. Correlation of Pharmacodynamic and Pharmacokinetic Parameters to Assess the Abuse Potential of Orally Administered Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets vs Immediate-Release Oxycodone/Acetaminophen Tablets in Recreational Users of Prescription

Opioids. The 2015 Annual Scientific Conference of the American College of Foot and Ankle Surgeons (ACFAS); February 19 - 22, 2015; Phoenix, AZ.

228. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Barrett T, Young JL, **Webster LR**. Comparison of subjective drug effects or orally administered biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets (MNK-155) versus immediate-release hydrocodone bitartrate/acetaminophen tablets in recreational users of prescription opioids. Poster #213; The 31st Annual Meeting of the American Academy of Pain Medicine (AAPM); March 19 - 22, 2015; National Harbor, MD.

229. Webster L, Iverson M, Pantaleon C, DiFalco R, Smith MD, Kinzler ER, Aigner S. Intranasal human abuse potential of a novel abuse-deterrent formulation of immediate-release oxycodone. Poster #237; The 31st Annual Meeting of the American Academy of Pain Medicine (AAPM); March 19 - 22, 2015; National Harbor, MD.

230. Wallace M, **Webster L**, Rauck RL, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study. Poster #244; The 31st Annual Meeting of the American Academy of Pain Medicine (AAPM); March 19 - 22, 2015; National Harbor, MD.

231. **Webster L**, Iverson M, Pantaleon C, DiFalco R, Smith MD, Kinzler ER, Aigner S. Intranasal human abuse potential of a novel abuse-deterrent formulation of immediate release oxycodone. Poster #245; The 31st Annual Meeting of the American Academy of Pain Medicine (AAPM); March 19 - 22, 2015; National Harbor, MD.

232. Chambers JF, Gleason RM, Kirsh KL, Passik SD, Twillman B, Webster L, Berner J. Hydrocodone rescheduling: the first 100 days survey. Poster #LB002; The 31st Annual Meeting of the American Academy of Pain Medicine (AAPM); March 19 - 22, 2015; National Harbor, MD.

233. Cheruvu NPS, Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Young JL, **Webster LR**. Influence of Pharmacokinetic Differences on Pharmacodynamic Measures of Abuse Potential: Comparison of Biphasic Immediate-Release/Extended-Release Hydrocodone Bitartrate/Acetaminophen Tablets and Immediate-Release Hydrocodone Bitartrate/Acetaminophen Tablets in Recreational Users of Prescription Opioids. Poster #202; The 2015 Annual Meeting & Exposition of the American Pharmacists Association (APhA); March 27 - 30, 2015; San Diego, CA.

234. Webster L, Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T. Correlation of Pharmacodynamic and Pharmacokinetic Parameters to Assess the Abuse Potential of

Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets vs Immediate-Release Oxycodone/Acetaminophen Tablets in Recreational Users of Prescription Opioids. Poster #203; The 2015 Annual Meeting & Exposition of the American Pharmacists Association (APhA); March 27 - 30, 2015; San Diego, CA.

235. Webster L, Hjelmstrom P, Sumner M, Welsh C, on behalf of the 007 study investigators. Titrating to Effective Dose of Zubsolv, an Advanced Formulation of Sublingual Buprenorphine/Naloxone, in Adults with Opioid Dependence. Poster #366; The 2015 Annual Meeting & Exposition of the American Pharmacists Association (APhA); March 27 - 30, 2015; San Diego, CA.

236. **Webster L**, Menzaghi F, Stauffer J, Tiseo P, Spencer R. CR845, a Novel Peripherally-Acting Kappa Opioid Receptor Agonist, Has Low Abuse Potential Compared with Pentazocine. *The Journal of Pain*, Volume 16(4), S81. April 2015.

237. Sumner M, **Webster LR**, Hjelmstrom P, Gunderson E, on behalf of the 006 and 007 Study Investigators. Advanced-formulation sublingual buprenorphine/naloxone tablet is effective in induction treatment of opioid-dependent adults. Poster #13; The 46th Annual Meeting of the American Society of Addiction Medicine (ASAM); April 23 - 26, 2015; Austin, TX.

238. Devarakonda K, Kostenbader K, Zheng Y, Montgomery JB, Young JL, Webster LR. Abuse quotient of biphasic immediate-release/extended-release hydrocodone bitartrate/acetaminophen tablets versus immediate-release hydrocodone bitartrate/acetaminophen tablets in recreational users of prescription opioids. Submitted to The 34th National Conference of the American Society of PeriAnesthesia Nurses (ASPAN); April 26-30, 2015; San Antonio, TX.

239. **Webster LR**, Menzaghi F, Spencer R. CR845, a novel peripherally-acting kappa opioid receptor agonist, has low abuse potential compared with Pentazocine. Poster #421; The 34th Annual Scientific Meeting of the American Pain Society (APS); May 13 - 16, 2015; Palm Springs, CA.

240. Bond M, Schoedel K, Rabinovich-Guilatt L, Gasior M, Malamut R, Ma Y, **Webster LR**. Evaluation of the relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. Poster #425; The 34th Annual Scientific Meeting of the American Pain Society (APS); May 13 - 16, 2015; Palm Springs, CA.

241. **Webster L**, Lappalainen J, Diva U, Tummula R, Sostek M. Treatment With Naloxegol Versus Placebo: Pain Assessment in Patients With Noncancer Pain and Opioid-Induced Constipation. Poster #444; The 34th Annual Scientific Meeting of the American Pain Society (APS); May 13

- 16, 2015; Palm Springs, CA.

242. **Webster LR**, Brenner DM, Barrett AC, Paterson C, Bortey E, Forbes WP. Analysis of opioid-mediated analgesia in studies with methylnaltrexone for opioid-induced constipation in patients with chronic noncancer pain. Poster #466; The 34th Annual Scientific Meeting of the American Pain Society (APS); May 13 - 16, 2015; Palm Springs, CA.

243. Rauck RL, Wallace M, **Webster L**, Rosenblum S, Hokett S, Alvarez-Horine S, Vanhove GF. Effect of concomitant antidepressant and anticonvulsant use on adverse events in patients receiving intrathecal ziconotide in a long-term extension study. Poster #92; The International Neuromodulation Society (INS) 12th World Congress; June 8 – 10, 2015; Montreal, Canada.

244. **Webster LR**, Smith MD. Abuse Quotient: An essential measure of opioid ADF HAP?. Poster #135; The 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 13-18, 2015; Phoenix, AZ.

245. Schoedel K, Rabinovich-Guilatt L, Gasior M, Malamut R, Ma Y, **Webster LR**, Bond M. Evaluation of relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. Poster #138; 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 13-18, 2015; Phoenix, AZ.

246. Bond M, Darwish M, Ma Y, **Webster LR**. Evaluation of the abuse potential of a hydrocodone extended-release bitartrate tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. Poster #139; The 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 13-18, 2015; Phoenix, AZ.

247. Stauffer JW, Menzaghi F, **Webster LR**, Spencer RH, Abrouk NES, Lewis ME, Chalmers D. CR845, a novel peripherally-acting kappa opioid: evidence for low abuse potential compared with Pentazocine. Poster #421; The 77th Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 13-18, 2015; Phoenix, AZ.

248. Bond M, Schoedel K, Rabinovich-Guilatt L, Gasior M, Malamut R, Ma Y, **Webster L**. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. Poster #15; PAINWeek 2015, September 8-12; Las Vegas, NV.

249. **Webster L**, Smith M, Lawler J, Dayno J. Human Abuse Potential of an Abuse-Deterrent (AD), Extended-Release (ER) Morphine Product Candidate (EG-001) Versus a Currently-Available non-AD, ER Morphine Product Administered Intranasally in Nondependent, Recreational

Opioid Users. PAINWeek 2015; September 8 – 12, 2015; Las Vegas, NV.

250. **Webster L**, Brenner D, Wolf Ray, Paterson C, Bortey E, Forbes W. Analysis of Opioid-Mediated Analgesia in Studies with Methylnaltrexone for Opioid-Induced Constipation in Patients with Chronic Noncancer Pain. Poster #137; PAINWeek 2015; September 8 – 12, 2015; Las Vegas, NV.

251. Viscusi E, **Webster L**, Kuss M, Daniels S, Bolognese J, Zuckerman S, Soergel D, Subach R, Cook E, Skobieranda F. TRV130, a G Protein-biased Ligand of the μ-opioid Receptor, Demonstrates Analgesic Efficacy Following Bunionectomy in an Adaptive Phase 2 Study. Poster #116; display and oral presentation at PAINWeek 2015; September 8 – 12, 2015; Las Vegas, NV.

252. **Webster L**, Gruener D, Kirby T, Xiang Q, Tzanis E, Finn A. Evaluation of the Tolerability of Switching Patients on Chronic Full Opioid Agonist Therapy to Buprenorphine HCI Buccal Film. PAINWeek 2015; September 8 – 12, 2015; Las Vegas, NV.

253. **Webster L**, Yamada T, Ferreira J. A Phase 2 randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation in patients with chronic non-cancer pain. PAINWeek 2015; September 8-12; Las Vegas, NV.

254. Bond M, Schoedel K, Rabinovic-Guilatt L, Gasior M, Malamut R, Ma Y, **Webster L**. Evaluation of the relative intranasal abuse potential of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in nondependent, recreational opioid users. PAINWeek 2015; September 8-12, 2015; Las Vegas, NV.

255. **Webster L**, Iverson M, Pantaleon C, DiFalco R, Shah M, Smith M, Kinzler E, Aigner S. Intranasal human abuse potential of a novel abuse-deterrent formulation of immediate release oxycodone. PAINWeek 2015: September 8-12, 2015; Las Vegas, NV.

256. Smith M, **Webster L**, Lawler J, Dayno J. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (EG-001) versus a currently available non-AD, ER morphine product administered orally in nondependent, recreational opioid users. PAINWeek 2015, September 8-12, 2015; Las Vegas, NV.

257. Smith M, **Webster L**, Lawler J, Dayno J. Human abuse potential of an abuse-deterrent (AD), extended-release (ER) morphine product candidate (EG-001) versus a currently available non-AD, ER morphine product administered intranasally in nondependent, recreational opioid users. PAINWeek 2015, September 8-12, 2015; Las Vegas, NV.

258. Bond M, Schoedel KA, Rabinovich-Guilatt L, Gasior M, Malamut R, Ma Y, **Webster LR**. Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users. The 26th Annual Clinical Meeting of the American Academy of Pain Management; September 17 - 20, 2015; National Harbor, MD.

259. **Webster L**, Gruener D, Kirby T, Xiang Q, Tzais E, Finn A. Evaluation of the Tolerability of Switching Patients on Chronic Full Opioid Therapy to BEMA Buprenorphine. The 26th Annual Clinical Meeting of the American Academy of Pain Management; September 17 - 20, 2015; National Harbor, MD.

260. Bass A, **Webster LR**, Matschke K, Malhotra B, Wolfram G. Effects of Intravenous Oxycodone Alone or in Combination with Naltrexone on End-Tidal Carbon Dioxide: A Randomized, Controlled Study. Poster #320; The American College of Emergency Physicians (ACEP) 2015 Research Forum; October 26-27, 2015; Boston, MA.

261. **Webster L**, Diva U, Tummala R, Sostek M. Treatment With Naloxegol Versus Placebo: Pain Assessments in Patients with Noncancer Pain and Opioid-Induced Constipation. Poster #219; The 32nd Annual meeting of the American Academy of Pain Medicine (AAPM); February 18-21, 2016; Palm Springs, CA.

262. Bond M, Darwish M, Ma Y, Webster L. Evaluation of the abuse potential of a hydrocodone extended-release bitartrate table formulated with abuse-deterrence technology in nondependent, recreational opioid abusers. The 32nd Annual meeting of the American Academy of Pain Medicine (AAPM); February 18-21, 2016; Palm Springs, CA.

263. **Webster L**, Stauffer J, Spencer R, Menzaghi, F. Subjective and Objective Evidence of Low Abuse Potential of the Peripherally-Acting Kappa Opioid CR845, Compared with Pentazocine. Poster #216; The 32nd Annual Meeting of the American Academy of Pain Medicine (AAPM); February 18-21, 2016; Palm Springs, CA.

264. **Webster L**, Lappalainen J, Diva U, Tummala R, Sostek M. Treatment with naloxegol versus placebo: pain assessment in patients with noncancer pain and opioid-induced constipation. The Canadian Pain Society (CPS) 37th Annual Scientific Program; May 24 – 27, 2016; Vancouver, BC.

265. **Webster L**, Smith M. Human Abuse Liability (HAL) Study of an Experimental Triple Monoamine Reuptake Inhibitor in Recreational Drug Abusers. The American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2016 Annual Meeting; March 8-12, 2016; San Diego, CA.

266. Viscusi E, **Webster** L, Soergel DG, Burt DA, Skibiernanda F. Rapid Onset of Pain Relief with Oliceridine (TRV130), a Novel μ Receptor G Protein Pathway Selective (μ-GPS) Modulator, vs. Morphine: a Phase 2a/b Study Analysis. 41st Annual Regional Anesthesiology & Acute Pain Medicine Meeting; March 31 – April 2, 2016, New Orleans, LO.

267. Viscusi ER, **Webster L**, Soergel DG, Burt DA, Skobieranda F. Sum of Pain Intensity Differences with Oliceridine (TRV130), a Novel μ Receptor G Protein Pathway Selective (μ-GPS) Modulator, vs. with Morphine: Analysis from a Phase 2a Randomized Study. The Society for Ambulatory Anesthesia 31st Annual Meeting, May 5-7, 2016, Orlando, FL.

268. **Webster L**, Smith M, Lawler J, Lindhardt K, Dayno J. Pharmacodynamic effects from a category 3 intranasal human abuse potential study of an abuse-deterrent, extended-release morphine product candidate in nondependent, recreational opioid users. Poster #422; The 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016, Austin, TX.

269. **Webster L**, Peppin J, Harper J, Israel R. Poster #480; Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. The 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016, Austin, TX.

270. **Webster L**, Viscusi E, Minkowitz H, Soergel D, Burt D, Subach R, Skobieranda F. Rapid reduction in pain intensity with oliceridine (TRV 130), a novel ***μ*** receptor G protein pathway selective modulator (***μ***-GPS), vs. morphine: an analysis of two phase 2 randomized clinical trials. Poster #433; The 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016, Austin, TX.

271. **Webster L**, Friedmann N. Clinical results of an abuse potential study with REMOXY, an abuse deterrent, extended release product. Poster #444; The 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016, Austin, TX.

272. **Webster L**, Nagata T, Yamada T, Ferriera, J. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Evaluate the Safety of Naldemedine in Patients with Chronic Non-Cancer Pain and Opioid-Induced Bowel Dysfunction. Poster #479; The 35th Annual Scientific Meeting of the American Pain Society, May 11-14, 2016; Austin, TX.

273. **Webster L**, Lembo A, Datto C, Sostek M. The effect of naloxegol on stool consistency in patients with noncancer pain and opioid-induced constipation. The 8th World Congress of the World Institute of Pain, May 20-23, 2016, New York, NY.

274. **Webster L**, Lappalainen J, Diva U, Tummala R, Sostek M. Treatment with Naloxegol versus placebo: pain assessment in patients with noncancer pain and opioid-induced constipation. Poster #161; Canadian Pain Society's 37th Annual Scientific Program, May 24-27, 2016; Vancouver, CA. Winner, First Place, Excellence and Innovation Award.

275. Mickel T, Guenther S, Roupe K, Zhou J, Dickerson D, **Webster L**. Pharmacokinetics and abuse potential of benzhydrocodone, a novel prodrug of hydrocodone, after intranasal administration in recreational drug users. Poster #38; The International Conference on Opioids, June 5-7, 2016, Boston, MA.

276. Levy-Cooperman N, Shram M, **Webster L**. No evidence of increased abuse potential of CL-108, a bilayered tablet containing hydrocodone/acetaminophen/promethazine, in recreational opioid users. Poster #324; The College on Problems of Drug Dependence, June 1-16, 2016, Palm Springs, CA.

277. Smith M, Johnson C, Grunspan R, Reis R, Shingleton R, Rowley B, Reedy C, **Webster L**. Select Characteristics of Recreational of Opioid Users Undergoing a Human Abuse Potential Study. Poster #536; The College on Problems of Drug Dependence, June 11-16, 2016, Palm Springs, CA.

278. **Webster L**, Lembo A, Datto C, Sostek M. The Effect of Naloxegol on Stool Consistency in Patients with Noncancer Pain and Opioid- Induced Constipation. The American Association of Nurse Practitioners 2016 National Conference, June 21 – 26, 2016, San Antonio, TX.

279. Shram M, Levey-Cooperman N, **Webster L**. No evidence of increased abuse potential of CL-108, a bi-layered tablet containing hydrocodone/acetaminophen/promethazine, in recreational opioid users. Poster #119; PAINWeek 2016, September 6-10, Las Vegas, NV.

280. **Webster L**, Nalamachu S, Yamada T, Reddy J, Baba Y, Ferreria J. Long-term safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Subjects with Chronic Non-cancer Pain Receiving Opioid Therapy: Results from a 52-Week Phase 3 Clinical Trial. Poster #7; PAINWeek 2016, Sept 6-10, Las Vegas, NV.

281. Smith M, **Webster L**, Lawler J, Lindhardt K, Dayno J. Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. Poster #142; PAINWeek 2016, September 6-10, Las Vegas, NV.

282. **Webster L**, Harper J, Israel R. Oral Methylnaltrexone Does Not Negatively Impact Analgesia in Patients with Opioid-Induced Constipation and Chronic Noncancer Pain. Poster #140;

PAINWeek 2016, September 6-10, Las Vegas, NV.

283. Darwish M, Bond M, Ma Y, Tracewell W, Robertson P, **Webster L**. Evaluation of the Abuse Potential of a Hydrocodone Bitrate Extended-Release Tablet Formulated with CIMA® Abuse-Deterrence Technology Platform in Nondependent, Recreational Opioid Users. Poster #18; PAINWeek 2016, Sept 6-10, Las Vegas, NV.

284. **Webster L**, Lembo A, Datto C, Sostek M. The Effect of Naloxegol on Stool Consistency in Patients with Noncancer Pain and Opioid-Induced Constipation. The American Society for Pain Management Nursing 26th National Conference, September 7 – 10, 2016, Louisville, KY.

285. **Webster L**, Grunspan R, Smith M. Randomized, Double-Blind, Placebo-and Comparator-Controlled Human Abuse Liability (HAL) Study of an Experimental Triple Monoamine Reuptake Inhibitor in Recreational Drug Abusers. The 2016 Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 25-27, 2016, Bethesda, MD.

286. Darwish M, Bond M, Ma Y, Tracewell W, Robertson P, **Webster L**. Oral Abuse Potential of Crushed and Intact Hydrocodone ER. The American Academy of Pain Management National Conference 2016, September 21 – 25, 2016, San Antonio, TX.

287. Bond M, Schoedel K, Rabinovich-Guillat L, Gasior M, Tracewell W, Malamut R, Ma Y, **Webster L**. Relative Intranasal Abuse Potential of Hydrocodone ER. The American Academy of Pain Management National Conference 2016, September 21-25, 2016, San Antonio, TX.

288. **Webster L**, Smith M, Lawler J, Lindhardt K, Dayno J. Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. Poster #420; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

289. **Webster L**, Smith M, Lawler J, Lindhardt K, Dayno J. Pharmacodynamic Effects from a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. Poster #427; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

290. **Webster L**, Backonja M, Irving G, Tobias J, Vanhove G. Weekly Response Following a single Administration of Qutenza, an 8% Capsaicin Patch, in Patients with Postherpetic Neuralgia: Results of Integrated Analyses. Poster #66; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

291. **Webster L**, Morton T, Kostenbader K, Montgomery J, Devarakonda K, Barrett T. Abuse Quotient of Orally Administered MNK-795 Extended-Release Oxycodone/Acetaminophen Tablets vs Immediate-Release Oxycodone/Acetaminophen Tablets in Recreational Users of Prescription Opioids. Poster #526; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

292. **Webster L**, Menzaghi F, Stauffer J, Tiseo P, Spencer R. CR845, a Novel Peripherally-Acting Kappa Opioid Receptor Agonist, Has Low Abuse Potential Compared with Pentazocine. Poster #146; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

293. Wallace M, Backonja M, Chen S, Irging G, Tobias J, Vanhove G, **Webster L**. Integrated Safety Analyses of Qutenza, an 8% Capsaicin Patch, in Patients with Postherpetic Neuralgia. Poster #54; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

294. Backonja M, Irving G, Tobias J, Vanhove G, **Webster L**. Qutenza (Capsaicin) 8% Patch for the Treatment of Postherpetic Neuralgia: Efficacy Results Across a Range of Patient Populations. Poster #58; The American Academy of Physical Medicine and Rehabilitation Annual Assembly, October 20-23, 2016, New Orleans, LA.

295. **Webster L**, Harper J, Israel R. Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain. Poster #3036; presented at the 15th Annual ASRA Pain Medicine Meeting, November 17-19, 2016, San Diego, CA, Best of Meeting Award.

296. **Webster L**, Harper J, Israel R. Oral methylnaltrexone is efficacious and well-tolerated for the treatment of opioid-induced constipation in patients with chronic noncancer pain taking concomitant methadone. Poster #3034; the 15th Annual ASRA Pain Medicine Meeting, November 17-19, 2016, San Diego, CA.

297. **Webster L**, Harper J, Israel R. Oral Methylnaltrexone Does Not Negatively Impact Analgesia in Patients with Opioid-induced Constipation and Chronic Noncancer Pain. The Postgraduate Assembly in Anesthesiology, December 9-13, 2016, New York, NY.

298. Lawler J, **Webster L**, Smith M, Lindhardt K, Dayno J. Pharmacodynamic Effects from a Category 3 Intranasal Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. Poster #170. The American Academy of Pain Medicine's 33rd Annual Meeting, March 16 – 19, 2017, Orlando, FL.

299. Dayno J, Smith M, **Webster L,** Lawler J, Lindhardt K. Pharmacodynamic Effects from a Category 3 Oral Human Abuse Potential Study of an Abuse-Deterrent, Extended-Release Morphine Product Candidate in Nondependent, Recreational Opioid Users. Poster #139; The American Academy of Pain Medicine's 33rd Annual Meeting, March 16 – 19, 2017, Orlando, FL.

300. Mickle T, **Webster L.** Pharmacokinetics and Abuse Potential of Benzhydrocodone, A Novel Prodrug of Hydrocodone, After Intranasal Administration in Recreational Drug Users. Poster #157; American Academy of Pain Medicine's 33rd Annual Meeting, March 16 – 19, 2017, Orlando, FL.

301. McCarberg B, Chey W, **Webster L**, Yamada T, Ferreira J. The Patient with Chronic Non-Cancer Pain and Opioid-Induced Constipation. Poster #200; American Academy of Pain Medicine's 33rd Annual Meeting, March 16-19, 2017, Orlando, FL.

302. **Webster L**, Harper J, Stambler N, Israel R. Analysis of Impact of Oral Methylnaltrexone for Opioid-Induced Constipation (OIC) on opioid Analgesia and Withdrawal Symptoms in Patients with Chronic Noncancer Pain (CNCP) Taking Methadone. Poster #244; The American Academy of Pain Medicine's 33rd Annual Meeting, March 16-19, 2017, Orlando, FL.

303. **Webster L**, Grunspan R, Hansen E, Rynders A, Mackin S. Ventilatory Response to Hypercapnia (VRH) Methodology. Poster #336; The 36th Annual Scientific Meeting of the American Pain Society, May 17-20, 2017, Pittsburgh, PA.

304. Zhao X, Shah D, Gandhi K, Wei W, Dwibedi N, Sambamoorthi U, **Webster L**. Clinical, humanistic, and economic burden of osteoarthritis among non-institutionalized adults in the United States (US). Accepted for podium presentation at the International Society for Pharmacoeconomics and Outcomes Research, May 19-23, 2017, Baltimore, MD.

305. **Webster L**, Pantaleon C, Iverson M, Smith M, Kinzler E, Aigner S. Pharmacokinetic Characteristics of Oral and Intranasal Administration of Morphine ARER (MorphaBond ER), a Novel Abuse Deterrent Formulation of Morphine. Presented at the International Conference on Opoids, June 11-13, 2017, Boston, MA.

306. Odinecs A, **Webster L,** Henningfield JE, Buchhalter AR, Siddhanti S, Lu L, Silowsky J, DiFonzo CJ, Eldon MA. NKTR-181 produces full CNS μ-opioid agonism with significantly lower abuse potential. Poster #31; International Conference on Opioid, June 11-13, 2017, Boston, MA.

307. Lawler J, Smith M, **Webster L**, Lindhardt K, Coyle E, Dayno J. Evaluation of an Abuse-Deterrent, Extended-Release Morphine Product in an Oral Human Abuse Potential Study in

Nondependent, Recreational Opioid Users. The American Academy of Nurse Practitioners Annual Meeting, June 20-25, 2017, Philadelphia, PA.

308. Dayno J, **Webster L**, Smith M, Lawler J, Brown C, Lindhardt K. Evaluation of an Abuse-Deterrent, Extended-Release Morphine Product in an Intranasal Human Abuse Potential Study in Nondependent, Recreational Opioid Users. The American Academy of Nurse Practitioners Annual Meeting, June 20-25, 2017, Philadelphia, PA.

309. **Webster L**, Ashwin R, Hansen E, Rooney K. Predicting Screen Failure Rates of Human Abuse Potential Studies. 30th European College of Neuropsychopharmacology Congress, September 2-5, 2017, Paris, France.

310. **Webster L**, Pantaleon C, Iverson M, Kinzler E, Aigner S. Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone-ARIR (RoxyBond™), a Novel Abuse-deterrent Formulation of Oxycodone. Poster #58; PAINWeek 2017, September 5-9, Las Vegas, NV.

311. Cicero T, Mendoza M, Cattaneo M, Dart R, Mardekian J, Polson M, Roland C, Schnoll S, **Webster L**, Park P. Real-World Misuse, Abuse & Dependence of Abuse Deterrent versus Non-Abuse-Deterrent Extended Release Morphine in Medicaid Patients. PAINWeek 2017, September 5-9, Las Vegas, NV.

312. **Webster L**, Smith MD, Brown C, Lawler J, Karsten L, Niebler G, Dayno J. A Responders Analysis of Morphine Abuse-Deterrent, Extended-Release, Injection-Molded Tablets in Oral and Intranasal Human Abuse Potential Studies. Poster #57: PAINWeek 2017, September 5-9, Las Vegas, NV.

313. **Webster L**, Pantaleon C, Iverson M, Smith M, Kinzler E, Aigner S. Phamacokinetic Characteristics of Oral and Intranasal Administration of Morphine ARER (MorphaBond™ ER), a Novel Abuse-Deterrent Formulation of Morphine. Poster #59: PAINWeek 2017, September 5-9, Las Vegas, NV.

314. **Webster L,** Nalamachu S, Yamada T, Reddy J, Baba Y, Ferreira J. Long-term safety and efficacy of naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: Results from a 52-week Phase 3 clinical trial. Submitted to The American Academy of Family Physicians Annual Meeting, September 12-16, 2017.

315. Zhao X, Shah D, Gandhi K, Wei W, Dwibedi N, **Webster L**, Sambamoorthi U. Opioid Use, Pain Interference with Activities (PIA), and their Associated Healthcare Costs and Wage Loss in a Nationally Representative Sample of Non-institutionalized Adults with Osteoarthritis (OA) in the United States (US). Accepted for display and gold ribbon at the Academy of Managed

Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, 23-26 April, 2018, Boston, MA.

316. **Webster L**, Kinzler E, Pantaleon C, Iverson M, Aigner S. The Relative Bioavailability of Oxycodone ARIR (RoxyBond™), a Novel Abuse-deterrent Formulation of Immediate-Release Oxycodone, Under Fed and Fasted Conditions Compared with Immediate-Release Oxycodone. 34th Annual Meeting of the American Academy of Pain Medicine, April 26-29, 2018, Vancouver, Canada.

317. **Webster L**, Pantaleon C, Iverson M, Kinzler E, Aigner S. Pharmacokinetic Characteristics of Intranasal Administration of Oxycodone ARIR (Roxybond™), a Novel-Abuse-deterrent Formulation of Immediate-Release Oxycodone. 34th Annual Meeting of the American Academy of Pain Medicine, April 26-29, 2018, Vancouver, Canada.

318. **Webster L**, Smith MD, Vaughn B, Brown C, Lawler J, Lindhardt K, Niebler G, Dayno J. A Responders Analysis of Morphine Abuse-Deterrent, Extended-Release, Injection-Molded Tablets in Oral and Intranasal Human Abuse Potential Studies. 34th Annual Meeting of the American Academy of Pain Medicine, April 26-29, 2018, Vancouver, Canada.

319. **Webster L**, Hansen E, Chambers J, Rynders A, Gonzales S, Ostler D, Lennon H. Oxycodone's Effect on Ventilatory Response to Hypercapnia. 34th Annual Meeting of the American Academy of Pain Medicine, April 26-29, 2018, Vancouver, Canada.

320. Friedmann N, de Kater A, Marsman M, **Webster L**. REMOXY is Associated with Lower Abuse Potential in Recreational Opioid Users Following Nasal Administration. 34th Annual Meeting of the American Academy of Pain Medicine, April 26-29, 2018, Vancouver, Canada.

321. Shah D, Xiaohui Z, Gandhi K, Wei W, Dwibedi N, Sambamoorthi U, **Webster L**. Opioid Use, Pain Interference with Activities, and Their Associated Burden in a Nationally Representative Sample of Adults with Osteoarthritis in the United States (US): Results of a Retrospective, Cross-Sectional Analysis. 34th Annual Meeting of the American Academy of Pain Medicine, April 26-29, 2018, Vancouver, Canada.

322. **Webster L**, Hansen E, Rynders A, Chambers J, Gonzales S, Ostler D, Lennon H. Oxycodone Effect on Ventilatory Drive. 9th World Congress of the World Institute of Pain, May 9-12, 2018, Dublin, Ireland.

323. **Webster L**, Magazine H, Yamada T. Safety of Naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: results of three global phase 3 clinical trials. Digestive Disease Week 2018, June 2 – 5, Washington,

DC.

324. **Webster L**, Kinzler E, Pantaleon C, Iverson M, Aigner S. The Effect of Food on the Pharmacokinetic Characterisits of Morphine ARER (MorphaBond^{TM}ER), an Abuse-deterrent Formulation of Extended-Release Morphine. The International Conference on Opioids, June 10 – 12, 2018, Boston, MA; Poster #7.

325. **Webster L**, Kinzler E, Pantaleon C, Iverson M, Aigner S. The Relative Bioavailability of Oxycodone ARIR (RoxyBond^{TM}), a Novel, Abuse-deterrent Formulation of Immediate-Release Oxycodone, Compared to Immediate-Release Oxycodone. The International Conference on Opioids, June 10 – 12, 2018, Boston, MA; Poster #39.

326. Turncliff R, **Webster L**, Stevens M, Gentry B. Initiation of "STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy" in Recreational Methamphetamine Abusers. In development for The College on Problems of Drug Dependence 80th Annual Scientific Meeting, June 9-14, 2018, San Diego, CA.

327. Schippers F, Pesic M, Stoehr T, **Webster L**, Hansen E, Turncliff R. A Phase 1 pilot trial to explore safety, pharmacokinetics, and bioavailability of intranasal remimazolam in healthy subjects. Drug Information Association, June 24-28, 2018, Boston, MA.

328. **Webster L**, Hansen E, Chambers J, Rynders A, Gonzales S, Ostler D, Lennon H. New methodology to evaluate a drugs effect on respiratory depression. Drug Information Association, June 24-28, 2018, Boston, MA.

329. Shah D, Zhao X, Gandhi K, Wei W, Dwibedi N, **Webster L**, Sambamoorthi U. A Longitudinal Study of the Impact of Opioid Use on Change in Pain Interference With Activities And Functional Limitations in A Nationally Representative Cohort of Adults with Osteoarthritis in the United States. PainWeek, September 4-8, 2018, Las Vegas, NV

330. **Webster L**,Kinzler E, Pantaleon C, Iverson M, Aigner S. The Relative Bioavailability of Oxycodone ARIR (RoxyBond™), a Novel Abuse-deterrent Formulation of Immediate-Release Oxycodone, Compared to Immediate-Release Oxycodone. PainWeek, September 4-8, 2018, Las Vegas, NV.

331. **Webster L**,Kinzler E, Pantaleon C, Iverson M, Aigner S. The Effect of Food on the Pharmacokinetic Characteristics of Oxycodone ARIR (RoxyBond™), a Novel Abuse-Deterrent Formulation of Immediate-Release Oxycodone. PainWeek, September 4-8, 2018, Las Vegas, NV.

332. **Webster L**, Magazine H, Yamada T. Safety of Naldemedine for the treatment of opioid-induced constipation in subjects with chronic non-cancer pain receiving opioid therapy: results of three global phase 3 clinical trials. PainWeek, September 4-8, 2018, Las Vegas, NV.

333. Hale M, Webster L, Yamada T, Wild J. A Renal Impairment Subgroup Analysis of the Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-Cancer Pain Receiving Opioid Therapy. International Association for the Study of Pain World Congress on Pain, September 12-16, 2018, Boston, MA.

334. Wild J, **Webster L**, Yamada T, Hale M. Safety and Efficacy of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients With Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥65 Years of Age. AMCP Nexus, October 22-25, 2018, Orlando, FL.

335. Webster L. Uncritical Publication of a Biased Study Leads to Misleading Media Reports. *Pain Medicine,* pny234. November 20, 2018. https://doi.org/10.1093/pm/pny234

336. Braeckman R, Guenther S, Mickle T, Barrett A, **Webster L**. Human Abuse Potential of Oral Serrdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin XR and Phentermine in Recreational Stimulant Abusers. APSARD, January 18-20, 2019, Washington, D.C.

337. Zebala J, Searle SL, **Webster L,** Schuler A, Maeda S, Kahn S. Desmetramadol has the safety and analgesic profile of tramadol but not its metabolic liabilities: double-blind, randomized, placebo-controlled trials in 103 subjects. Presented at APS 2019, April 3-6, 2019, Milwaukee, WI.

338. **Webster L**, Iverson M, Pantaleon C, Smith M, Kinzler E, Aigner S. A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Intranasal Human Abuse Potential Study of Oxycodone ARIR, a Novel, Immediate-Release, Abuse-Deterrent Formulation. *Pain Medicine*, April 1, 2019; 20(4):747-757. doi: 10.1093/pm/pny043.

339. Cicero TJ, Mendoza M, Cattaneo M, Dart RC, Mardekian J, Polson M, Roland CL, Schnoll SH, **Webster LR**, Park PW. Real-world misuse, abuse, and dependence of abuse-deterrent versus non-abuse-deterrent extended-release morphine in Medicaid non-cancer patients. *Postgraduate Medicine*. April 2019; 131(3): 225-229. Doi: 10. 1080/00325481.2019.1585688.

340. **Webster L,** Mallick-Searle T, Adler J A, Greuber E, Patel K, Vought K. ZTlido® (Lidocaine Topical System) 1.8% has superior adhesion compared to generic Mylan Lidocaine Patch 5%. Presented at PainWeek 2019, September 3-7, 2019, Las Vegas,NV.

341. **Webster L**, Smith T. Study Design of a Phase 1 Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Filam and Oral Oxycodone Hydrochloride on Respiratory Depression, Tolerability, and Pharmacokinetics. Presented at PainWeek 2019, September 3-7, 2019, Las Vegas,NV.

342. Wild J, **Webster L,** Yamada T, Hale M. Safety and Efficaacy of Naldemedine for the Treatment of Pioid-Induced Constipation in Patients with Chronic Non-Cancer Pain Receiving Opioid Therapy: A Subgroup Analysis of Patients ≥65 Years of Age. Presented at UEG Week 2019, October 19-23, 2019, Barcelona, Spain.

343. Wild J, **Webster L,** Yamada T, Hale M. Safety of Naldemedine for the Treatment of Opioid-Induced Constipation in Subjects with Chronic Non-Cancer Pain Receiving Opioid Therapy: Results of Three Global Phase 3 Clinical Trials. Presented at UEG Week 2019, October 19-23, 2019, Barcelona, Spain.

344. Zhao X, Shah D, Gandhi K, Wei, W, Dwibedi N, **Webster L**, Sambamoorthi U. The association of pain interference and opioid use with healthcare utilization and costs, and wage loss among adults with osteoarthritis in the United States. *Journal Medical Economics* November 2019; 22 (11): 1192-1201. doi: 10.1080/13696998.2019.1658590

345. **Webster L**, Hansen E, Cater J, Smith T. AAPM Respiratory Drive: A Phase I Placebo-Controlled Trial Comparing the Effect of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory Drive. Presented at the American Academy of Pain Medicine (AAPM) Annual Meeting, February 26 - March 1, 2020, National Harbor, MD.

346. **Webster L**, Brenner D, Israel R, Stambler N, Slatkin N. Reductions in All- Cause Mortality Associated with the Use of Methylnatrexone for Opioid-Induced Bowel Disorders: A Pooled Analysis. Presented at Digestive Disease Week Annual Meeting, May 2-5, 2020, Chicago, IL.

347. **Webster, Lynn MD,** Cater, Jacqueline, PhD, Smith, Thomas MD. The Pharmacodynamics and Pharmacokinetics of Buprenorphine Buccal Film Versus Oral Oxycodone Hydrochloride: Results of aPhase 1 Placebo-Controlled Trial. Presented at PainWeek, September 8-12, 2020. Virtual.

348. **Webster, Lynn MD,** Cater, Jacqueline, PhD, Smith, Thomas MD. Secondary Outcomes of a Phase 1 Placebo-Controlled Trial Comparing the Effects of Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride on Respiratory Drive. Presented at PainWeek, September 8-12, 2020. Virtual.

349. **Webster, Lynn MD,** Cater, Jacqueline, PhD, Smith, Thomas MD. Benefit of Buprenorphine Buccal Film Versus Oral Oxycodone Hydrochloride on Respiration: A Phase 1 Placebo-Controlled Trial. Presented at PainWeek, September 8-12, 2020. Virtual.

350. **Webster, Lynn MD,** Cater, Jacqueline, PhD, Smith, Thomas MD. Buprenorphine Buccal Film and Oral Oxycodone Hydrochloride: Effects on Pupillometry in a Phase 1 Placebo-Controlled Trial. Presented at PainWeek, September 8-12, 2020. Virtual.

351. **Webster, Lynn MD**, Cater, Jacqueline, Smith, Thomas MD. Secondary Respiratory Outcomes of a Phase 1 Placebo-Controlled Trial: Buprenorphine Buccal Film Versus Oral Oxycodone. Presented at 2021 North American Neuromodulation Society Meeting (NANS), January 15-16, 2021. Virtual.

352. **Webster, Lynn MD**, Cater, Jacqueline, Smith, Thomas MD. The Pharmacokinetics From a Phase 1 Placebo-Controlled Trial Comparing Buprenorphine Buccal Film and Oral Oxycodone. Presented at 2021 North American Neuromodulation Society Meeting (NANS), January 15-16, 2021. Virtual.

353. **Webster, Lynn MD**, Cater, Jacqueline, Smith, Thomas MD. Buprenorphine Buccal Film Versus Oral Oxycodone: Effects on Pupillometry From a Phase 1 Placebo-Controlled Trial. Presented at AAPM 2021 Annual Meeting, April 23-25, 2021. Virtual.

354. **Webster, Lynn MD**, Cater, Jacqueline, Smith, Thomas MD. Risk Stratification of Respiratory Depression With Buprenorphine Buccal Film Versus Oxycodone: Outcomes From a Phase 1 Placebo-Controlled Trial. Presented at AAPM 2021 Annual Meeting, April 23-25, 2021. Virtual.

355. **Webster, Lynn MD**, Brenner, Darren, Israel, Robert, Stambler, Nancy, Slatkin, Neal. All-cause mortality reduction associated with the use of methylnaltrexone for opioid-induced bowel disorders: a pooled analysis. Presented at the 46th Annual Regional Anesthesiology and Acute Pain Medicine Meeting (ASRA Spring), May 13-15, 2021. Virtual.

356. **Webster, Lynn MD**, Cater, Jacqueline, Smith, Thomas. Buprenorphine Buccal Film Versus Oral Oxycodone: Secondary Respiratory, Pharmacokinetic, and Pupillometry Outcomes From a Phase 1 Placebo-Controlled Trial. Presented at AAPM 2021 Annual Meeting, April 23-25, 2021. Virtual.

357. **Webster, Lynn MD**. Buprenorphine Buccal Film Versus Oral Oxycodone: Effects on Pupillometry and Respiratory Depression in a Phase 1 Placebo-Controlled Trial. Presented at PAINWeek 2021, September 7-11, 2021. The Cosmopolitan of Las Vegas.

358. **Webster, Lynn MD**. Risk Stratification of Respiratory Depression With Buprenorphine Buccal Film Versus Oxycodone: Outcomes From a Phase 1 Placebo-Controlled Trial. Presented at PAINWeek 2021, September 7-11, 2021. The Cosmopolitan of Las Vegas.

359. **Webster, Lynn MD**. Buprenorphine Buccal Film Versus Oral Oxycodone: Secondary Respiratory, Pharmacokinetic, and Pupillometry Outcomes From a Phase 1 Placebo-Controlled Trial. Presented at PAINWeek 2021, September 7-11, 2021. The Cosmopolitan of Las Vegas.

360. **Webster, Lynn MD**. Proposed Risk Stratification of Drug Effect on Inducing Respiratory Depression. Presented at PAINWeek 2021, September 7-11, 2021. The Cosmopolitan of Las Vegas.

361. **Webster, Lynn MD**, Cater, Jacqueline, Smith, Thomas. Buprenorphine Buccal Film Versus Oral Oxycodone: Secondary Respiratory, Pharmacokinetic, and Pupillometry Outcomes From a Phase 1 Placebo-Controlled Trial. Presented at AAPM 2021 Annual Meeting, April 23-25, 2021. Virtual.

362. Schmidt, William K PhD, Evans, Cari, Pestano, Linda PhD, **Webster, Lynn MD**, Kirkpatrick, D. Lynn PhD. Intranasal Human Abuse Potential of PF614: A Novel 'Next Generation' Trypsin Activated Abuse Protected (TAAP) Opioid. Late Breaking Oral Presentation. Presented at CPDD 2023, June 17-21, 2023. Downtown Denver Sheraton.

363. Schmidt, William K PhD, Evans, Cari, Pestano, Linda PhD, **Webster, Lynn MD**, Kirkpatrick, D. Lynn PhD. Poster #16023. Oral Human Abuse Potential of PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug With Overdose Protection. Oral and Poster presentation at PAINWeek 2023, September 5-8, 2023. The Cosmopolitan of Las Vegas.

364. Schmidt, William K PhD, Evans, Cari, Pestano, Linda PhD, **Webster, Lynn MD**, Kirkpatrick, D. Lynn, PhD. Poster #15923. Intranasal Human Abuse Potential of PF614: A Novel 'Next Generation' Trypsin Activated Abuse Protected (TAAP) Opioid. Poster presentation at PAINWeek 2023, September 5-8, 2023. The Cosmopolitan of Las Vegas.

365. Schmidt, William K PhD, Evans, Cari, Pestano, Linda PhD, **Webster, Lynn MD**, Kirkpatrick, D. Lynn, PhD. Poster #017. Intranasal Human Abuse Potential of PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug. ACCP 2023, September 10-12, 2023. Bellevue, WA.

366. Schmidt, William K PhD, Evans, Cari, Pestano, Linda PhD, **Webster, Lynn MD**, Kirkpatrick, D. Lynn PhD. Poster #016. Oral Human Abuse Potential of PF614: A Novel Trypsin Activated Abuse Protected (TAAP) Extended-Release Oxycodone Prodrug. ACCP 2023, September 10-12, 2023. Bellevue, WA.

367. **Webster, Lynn MD,** Hull S**.** Ventilatory Response to Hypercapnia as a Model to Study Respiratory Drive. Presented at the 17th Annual Pain Therapeutics Summit, San Diego CA, October 19-20, 2023.

368. **Webster L,** Hull S. Ventilatory Response to Hypercapnia as a Model to Study Respiratory Drive. Presented at the CNS Sumit 2023, Everett, MA, November 8-11, 2023.

369. **Webster, Lynn**, Gudin, Jeff. Curbing Opioid Abuse: Real-World Evidence of Abuse-Deterrent Formulations. AAPM 2024, Scottsdale, AZ, March 7-10, 2024.

370. **Webster L**, Cashion, S. Tailoring Technology for Pain Management: A Qualitative Comparison of Digital Health Platforms. Sixth Annual ASPN Conference, Miami Beach, FL. July 11-14, 2024.

371. **Webster, L.** BUPE2024: Buprenorphine in Medicine: Clinical and Public Policy Implications. Virtual Conference & Online Resource. August 5, 2024-August 5, 2025.
372. **Webster, L.**, Cashon, S., Jeff, and Cohen, D. Poster No. 321. Multi-specialty RTM outcomes: A preview of 2.7M+ ePROs from national observational cohort. Poster presented at the American Society of Pain & Neuroscience (ASPN) 2025 Annual Conference, Miami, FL. July 17–20, 2025.

373. **Webster, L.,** Cashon, S., Huynh, J., and Cohen, D. Poster No. 320. Remote Therapeutic Monitoring (RTM): Key criteria for evaluation and implementation. Poster presented at the American Society of Pain & Neuroscience (ASPN) 2025 Annual Conference, Miami, FL. July 17–20, 2025.

374. **Webster, L. R.**, Cashon, S., Huynh, J., & Cohen, D. *Improving Engagement and Outcomes in Chronic Pain Management: Multi-Specialty Real-World Evidence from a Remote Therapeutic Monitoring Platform.* Abstract presented at the Business of Pain: The Next Big Thing (Vagus Nerve Society), Eden Roc Miami Beach, Miami, FL. October 23-October 26, 2025. Winner of Top Abstract Award.

375. **Webster, L. R.**, Cashon, S., Huynh, J., & Cohen, D. *Not All RTM Is Created Equal: Understanding Platform Variability in Patient Engagement, Clinical Utility, and Audit Risk.* Abstract presented at the Business of Pain: The Next Big Thing (Vagus Nerve Society), Eden Roc Miami Beach, Miami, FL. October 23–26, 2025).

PRESS

1. Webster LR. Chronic pain takes quality of life from Utah teen. *Salt Lake Tribune*. April 11, 1999; Salt Lake City, UT.

2. O'Neill P. Guest speaker says pain medicine often under prescribed. *Independent Record.* February 14, 2006; Helena, MT.

3. Webster LR. Many kinds of abuse. *Salt Lake Tribune*. February 15, 2004.

4. Managing chronic pain: condition may require multiple therapies, but the first step is diagnosis. *Deseret News*. July 25, 2005.

5. Webster LR. Emerging solutions in pain. *ABC News.* March 5, 2006.

6. Pain and complexities of treatment. *The Doug Wright Show, KSL News.* April 6, 2006.

7. Zero unintentional deaths. *The Doug Wright Show, KSL News*. April 13, 2006.

8. Yeates E. Study offers hope for migraine sufferers. *KSL News*. May 18, 2006.

9. The brainiac. *Utah Education Network*. May 27, 2006.

10. Zero unintentional deaths. *The Charleston Gazette.* June 4-5, 2006; Charleston, WV.

11. Zero unintentional deaths. *KSL News.* June 15, 2006; Salt Lake City, UT.

12. Zero unintentional deaths. *The Standard Examiner*. June 22, 2006; Ogden, UT.

13. Zero unintentional deaths. *The Vernal Express Newspaper*. June 26, 2006; Vernal, UT.

14. Yeates E. Migraine sufferers have hope of pain-free future. *KSL News*. August 14, 2006.

15. Zero unintentional deaths. *KTVX Television*. September 22, 2006; Salt Lake City, UT.

16. Methadone overdoses. *20/20 ABC News*. September 22, 2006.

17. Methadone overdoses. *Catherine Crier Live on Court TV*. September 27, 2006.

18. Zero unintentional deaths. *KCSG TV*. October 4, 2006; St. George, UT.

19. Methadone overdoses. *People Magazine*. October 16, 2006.

20. Lampros J. Utah physician fighting accidental overdoses. *Standard-Examiner*. October 27, 2006; Ogden, UT.

21. Zero unintentional deaths. *The Charleston Gazette*. November 28, 2006; Charleston, WV.

22. Zero unintentional deaths. *KSL News*. November 28, 2006; Salt Lake City, UT.

23. Lampros J. Methadone deaths higher. *Standard-Examiner*. January 2, 2007; Salt Lake City, UT.

24. Yeates E. New skin patch may replace needle injections. *KSL News*. January 8, 2007; Salt Lake City, UT.

25. Webster LR. Emerging solutions in pain: clinical commentary on prescription drug abuse with a focus on methadone. February 7, 2007.

26. Methadone. *KUTV Television*. February 19, 2007; Salt Lake City, UT.

27. Methadone and zero unintentional deaths. *KSL News*. March 5, 2007; Salt Lake City, UT.

28. Carlisle N. Anti-drug activist dies from apparent prescription abuse. *Salt Lake Tribune*. April 4, 2007; Salt Lake City, UT.

29. Webster LR. Methadone and zero unintentional deaths. *CBS Evening News*. April 12, 2007.

30. Webster LR. Chronic pain and drug abuse. *Feedback with Scott Winter.* May 6, 2007.

31. Collins LM, Jarvik E. Dying to feel better: pain medication overdose deaths have become a Utah epidemic. *Deseret News*. May 10, 2007; Salt Lake City, UT.

32. Carlisle N. Case against Murray doc took years. *Salt Lake Tribune.* May 19, 2007; Salt Lake City, UT.

33. Lifetree Clinical Research now utilizing new technology to evaluate the abuse liability of test medications. *Pharmalive.com* August 31, 2007.

34. Jenkins A. Higher risk of sleep apnea when patients use opioid-based medications. *Medical News Today*. September 11, 2007.

35. Collins LM. Painkillers linked to sleep apnea: Salt Lake researcher says disorder may be factor in fatalities. *Deseret News*. October 2, 2007; Salt Lake City, UT.

36. Yeates E. New findings show pain medications may cause sleep apnea. *KSL News*. October 5, 2007; Salt Lake City, UT.

37. May J. Drug designed to fail the test: Alpharma developing tamper-resistant pain pill to help deter abuse. *The Star-Ledger.* November 9, 2007.

38. Yeates E. Ledger's death focusing attention on prescription drugs. *KSL News*. February 8, 2008; Salt Lake City, UT.

39. Webster LR. Drug abuse. *CBS Evening News with Katie Couric.* February 20, 2008.

40. Webster LR. Drug abuse. *CBS Local News with Christina Flores*. February 20, 2008; Salt Lake City, UT.

41. LaPook, J. Relieving pain with abuse-proof drugs. *CBS News*. February 20, 2008.

42. Skowran SM. Methadone deaths increase as its use as painkiller grows. *The News & Observer*. July 13, 2008; Raleigh, NC.

43. State tries to reduce prescription overdoses. *Deseret News*. December 8, 2008.

44. May H. Utah patients who need pain pills will be scrutinized. *Salt Lake Tribune*. March 26, 2009.

45. Rethinking chronic pain relief. *Minnesota Public Radio*. July 17, 2009.

46. Rosenfeld D. Jackson case highlights medical ethics. *Pacific Standard Magazine*. July 22, 2009.

47. Neighmond P. To help healing, doctors pay more attention to pain. *National Public Radio*. November 16, 2009.

48. Webster LR. Impact of overdosing drugs, including the facts of Michael Jackson's overuse of drugs. *NewsRadio 1620 AM, WNRP with Dave McDonald.*

49. Webster LR. Embeda. *KCBS 24-hour News with Ted Goldberg*.

50. Collins TR. Deaths from methadone overdose disproportionate to number of prescriptions. *Medscape Medical News*. February 8, 2010.

51. Leavitt SB. Factors behind Rx-opioid related overdose deaths examined. *Pain-Topics.org*. February 19, 2010.

52. Would changes in opioid formulation help deter abuse? *Addiction Intervention.* May 17, 2010.

53. Ravn K. When pain becomes chronic. *Los Angeles Times*. July 5, 2010.

54. Tilghman A, McGarry B. Rx for death: troop deaths soar with prescriptions for war wounded. *Navy Times*. September 3, 2010.

55. Santich K. Raising awareness of methadone's danger. *Los Angeles Times.* September 27, 2010.

56. O'Reilly, KB. Opioid safety is focus of $1 million-a-year educational initiative. *American Medical News*. October 25, 2010.

57. Blank C. Chronic pain patients, providers get new website. *Drug Topics*. December 15, 2010.

58. Haddad A. Conversation: Lynn Webster, MD, on launching PainSAFE, an educational initiative aimed at preventing deaths related to pain treatment. *Topics in Pain Management*. December 2010; 26(5):7-9.

59. Education a must for safe delivery of pain management therapies. *Patient Education Management*. December 2010; 17(12):133-144.

60. Goodman A. Morphine/Oxycodone combination superior to separate components. *Anesthesiology News*. January 2011.

61. Webster LR. Patients suffer when doctors are too scared to prescribe pain pills. *Washington Post*. January 11, 2011.

62. Is prescription drug abuse an epidemic? *Minnesota Public Radio News*. March 17, 2011.

63. Szalavitz M. U.S. aims to reduce overdose deaths, but will the new plan work? April 20, 2011.

64. Shorman J. Treatment up for prescription drug, alcohol abuse. *USA Today*. June 24, 2011.

65. Naltrexone leaves patients with limited options for acute pain. *Alcoholism & Drug Abuse Weekly*. July 11, 2011;23(26):3-4.

66. Ceniceros R. State reduces opioid prescriptions in workers comp cases. *Business Insurance*. October 2, 2011.

67. Waters H. Abuse-resistant painkillers get mixed FDA response. *Nature Medicine*. August 4, 2011:905.

68. Haley H. Opioid safety is job one. *Pain Live*. August 22, 2011.

69. Fattah G. Study shows Utah a leading state in painkiller deaths. *Deseret News*. November 2, 2011.

70. Decker R. Utah 4th worst in nation for prescription drug overdose deaths. *KUTV Channel 2 News*. November 3, 2011; Salt Lake City, UT.

71. Academy of Pain Medicine announces two-day course for safe prescribing for your primary physician. *Market Watch.* Press Release; November 4, 2011.

72. Ault A. Stratify patients for opioid misuse and abuse risk. *Internal Medicine News*. December 5, 2011.

73. Berens MJ, Armstrong K. New state law leaves patients in pain. *The Seattle Times*. December 11, 2011.

74. Wertich L. The chronic pain problem. *A Woman's Health*. Accessed December 19, 2011

75. Webster LR. Tackling opioid abuse & preventing drug-related deaths. *Physician's Weekly.* January 4, 2012.

76. Baxter C. N.J. Attorney General announces new prescription drug addiction program. *NJ.com*. January 19, 2012.

77. Ricks D. UN: U.S. consumes 80% of world's oxycodone. *Newsday*. January 21, 2012.

78. Pompei D. Urlacher says Toradol use isn't rampant. *Chicago Tribune*. January 25, 2012.

79. Fauber J. Painkiller boom fueled by networking. *Milwaukee Journal Sentinel*. February 18, 2012.

80. Fauber J. Chronic pain fuels boom in opioids. *Medpage Today*. February 19, 2012.

81. Deepak Chopra MD and Pondera Pharmaceuticals announce partnership. *Market Watch (The Wall Street Journal).* February 24. 2012.

82. Ko J. Morning dosing of extended-release hydromorphone results in fewer respiratory events than evening dosing. *Monthly Prescribing Reference*. February 26, 2012.

83. Nektar presents positive proof-of-concept clinical data for its new opioid molecule, NKTR-181, at American Academy of Pain Medicine's 28th Annual Meeting. *PR Newswire*. February 27,

2012.

84. Webster LR. Advocate perspectives with: Lynn Webster, MD; Medical Director and Founder, Lifetree Clinical Research & Pain Clinic. *In the Face of Pain*. March 1, 2012.

85. Johnson K. Experts propose urine drug testing guidance for opioid therapy. *Medscape News Today*. March 1, 2012.

86. LifeSource Co-Founder Lynn R. Webster, M.D. receives inaugural AAPM Presidential Excellence Award for Education. *PRWeb.com*. Press release; March 2, 2012.

87. Kever J. New tools tackle chronic pain. *Star Chronicle.* March 4, 2012.

88. Webster LR. What Whitney Houston teaches us. National Rx Drug Abuse Summit Newsletter. March 8, 2012.

89. Deaths related to prescription opioid therapy. *Addiction Treatment Strategies*. March 11, 2012.

90. Research finds overdose deaths occur when changing opioids. *PR Newswire*. March 29, 2012.

91. Hollenhorst J. Opiate conversion charts killing patients. *KSL News*. April 1, 2012. Salt Lake City, UT.

92. Hollenhorst J. Doctors kill thousands due to 'death tables,' Utah expert says in new study. *Deseret News*. April 1, 2012. Salt Lake City, UT.

93. Anson P. Changing opioids causing more overdose deaths. *American News Report*. April 2, 2012.

94. Ogozaly S. Inaccurate dosing tables implicated in overdose. *Pain Live.* April 2, 2012.

95. Tawoda T. Switching opioids increases risk of overdose death, study says. *Becker's Spine Review*. April 3, 2012.

96. Klimas L. 'Death Tables': 'Notoriously Inaccurate' Medical Reference Tool Could Be Killing Thousands. *The Blaze Magazine*. April 3, 2012.

97. Anderson P. Opioid rotation practices linked to fatalities. *Medscape News Today*. April 5,

98. Leavitt SB. New perspective on safer opioid rotation. *Pain-topics.org*. April 5, 2012.

99. Anson P. Senate probe targets drug makers, pain organizations and pain physicians. *American News Report.* May 9, 2012.

100. Nektar to host investor and analyst R&D day in New York City. *Yahoo Finance*. April 10, 2012.

101. Han DH. Liquid capsaicin (NGX-1998) provides PHN relief after five minutes. *Monthly Prescribing Reference*. May 19, 2012.

102. Moyer CS. More newborns showing ill effects of maternal opioid use. *American Medical News*. May 21, 2012.

103. Anson P. Pain doc: "Physicians can't be cops. We're treating pain patients." *American News Report.* May 22, 2012.

104. Berry J. Addiction epidemic: Americans' problems with pain meds go back a century. *Nashuatelegraph.com*. June 25, 2012.

105. Leys T. Iowa health pain patients struggle to find new care. *Indystar.com*. June 28, 2012.

106. Perrone M. FDA unveils safety measures for opioid painkillers. *Associated Press*. July 9, 2012.

107. Moyer CS. FDA opioid safety plan focuses on physician education. *American Medical News*. July 23, 2012.

108. Pizzi D. Senate investigation: conversation with Lynn Webster, MD. *Pain Medicine News* (podcast). July 26, 2012.

109. Knopf A. Little known about stories behind OD deaths, says pain expert. *Alcoholism & Drug Abuse Weekly*. September 17, 2012;24(35):3-4.

110. Kreimer S. FDA warns of serious skin burns from topical pain relievers. *ABC News Radio*. September 17, 2012.

111. Webster LR. Physicians at the forefront. *Chronic Pain (Supplement to USA Today).* September 2012.

112. Lewis D. Utahns honored for healthcare contributions. *Utah Business*. October 11, 2012; Salt Lake City, UT.

113. Hartman C. Prescription drug abuse. *The Chad Hartman Show (CBS Radio).* October 17, 2012. Minneapolis, Minnesota.

114. Bankhead C. Drug relieves opioid-induced constipation. *Medpage Today*. October 24, 2012.

115. The joint commission and the FDA take steps to curb adverse events related to the use and misuse of opioid drugs. *ED Management*. 2012;24(10):112-116.

116. Walker AK. Meningitis outbreak brings attention to treatment of back pain. *The Baltimore Sun*. November 4, 2012.

117. Krisberg K. Chronic pain patients caught in the middle of growing opioid abuse problem. *Science Blogs*. November 9, 2012.

118. Glover S, Girion L, Baylen LO. Dying for relief | A Times Investigation: Legal drugs, deadly outcomes. *Los Angeles Times*. November 11, 2012.

119. Albert-Henry T. AMA webinar spells out 8 ways physicians can curb opioid misuse. *American Medical News.* November 14, 2012.

120. Krisberg K. Physicians take lead role in confronting opioid misuse, but still face hurdles. *Science Blogs' The Pump Handle*. November 16, 2012.

121. Butterworth T. Is the era of OxyContin abuse over? *Forbes*. December 13, 2012.

122. Ochoa G. FDA document supports maintaining schedule III status for hydrocodone combination products. *Pain Medicine News*. 2013;11.

123. Thomas K, Meier B. Drug makers losing a bid to foil generic painkillers. *The New York Times*. January 1, 2013.

124. Sullivan T. American Academy of Pain Medicine incoming President asks: without industry involvement – where will the education and research funds come from? *Policy and Medicine*. January 4, 2013.

125. Leger DL. FDA might tighten reins on Vicodin. *USA Today*. January 10, 2013.

126. Webster LR. Making opioid drugs less alluring. *The Wall Street Journal*. January 13, 2013.

127. O'Reilly KB. Reformulated opioids thwart misuse of the painkillers. *American Medical News*. January 14, 2013.

128. Stein R. Painkiller paradox: Feds struggle to control drugs that help and harm. *National Public Radio.* January 23, 2013.

129. Fauber J, Gabler E. FDA to weigh tighter rules on Vicodin. *Journal Sentinel.* January 23, 2013.

130. Fauber J. Will FDA limit Vicodin Rx? *Medpage Today*. January 23, 2013.

131. Gardner A. FDA panel weighs tougher restrictions on some prescription painkillers. *Health Day News – U.S. News & World Report*. January 24, 2013.

132. Catan T, Martin TW. FDA panel calls for new curbs on common painkiller. *The Wall Street Journal*. January 25, 2013.

133. Gehrke J. After Mike Bloomberg's rule for hospitals, FDA panel votes to restrict use of painkillers. *The Washington Examiner*. January 25, 2013.

134. Fiore K. FDA panel votes for tighter controls on Vicodin. *Medpage Today*. January 25, 2013.

135. Stein R. To fight addiction, FDA advisers endorse limits on Vicodin. *National Public Radio.* January 25, 2013.

136. Gardner A. FDA panel votes for tougher curbs on Vicodin, other painkillers. *HealthDay.* January 25, 2013.

137. Fauber K, Gabler E. FDA panel votes to place tighter controls on narcotic painkillers like Vicodin. *Milwaukee Journal Sentinel*. January 26, 2013.

138. Wildsmith S. Half steps little help in fighting addiction. *The Daily Times*. January 27, 2013.

139. Garcia A. FDA panel pushing for new limits on access to Vicodin. *The Raw Story*. January 26, 2013.

140. Smith P. FDA panel wants tighter control over pain pills. *Stopthedrugwar.org* January 28, 2013.

141. Argoff CE. We must have tamper-proof drugs. *The Wall Street Journal*. January 28, 2013.

142. FDA panel seeks for greater restrictions on Hydrocodone. *RTT News.* January 28, 2013.

143. Nordqvist C. Limits urged on painkillers by FDA advisory panel. *Medical News Today*. January 28, 2013.

144. Mechcatie E. FDA panel backs more restricted hydrocodone prescribing. *Clinical Psychiatry News*. January 29, 2013.

145. Santo A. New limits on addictive pain pill. *Times Union*. January 31. 2013.

146. Green-Miner B. Trolley Square shooting survivor speaks out against hydrocodone changes. *Fox13 News.* February 7, 2013.

147. Rascon D. FDA decision could be devastating to Trolley Square shooting victim. *KUTV Channel 2 News*. February 7, 2013.

148. Wild D. FDA issues draft guidance for abuse-deterrent opioid development. *Pain Medicine News*. February 2013.

149. Zimmer R. Exclusive: more work ahead on opiates. *Media Network of Central Ohio.* February 15, 2013.

150. Usero A. Painkiller abuse reaches epic proportion. *RT America*. February 20, 2013.

151. Webster L. A responsible way to treat patients, pain. *Milwaukee Journal Sentinel*. March 5, 2013.

152. Glover S, Girion L. Bill aims to tighten restrictions on painkiller hydrocodone. *Los Angeles Times*. March 20, 2013.

153. Derr E. Lawmakers want more limits on hydrocodone – vicodin, norco, lortab. *Latinos Post*. March 22, 2013.

154. Glover S, Girion L. Deaths tied to painkillers continue to rise in the U.S. *The Los Angeles Times*. March 29, 2013.

155. Stein R. How much does it hurt? Let's scan your brain. *National Public Radio*. April 10, 2013.

156. 'Pain signature:' Scientists map aching and its intensity in brain. *RT*. April 11, 2013.

157. Susman E. Prop ketamine may lower pain in fibromyalgia. *Medpage Today*. April 13, 2013.

158. Susman E. BMI doesn't seem to dull efficacy of opioid patch. *Medpage Today*. April 14, 2013.

159. New President of American Academy of Pain Medicine plans bold advances in pain education, research and pain care delivery. *PR Newswire*. April 15, 2013.

160. New AAPM President plans 'bold advances' in pain education, research and pain care delivery. *Pain Medicine News*. April 16, 2013.

161. Ali I. FDA approves painkiller Obama administration warned of in December. *All Voices*. April 17, 2013.

162. Shute N, Carlsen A. FDA's rejection of generic oxycontin may have side effects. *National Public Radio*. April 18, 2013.

163. Anderson P. Physician education among goals for new AAPM President. *Medscape Today*. April 18, 2013.

164. CRI Lifetree chief medical director Dr. Lynn Webster named president of the American Academy of Pain Medicine (AAPM). *Business Wire*. April 23, 2013.

165. Miller S. Eight principles for safe opioid prescribing. *The Oncology Report*. May 2, 2013.

166. Pizzi D. Pressure on FDA for abuse-deterrent generic opioid analgesics mounts. *Pain Medicine News*. May 2013;11.

167. Moyer CS. Opioid abuse crackdown puts heroin back in style. *American Medical News*. June 10, 2013.

168. Lynn Webster, MD and pain specialist develops safer and more effective therapies for chronic pain. *PRLog*. June 10, 2013.

169. CRI Lifetree expert Lynn Webster, MD, to discuss human abuse liability at DIA annual meeting. *Business Wire*. June 12, 2013.

170. Nektar issues data from human abuse liability study for NKTR-181. *Bezinga*. June 19, 2013.

171. Nektar Therapeutics presents positive data from human abuse liability study for NKTR-181. *PharmaLive*. June 19, 2013.

172. Eight principles for safer opioid prescribing: an interview with Lynn Webster, MD. *Pain Medicine News*. June 2013;11.

173. Ruggles R. Antidepressant increasingly used – with success – to treat chronic pain. *Omaha World Herald*. June 22, 2013.

174. Lynn Webster, MD launches first of three interviews discussing his goals as President of the American Academy of Pain Medicine. *PRLog*. June 26, 2013.

175. Girion L, Glover S. Doctors prescribe narcotics too often for pain, CDC chief says. *Los Angeles Times*. July 2, 2013.

176. Naudziunas J, Neighmond P. A surge in painkiller overdoses among women. *National Public Radio*. July 3, 2013.

177. Neighmond P. Deadly painkiller overdoses affecting more women. *National Public Radio*. July 3, 2013.

178. Flores C. More women dying from prescription pain pill overdoses. *KUTV*. July 4, 2013.

179. Miller N. Eight principles outlines for safe opioid prescribing. *ACEP News*. July 11, 2013.

180. Miseta E. Will pharma and the FDA act to control opioid abuse? *Outsourced Pharma*. August 13, 2013.

181. 'We have an epidemic on our hands and the status quo is failing us': an interview with Lynn Webster, MD. *Pain Medicine News*. August 2013;10.

182. Keilman J. Prescription drugs take deadly toll on roads. *Chicago Tribune*. August 17, 2013.

183. Mallinckrodt Pharmaceuticals reports human abuse liability (HAL) data for MNK-795, an extended-release oxycodone/acetaminophen combination. *Business Wire*. September 4, 2013.

184. 'The answer certainly does not lie with current opioids': an interview with Lynn Webster, MD. *Pain Medicine News*. September 2013;32.

185. Dandurant K. Treating pain without creating an addiction. *Seacostonline.com* September 8, 2013.

186. Anson P. FDA makes labeling changes for opioid painkillers. *AmericanNewsReport.com*. September 10, 2013.

187. Catan T, Martin TW. FDA toughens warning on pain drugs. *Wall Street Journal*. September 10, 2013.

188. Davis J. FDA set to change opioid labeling. *Arthritis Today*. September 13, 2013.

189. Beyond the headlines: what the FDA decisions on extended-release and long-acting opioids mean for people with pain. *PR Newswire*. September 17, 2013.

190. Pizzi D. FDA makes opioid labeling changes, requires more postmarketing data; REMS next. *Pain Medicine News*. September 2013;11.

191. Cashin-Garbutt A. MNK-795 for acute pain management: an interview with Dr. Lynn Webster. *News Medical*. October 8, 2013.

192. Pizzi DM. The last word on FDA opioid labeling? *Pharmacy Practice News*. October 2013;40.

193. Thompson D. FDA urges tighter controls on certain prescription painkillers. *HealthDay*. October 24, 2013.

194. Guarino B. Will opioid scrutiny spur NSAID overuse? *Pain Medicine News*. November 2013;11.

195. Vlessides M. Study shows marijuana use may be linked to opioid noncompliance. *Pain Medicine News*. November 2013;11.

196. Thompson D. Brain scan shows fibromyalgia patients process pain differently. *HealthDay*. November 5, 2013.

197. Lynn Webster MD weighs in on recent FDA recommendation. *PRLog*. November 7, 2013.

198. Ross V. The FDA's new rules for painkillers. *Men's Journal*. November 8, 2013.

199. Craig DS, Gevirtz C, Gharibo C, Nelson LS, Webster LR. Risk evaluation and mitigation strategy for extended-release and long-acting opioids: clinicians weigh in. *Pain Medicine*

News. December 2013.

200. **Webster LR**. The role of urine drug testing in chronic pain management: 2013 update. *Pain Medicine News.* December 2013.

201. Friedman E. Stopping Dr. Feelgood: The Challenge of Overprescribing. *Hospitals & Health Networks.* February 4, 2014.

202. Fiore K. Killing pain: script by script. *Medpage Today*. February 27, 2014.

203. New online community from **Dr. Lynn Webster** helps clients with chronic pain management. *PRWeb.com*. March 18, 2014.

204. Fikes B. Computer accurately detects pain. *San Diego Union-Tribune.* March 20, 2014.

205. Fikes B. Abuse of painkillers hurts real patients. *San Diego Union-Tribune.* March 22, 2014.

206. Dunleavy BP. Potential hydrocodone-combination product rescheduling sparks debate. *Pain Medicine News*. 2014;12(4).

207. Edlin M. Higher costs of doctor-dispensed drugs draw state reform efforts. *DrugTopics.com*. April 10, 2014.

208. Bufano P. Naloxone auto-injector approval for opioid overdose will save lives, better pain drugs still needed, expert says. *Pain Medicine News*. April 11, 2014.

209. Leys T. Judge dismisses 2 manslaughter charges in Baldi trial. *Des Moines Register*. April 29, 2014.

210. Ollove M. States challenge FDA over painkiller Zohydro. *The Patriot Ledger*. April 29, 2014.

211. Kim ET. A Lazarus drug goes mainstream in the heroin war. *Al Jazeera America*. June 2, 2014.

212. Webster L. When physicians get sued, patients pay. *Des Moines Register*. June 5, 2014.

213. Webster L. When prosecution replaces prescription. *Pain Medicine News*. June 11, 2014.

214. Trevena's phase 1b data for TRV130 published in the journal Pain. *News-Medical.net*. June 24, 2014.

215. Stewart K. Prominent Utah pain doc no longer under scrutiny for patient deaths. *Salt Lake Tribune*. June 29, 2014.

216. Shurman JR, Shurman G, Groza A, Groza A, Smith C, Alfenbaum M, Adler J. DEA and doctors working together. *Practical Pain Management*. June 1, 2014.

217. Webster L. Op-ed: My experience shows we need better pain care. *Salt Lake Tribune*. July 18, 2014.

218. Girion L. FDA approves new opioid pain reliever designed to be hard to abuse. *Los Angeles Times*. July 23, 2014.

219. Frei R. Small study examines inflammatory response to combination of acute pain and opioids. *Pain Medicine News*. August 2014.

220. Webster L. Intimidating doctors won't solve the chronic pain epidemic. *KevinMD.com*. August 11, 2014.

221. Webster L. Finding a life with meaning by managing pain. *The Washington Post*. August 22, 2014.

222. Brooks C. Vicodin as dangerous as meth, U.S. reclassifies drug. *China Topix*. August 23, 2014.

223. Young S. Medical marijuana laws may reduce painkiller overdoses. *CNN*. August 25, 2014.

224. Webster L. NFL players reveal nation's poor treatment of chronic pain. *Chicago Sun-Times*. August 26, 2014.

225. DEA ends investigation of pain doctor. *Pain Medicine News*. September 2014.

226. Frei R. Small study examines inflammatory response to combination of acute pain and opioids. *Anesthesiology News*. September 2014.

227. Grabowski C. Medical marijuana reduces painkiller overdose rates. *News Channel Daily*. September 1, 2014.

228. Mallinckrodt Pharmaceuticals releases human abuse liability (HAL) data for investigational MNK-155, an extended-release hydrocodone/acetaminophen combination. *MarketWatch*. September 3, 2014.

229. Anson P. Pain experts predict problems with hydrocodone rescheduling. *NationalPainReport.com*. September 5, 2014.

230. Anderson P. New screening tool for chronic migraine. *Medscape.* September 5, 2014.

231. Anderson P. The changing face of opioid addiction. *Medscape.* September 8, 2014.

232. Anderson P. Updated 'tool kit' to prevent opioid overdose. *Medscape*. September 8, 2014.

233. Anderson P. The opioid constipation 'disconnect'. *Medscape*. September 9, 2014.

234. Cara Therapeutics to sponsor symposium at American Academy of Pain Management 2014 Annual Clinical Meeting. *MarketWatch*. September 17, 2014.

235. Webster L. When prosecution replaces prescription. *Anesthesiology News*. September 2014.

236. Fiore K. AAN warns against opioids in chronic noncancer pain. *Medpage Today*. September 29, 2014.

237. Browning D. Study calls lack of data on widely used opioid painkillers 'shocking.' *Star Tribune*. October 10, 2014.

238. Cara Therapeutics (CARA) reports positive data from HAL trial of CR845 IV formulation. *Streetinsider.com*. October 29, 2014.

239. Browne C. Cara Therapeutics Inc soaring on good news in opioid agonist trial. ValueWalk. October 29, 2014.

240. Widespread chronic pain seen in study of U.S. military. *Pain Medicine News*. November 2014;12(11).

241. Methadone suppresses sex hormones in men, but not women. *Pain Medicine News*. 2014;12(11).

242. Anson P. Pain experts say new opioid has 'enormous' potential. *National Pain Report*. November 5, 2014.

243. Anson P. Pain patients forced to go 'cold turkey' from hydrocodone. *National Pain Report*. November 7, 2014.

244. Ungar L. Non-addictive narcotic painkillers may be close. *The Courier-Journal*. November 11, 2014.

245. Local couple wins national scholarships to help people with chronic pain in Virginia. *The Progress-Index*. November 16, 2014.

246. Trevena announces positive top-line results from phase 2a/b study of TRV130 in acute postoperative pain. *BusinessWire*. November 17, 2014.

247. ACT buys AGN, NBS needs a close watch, no pain for TRVN TKMR does a deal. *RTT News*. November 18, 2014.

248. Dunleavy B. Widespread chronic pain seen in study of U.S. military. *Anesthesiology News*. December 2014;40(12).

249. **Webster L**. Opioid prescribing: understanding the risks. *National Pain Report.* December 8, 2014.

250. Argoff C, A, Diatchenko L, Gupta, **Webster LR**. Pharmacogentic testing in pain medicine: experts weigh in. *Pain Medicine News*. December 2014; 12(12).

251. **Webster LR**. VA announcement a new front in fight against chronic pain among veterans. *Pain Medicine News*. January 2015; 13(1).

252. Dunleavy B**.** Lessons learned from Abington Memorial Hospital's new institutional methadone policy. *Pain Medicine News*. January 2015;13(1).

253. Anderson P. Scant evidence for long-term opioid therapy in chronic pain. January 13, 2015.

254. Egalet announces positive top-line results from oral human abuse liability study of abuse-deterrent morphine, Egalet-001. *Globe Businesswire*. January 22, 2015.

255. Lakhan SE. Opioids for chronic pain – an interview with Dr. Webster, pain guru. *BrainBlogger.com.* January 30, 2015.

256. Study suggests physician dispensing of opioids in Florida led to overprescribing. *Pain Medicine News*. February 5, 2015.

257. Dreier F. The debate over running while high. *The Wall Street Journal*. February 9, 2015.

258. Webster L. Jennifer Aniston nails her role in 'Cake,' living with chronic pain. *Sun Sentinel*. February 10, 2015.

259. Webster L. DEA should not interfere with physicians, pain patients. *Orlando Sentinel*. February 19, 2015.

260. McCord K. New technology may help prevent abuse of pain medications. *KSL*. February 20, 2015.

261. Webster LR. Time for a more rational cannabis policy. *Pain Medicine News*. March 2015; 13(3).

262. Webster L**.** My view: Opioid technology can save Utah lives. *Deseret News*. March 3, 2015.

263. Webster LR. Opioid tech can save Utah lives. *InsuranceNewsNet.com*. March 3, 2015.

264. Whalen J. Holy Grail: Pain Pills without the High. *Wall Street Journal*. March 17, 2015.

265. Cara Therapeutics to sponsor symposium and present poster at the American Academy of Pain Medicine's 31st annual meeting. GlobeNewswire. March 19, 2015.

266. Webster L. Prescription Drug Monitoring Programs – Much Promise But Limited Progress. *BrainBlogger.com*. March 22, 2015.

267. Proove Biosciences hosts symposium on incorporating genetic testing to optimize the management of pain. *PRWeb.com*. March 25, 2015.

268. Bourg A. Chronic pain a constant struggle for many Americans. *ABC2News WMAR Baltimore*. March 26, 2015.

269. Anson P. Study claims 10% of pain patients addicted to opioids. *Pain News Network.* March 31, 2015.

270. Webster LR. Jennifer Aniston's Oscar-Worthy Performance Shows Life with Chronic Pain. *Pain Medicine News*. April 2015;13(4).

271. Kean N, Webster LR. Abuse-deterrent Guidelines Issued by FDA. *Practical Pain Management*. April 2, 2015.

272. Anson P. U.S. Hydrocodone Prescriptions Dropping. *Pain News Network*. April 14, 2015.

273. Webster LR. Report on Opioids During Pregnancy Harms Pain Community. *Neurology Advisor*. April 15, 2015.

274. Webster LR. Acceptance with Resilience – Living with Chronic Pain. *BrainBlogger.com*. April 30, 2015.

275. Webster LR. Patients suffered first 100 days after hydrocodone rescheduling. *Pain Medicine News*. May 2015;13(5).

276. Webster LR. What is an Expert Witness? www.PainDr.com. May 11, 2015.

277. Naldemedine safely improved opioid-induced constipation in patients with chronic noncancer pain. *Healio Gastroenterology.* May 22, 2015.

278. Webster LR. The ongoing push for human abuse liability studies in the EU. *Clinical Leader*. May 26, 2015.

279. Webster LR**.** Six ways to end the opioid crisis. *Morrow County Sentinel*. June 1, 2015.

280. Neighmond P. To ease pain, reach for your playlist instead of popping a pill. *National Public Radio (NPR)*. June 22, 2015.

281. Pacenti J. Justin Bieber to the rescue? Study finds music indeed heals. *Palm Beach Post*. June 23, 2015.

282. Gold M. Have a Headeache? An Hour at the Beach Might Be as Effective as a Painkiller. *Glamour*. July 3, 2015.

283. Snook G. Opinion: The Voice of the Chronic Pain Patient Is Not Being Heard. *National Pain Report.* July 4, 2015.

284. Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California. *PRWeb.com*. July 6, 2015.

285. Salamon M. Study finds drinking may ease fibromyalgia pain, but doctors wary. *News 9 Oklahoma.* July 30, 2015.

286. Bannow T. When pot means no prescription for pain: Doctor/patient divide over marijuana. *The Bend Bulletin*. August 10, 2015.

287. Anson P. Experts Say Epidural Steroid Injections Overused. *Pain News Network.* August 19, 2015.

288. Smardon A. Could Medical Marijuana Reduce Dependence on Opiates in Utah? *KUER.ORG (NPR UTAH)*. August 19, 2015.

289. Webster L**.** The Painful Truth: How Patients Are Treated Shamefully. *Pain News Network.* August 26, 2015.

290. Anderson P. Opioid Switch to Buccal Buprenorphine May Limit Withdrawal. *Medscape.* September 11, 2015.

291. Endo Pharmaceuticals and BioDelivery Sciences Present New Data on Investigational Product Buprenorphine HCI Buccal Film for Chronic Pain Management. *Virtual Pres Office.com*. September 9, 2015.

292. Swenson J. Dubuque doctor: More pills not always answer to chronic pain. *Tri-State News*. September 30, 2015.

293. Webster L**.** OTC Painkillers That Can Be Deadly. *Bottom Line Personal*. October 1, 2015.

294. Neild D. Listening to Music Can Help Cure a Hangover – If You Pick The Right Tunes. *Science Alert.* October 24, 2015.

295. 5 Pain Medicine Specialists who are Making a Difference. *Board Vitals*. October 26, 2015.

296. Martin A. Dr. Lynn Webster of PRA Health Sciences Interviewed. *Serene Science*. December 2015.

297. Webster L. 'My Country is Failing Me': A Call to Action for the Pain Community. *Pain Medicine News*. November 2015.

298. Webster L. Heroin Documentary is a Start. *The Morrow County Sentinel.* January 12, 2016.

299. Chen D. Medical marijuana gets another shot. *Deseret News*. January 13, 2016

300. Webster L**.** Is Marijuana the Holy Grail for Pain Medicine? *Aptos Times*. January 14, 2016

301. Moraff C. Feds' pill Crackdown Drives Pain Patients to Heroin. *The Daily Beast*. April 14, 2016.

302. Olson S. Painkiller Prescriptions Decline for the First Time in 20 Years, But Fatal Overdoses Still Climbing. *The Grapevine*. May 22, 2016.

303. Berlatsky N. Chronic pain patients are suffering because of the US government's ongoing War on Drugs. *Quartrz.* May 31, 2016.

304. Rosenthal M. New Abuse-Deterrent Opioid One Step Closer to Approval. *Pharmacy Practice News*. June 8, 2016.

305. Pizzi D. Overdose Death of Prince Puts New Celebrity Face on Opioid Epidemic. *Pain Medicine News*. June 3, 2016.

306. Chen D. Utah's prescription painkiller epidemic 'crosses every socioeconomic boundary. *Deseret News.* June 9, 2016.

307. Saunders D. Opioid Epidemic Needs to Stop. *World Report Now*. June 10, 2016.

308. Webster L**.** The CDC and DEA want to be your ghost doctor. *Pain News Network.* June 29, 2017.

309. Webster L. Letter to the Editor. *New England Journal of Medicine* 375;1. July 7, 2016.

310. Anson P. Surgeon General Launches Anti-Opioid Campaign. *Pain News Network*. August 25, 2016.

311. Webster L**.** Op-ed: To solve the opioid crisis, we must first address people's pain. *The Salt Lake Tribune.* August 27, 2016.

312. Webster L. Surgeon General Call to Action Falls Short. *The Huffington Post*. September 8, 2016.

313. Anderson P. Knee Pain Linked to Pain Elsewhere. *Medpage Today*. September 18, 2016.

314. Kuehn B. PBM Boosts Effort to Lessen Lethal Misuse of Opioids. *Pain Medicine News*. September 21, 2016.

315. Webster L. Grants and Funding: Is 'Fahrenheit 451' Today's Reality? *Pain Medicine News.* September 22, 2016.

316. Ullman K. Fight the Cold. *Pain-Free Living.* October/November 2016.

317. Holzman D. Study: Hydrocodone Rescheduling Affects Prescribing. *Pain Medicine News*. November 1, 2016.

318. Anson P. Pain Patients Say Insurers Interfering with Treatment. *Pain News Network*. November 10, 2016

319. Anson P. Iowa Lawmaker Calls Cancer Pain 'Regular Ailment.' Pain *News Network.* November 18, 2016.

320. Webster L. Will Insurance Companies Impede Surgeon General's Plan to Treat Addiction as a Disease? *The Hill*. November 30, 2016.

321. Piller C. Called 'hogwash,' a gene test for addiction risks exploits opioid fears. *STAT*, December 13, 2016.

322. Webster L. Medical illiteracy contributes to the opioid crisis. *The Hill*. December 20, 2016.

323. Webster L. What should Trump look for in a new CDC director? *The Hill*. January 12, 2017.

324. Webster L. Pain patients suffer when medical community fights about opioid epidemic. *The Hill*. January 30, 2017.

325. Webster L. Republicans are moving to take choice away from physicians. What will Tom Price do? *The Hill*. March 4, 2017.

326. Anson P. PBS Documentary Brings Chronic Pain Out of Shadows. *Pain News Network*. March 6, 2017.

327. Webster L. White House 'reefer madness' clouding marijuana law. *The Hill*. May 4, 2017.

328. Cioppa C. Fibromyalgia and alcohol: To drink or not to drink? *Fibromyalgiatreating.com*. May 8, 2017.

329. Webster L. Rep. Raúl Labrador, people do die from lack of insurance. *The Hill*. May 10, 2017.

330. Webster L. New and Emerging Alternatives to Opioids for Pain. *Wavelength by PRA Health Sciences.* June 9, 2017.

331. Anson P. Health Insurer to Adopt 5 Day Limit on Opioids. *Pain News Network.* June 27, 2017.

332. Lauerman J. Surgeons Are Ditching Opioids for Ibuprofen and Novocain in the OR. *Bloomberg*. July 6, 2017.

333. Brewer R. Reducing opioid addiction must balance patient needs. *Shreveport News.* July 17, 2017.

334. Holzman D. Survey Elucidates Chronic Pain Patient, Household Member Perceptions of Long-Term Opioid Therapy. *Pain Medicine News*. July 20, 2017.

335. Webster L. Who is to blame for skyrocketing drug prices? *The Hill*. July 27, 2017.

336. Webster L. Congress needs to recognize the seriousness of football-related brain injuries. *The Hill*. August 9, 2017.

337. Ehrenfeld T. Why are more seniors using marijuana? *Healthline*. September 6, 2017.

338. May B. Morphine and Oxycodone Abuse-Deterrent Formulations Lower Absorption Rates. *Clinical Pain Advisor*. September 7, 2017.

339. Webster L. Americans need to ditch opioids for more effective and safer alternatives. *The Hill*. September 14, 2017.

340. Writing Staff. Naloxegol Has No Effect on Opioid Dose in Opioid-Tied Constipation. *Doctors' Lounge*. September 20, 2017.

341. **Webster L**, Katz N, Passik S. Abuse-Deterrent Opioids: Why Rush to Judgement? *Practical Pain Management*. September 27, 2017.

342. Anson P. The Secret Role of Insurers in Medicare Opioid Policy. *Pain News Network*. October 19, 2017.

343. Knapp G. #OurPain: Opioid crisis leaves legitimate pain patients struggling. *LasVegasNOW.* November 6, 2017.

344. Knapp G. #OurPain: Woman says she is made to feel like a drug addict. *LasVegasNOW.* November 8, 2017.

345. Courvoisier D. #OurPain: How money factors into the opioid debate. *LasVegasNOW*. November 9, 2017.

346. Raj A. New Joint Commission Pain Standards a Good Start, but Devil's in the Details: Experts. *Pain Medicine News*. November 16, 2017.

347. **Webster L**. We have a drug overdose crisis, not a prescription opioid crisis. *The Hill.* November 16, 2017.

348. Knapp G. #OurPain: Pain doctor who defends opioids under investigation. *LasVegasNOW*. November 21, 2017.

349. **Webster L**. Evaluating the CEA's cost estimates of the opioid crisis. *The Hill*. November 29, 2017.

350. **Webster L**. Commentary: The Tribune was wrong. Medicine often involves a risk to the patient. *The Salt Lake Tribune*. December 10, 2017.

351. **Webster L**. Expert Panel Report on Urine Drug Monitoring for At-Risk Chronic Pain Patients. *Practical Pain Management.* December 12, 2017.

352. **Webster L**. Arachnoiditis More Common Source of Pain Than Previously Believed. *Pain Medicine News*. December 20, 2017.

353. **Webster L**. Downsizing vocabulary by the CDC show a desire to manipulate messages. *The Hill.* December 28, 2017.

354. **Webster L.** The hidden story behind lower life expectancy. *The Hill.* January 10, 2018.

355. **Webster L**. Trump divides the nation with his 'us vs. them' mentality regarding our drug problem. *The Hill*. January 22, 2018.

356. **Webster L.** White House opioid summit failed to deliver any real solution. *The Hill*. March 7, 2018.

357. Sullum J. New Medicare Rule Promises Needless Suffering for Pain Patients. *Reason.* March 28, 2018.

358. **Webster L**. CMS proposes to force patients off effective opioid doses without their physician's approval. *The Hill*. March 29, 2018.

359. Sullum J. America's War on Pain Pills is Killing Addicts and Leaving Patients in Agony. *Reason*. April 2018.

360. Anson P. Medicare Finalizes Plan to Reduce High Dose Opioids. *Pain News Network.* April 2, 2018.

361. **Webster L**. Should sugar be classified in the same category as heroin? *The Hill*. April 29, 2018.

362. Anson P. Study Finds Opioid Medication Effective for Chronic Pain. *Pain News Network*. May 3, 2018.

363. **Webster L**. Stop labeling babies as 'born addicted' — it stigmatizes them and is inaccurate. *The Hill*. June 19, 2018.

364. **Webster L**. President Trump's border policy is a catalyst for drug addiction. *The Hill*. June 29, 2018.

365. **Webster L**. Letter Written to the Oregon Health Evidence Review Commission. Submitted July 28, 2018.

366. Schatman M, **Webster L**, Twillman R, Hoffman D, Beletsky L, Goldberg D, Rieder T, Nicholson K, Mayer J, Ziegler S, Lewis T, Laird D, Murphy J. U.S. Chronic Pain Practitioners and Scientists Comment on Oregon Forced Taper Proposal. *National Pain Report*. July 31, 2018.

367. **Webster L**. CDC opioid guideline is causing harm to people in chronic pain. *The Hill*. August 16, 2018.

368. Holzman D. History of Child Abuse Linked to Risk Factors, Pain Pathways in Adults. *Pain Medicine News*. August 21, 2018.

369. Berlatsky N. The Opioid Crisis is Also a Crisis of Speech. *Pacific Standard.* August 24, 2018.

370. **Webster L**. Can Scott Gottlieb reverse the opioid crisis? *The Hill*. August 31, 2018.

371. **Webster L**. Truth isn't truth — why our brains can sometimes accept lies. *The Hill*. September 20, 2018.

372. New Ventilatory Response to Hypercapnia Model Seeks to Evaluate Risk for Respiratory Depression. *Anesthesiology News*. October 5, 2018.

373. Anson P. Is Walmart Blacklisting Doctors? *Pain News Network.* October 08, 2018.

374. Drash W. Trump claims on opioid crisis met with mix of skepticism and hope by experts as deaths plateau. *CNN.* October 24, 2018

375. Sullum, J. Medicare Rule Will Create New Challenges for Chronic Pain Patients. *Practical Pain Management.* November 15, 2018.

376. Burch, K. The Other Side of the Opioid Epidemic: Chronic Pain Patients. *the fix.*November 26,2018.

377. Ramseth, L. Opioid makers pent nearly a million dollars on Utah doctors in recent years, ties now used against the companies in lawsuits. *The Salt Lake Tribune.* November 25,2018.

378. Webster, L. Hemp is not marijuana. *Omaha World-Herald.* December 9, 2018.

379. Llorente E. Doctors caught between struggling opioid patients and crackdown on prescriptions. *FoxNews.com.* December 11,2018.

380. Webster, L. Sen. Wyden Wants to Censor Pain Experts' Opinions. *Pain News Network.* January 04,2019.

381. Air Talk hosted by Larry Mantle. How your eyeballs could be the key to helping physiciaans develop an objective benchmark for pain. January 15,2019.

382. Webster, L. How Hollywood Romanticizes Addiction. *Pain News Network.* January 19, 2019

383. Webster, L. How Government Shutdowns Worsen the Opioid Crisis. *Pain News Network.* January 28, 2019.

384. Anson, P. Federal Prosecutors Warn Top Opioid Prescribers in Wisconsin. *Pain News Network.* February 05,2019

385. Webster L. Are Most Retired NFL Players Really Addicts? *Pain News Network.* February 08, 2019.

386. Webster L. Prevalence of Chronic Pain Increasing. *Pain New Network.* February 22, 2019.

387. Webster L. How Has CDC Opioid Guideline Affected You? *Pain New Network.* March 2, 2019.

388. Webster L. When Will Forced Tapering of Opioids End? *Pain News Network.* April 17, 2019.

389. Webster L. Is Fentanyl a Weapon of Mass Destruction? *Pain News Network.* April 27, 2019.

390. Webster L. Honoring our Veterans on Memorial Day *Pain News Network.* May 25, 2019.

391. Webster L. Emmy Winning Video Perpetuates Myths About Addiction *Pain News Network.* May 31, 2019.

392. Webster L. Federal Task Force Releases 'Roadmap' to Treat Pain Crisis *Pain News Network.* June 08, 2019.

393. Webster L. Should Postpartum Pain Control Be a Crap Shoot? *Pain News Network.* June 08, 2019.

394. Webster L. What 'Rocketman' Tells Us About Pain and Addiction *Pain News Network.* June 15, 2019.

395. Webster L. Teaching Children How to Cope with Pain *Pain News Network.* July 06, 2019.

396. Metzer S. Opioid trial: Expert points to nation's rise in chronic pain. *The Journal Record.* July 10, 2019.

397. Ellis R. Doctor defends 'pseudoaddiction,' blames insurance companies in opioids trial. *Tulsa World.* July 11,2019.

398. Webster L. 'Trapped in a Bottle' Billboard Misses the Mark. *Pain News Network.* July 13, 2019.

399. Webster L. Addiction and the 2020 Presidential Race. *Pain News Network.* July 27,2019.

400. Webster L. Empathy Must Be Included in Pain Management Education. *Pain News Network.* August 03,2019.

401. Webster L. Are Rx Opioids Scapegoats for the Opioid Crisis? *Pain News Network.* August 10, 2019.

402. BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWEEK 2019 National Conferece on Pain Management. *Nasdaq*. August 28, 2019.

403. Webster L. Johnson & Johnson opioid verdict is no victory for those who suffer chronic pain. *NBC News THINK.* August 30,2019.

404. Webster L. Is Your Pain Medication Effective or Was It Placebo Effect? *Pain News Network.* August 31, 2019.

405. Webster L. The Visible Few Pain Patients. *Pain News Network.* September 07, 2019.

406. Webster L. Chronic Pain Accelerates Dementia. *Pain News Network.* September 14, 2019.

407. DPP RALLY TALK SHOW w/ CLAUDIA on CAW360 Network https://www.youtube.com/watch?v=zYIk2RtTL7k Host: Claudia Merandi. September 15, 2019.

408. Webster L. The Opioid Risk Tool Has Been Weaponized Against Pain Patients. *Pain News Network.* September 21, 2019.

409. Webster L. Can Prayer Ease Chronic Pain? *Pain News Network.* September 28, 2019.

410. Webster L. How Children Process Pain. *Pain News Network.* October 5, 2019.

411. Webster L. Seeing Red: How Colors Affect Pain. *Pain News Network.* October 26, 2019.

412. Webster L. Survey Repudiates Canada's Pain Care Policies. *Pain News Network.* November 02, 2019.

413. Webster L. Survey Repudiates Canada's Pain Care Policies. *Pain News Network.* November 02, 2019.

414. Webster L. Utah law increases rate of babies born with opioid withdrawal. *The Salt Lake Tribune.* November 14,2019.

415. Webster L. EPA Decision Will Stifle Animal Research on New Pain Treatments. *Pain News Network.* November 16, 2019.

416. Webster L. Criminalizing Pregnant Women for Drug Abuse Is a Terrible Idea. *Pain News Network.* November 23, 2019.

417. Webster L. Consumer DNA Tests Do Not Accurately Predict Disease. *Pain News Network.* November 30, 2019.

418. Anderson P. Discontinuing Buprenorphine Too Soon 'Life-Threatening.' *Medscape.* December 03, 2019.

419. Webster L. Opioids Are Not the Only Pain Meds That Can Be Abused. *Pain News Network.* December 07, 2019.

420. Webster L. Living with Chronic Pain During the Holiday Season. *Pain News Network*. December 14, 2019.

421. Anson P. Medical Examiner: 'I Can't Remember Last Death from Prescribed Fentanyl'. *Pain News Network.* December 23, 2019.

422. Webster L. The 2019 Event With Major Impact for Millions of Pain Patients. *Pain News Network.* December 28, 2019.

423. Webster L. Flushing Out the Truth About Disposing of Unused Pain Medication. *Pain News Network.* January 04, 2020.

424. Webster L. The Real Reasons People Become Addicted. *Pain News Network.* January 18, 2020.

425. Webster L. A Cautionary Tale About Living Wills. *Pain News Network.* January 25, 2020.

426. Side Chats: Conversations on Pain Management. Episode 1: 20/20 With Lynn Webster, MD. *Practical Pain Management*. January 30, 2020.

427. Webster L. This Film is Far from a Joke. *Pain News Network.* February 8, 2020.

428. Webster L. Are You at Higher Risk for Coronavirus? Pain News Network. February 15, 2020.

429. Webster, L. Why Most People Keep Their Leftover Rx Opioids, Pain News Network. February 29, 2020.

430. Webster, L. People With Chronic Pain Must Prepare for Coronavirus, Pain News Network. March 12, 2020.

431. Webster, L. How Fear Can Make the Coronavirus Worse, Pain News Network. March 28, 2020.

432. **Webster L.** Misdirected Anger at the Opioid Crisis Hurts Innocent People. Pain News Network, March 21, 2020.

433. Anson, P. How has the Coronavirus Affected You? *Pain News Network,* April 06, 2020.

434. **Webster L** Why we don't yet have a treatment for COVID-19. Salt Lake Tribune, April 9, 2020.

435. **Webster L**. Now It's Our Turn. *Pain News Network.* April 12, 2020.

436. Planning for Chronic Pain Patient Care is Imperative in the Time of COVID-19. *Pain News Network,* April 16,2020.

437. **Webster L** Why Can't We Find a Cure for COVID-19 More Quickly? *Pain News Network*, April 18, 2020,

438. Kronemyer B. Mind-Body Therapies May Reduce Pain, Opioid Dose. *Specialty Pharmacy Continuum,* April 22, 2020.

439. Relistor reduces mortality in patients with opioid-induced constipation. *Healio,* May 21,2020.

440. **Webster L.** Why We Need Connections. *Pain News Network,* May 23, 2020.

441. **Webster L.** Pain, Protests and Prejudice. *Pain News Network,* June 6, 2020.

442. **Webster L.** White Privilege and People in Pain. *Pain News Network,* June 28, 2020.

443. **Webster L.** A Painful Privilege: Your Right to Protest. *Pain News Network,* July 3, 2020.

444. **Webster L.** New Podcast Discusses Pain and Politics. *Pain News Network,* July 12, 2020.

445. **Webster L.** Honoring Black Pioneers in Medicine. *Pain News Network, July 19, 2020.*

446. **Webster L.** 'First, Do No Harm' Doesn't Mean 'No RX Opioids'. *Pain News Network,* July 26, 2020.

447. **Webster L.** Genetic Studies Could Pave the Way to New Pain Treatments. *Pain News Network,* August 1, 2020.

448. **Webster L.** How to Say Goodbye When Someone is Dying. *Pain News Network,* August 9, 2020.

449. **Webster, L**, Gudin, J, Fudin, J. 20/20 With Lynn Webster, M.D. *Practical Pain Management*. January/February 2020.

450. Anson, P. Senate Report Finds Opioid Makers Paid Millions to Non-Profits. Pain News Network. December 17, 2020.

451. Jennings, S. Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management. Patient Care. September 29, 2022.

452. Understanding Chronic pain: an interview with Dr Lynn Webster and Micke Brown R.N. of American Pain Foundation. A Woman's Health. July 29, 2018.

453. Leinwand Leger, D. FDA Might Tighten Reins on Vicodin. USA Today. January 9, 2013.

454. Anson P. FDA Approves Genetic Test for Opioid Addiction Risk. *Pain News Network*. December 21, 2023.

PRESENTATIONS

1. Webster LR. White blood cell phagocytosis after artificial heart implantation. The 1978 Annual Meeting of the American Society of Artificial Internal Organs; April, 1978; Chicago, IL.

2. Webster LR. Plasma cortisol and ADH concentrations after artificial heart implantation. The 1978 Annual Meeting of the American Society of Artificial Internal Organs; April, 1978; Chicago, IL.

3. Webster LR. The effects of intravenous nitroglycerin on hypoxia pulmonary vasoconstriction. The 1978 Western Anesthesia Residents' Conference; May 1978; Pasadena, CA.

4. Webster LR. The effects of intravenous nitroglycerin on hypoxia pulmonary vasoconstriction. The 1978 Annual Meeting of the Canadian Anesthesiologists' Society; June 1978; Ottawa, Canada.

5. Webster LR. Electrical and pneumatic artificial hearts on phagocytosis. The 31st Annual Conference on Engineering in Medicine and Biology; October 21-25, 1978; Atlanta, GA.

6. Webster LR. Comparison of intravenous nitroglycerin and sodium nitroprusside on hypoxia pulmonary vasoconstriction. The 1978 Annual Meeting of the American Society of Anesthesiologists; October 1978; Chicago, IL.

7. Webster LR. Comparison of cardiopulmonary bypass with membrane and bubble oxygenerators on leukocyte phagocytosis during halothane anesthesia. The 1978 Annual Meeting of the American Society of Anesthesiologists; October 1978; Chicago, IL.

8. Webster LR. Comparison of intravenous Tolazoline on hypoxic pulmonary vasoconstriction. The 1979 Western Anesthesia Residents' Conference; April 1979; Colorado.

9. Webster LR. Digitization of x-rays: input for diagnostic and therapeutic applications for microcomputers. The 1986 Annual Meeting of the American Association for Medical Systems and Informatics (AAMSI); May 8 – 10, 1986; Anaheim, CA.

10. Webster LR. Managed care outlook 1990. Presented: October 1989; Salt Lake City, UT.

11. Webster LR. Neurophysiology pain. Presented: March 1993; Salt Lake City, UT.

12. Webster LR. Basic pain management technique. Presented: June 1993; Salt Lake City, UT.

13. Webster LR. Community pain management. Presented: September 1993; Salt Lake City, UT.

14. Webster LR. Reflex sympathetic dystrophy. Presented: October 1993; Salt Lake City, UT.

15. Webster LR. Acute pain service. Presented: October 1993; Salt Lake City, UT.

16. Webster LR. Pain management. Presented: November 1993; Ogden, UT.

17. Webster LR. Current trends in pain service. Presented: February 1994; Salt Lake City, UT.

18. Webster LR. Chronic & acute pain management. Presented: April 1994; Salt Lake City, UT.

19. Webster LR. Manpower & practice strategies for Utah anesthesiologists. The Spring Quarterly Meeting of the Utah Society of Anesthesiologists; April 1994; Salt Lake City, UT.

20. Webster LR. Morbidity mortality conference, a case presentation & panel discussion. Presented at: Continuing Medical Education Conference; June 1994; Payson, UT.

21. Webster LR. Management of pain. Presented: September 1994; Payson, UT.

22. Webster LR. Acute pain management. Presented at: HealthTrust, Inc. Physician Advisor Meeting; October 1994; Ogden, UT.

23. Webster LR. Pain management. Presented: October 1994; Snowbird, UT.

24. Webster LR. Decision making on resource utilization and cost. Presented at: HTI Western Region Pharmacy Directors Meeting; November 1994; Salt Lake City, UT.

25. Webster LR. Epidural analgesia for acute and cancer pain. Presented at: "Pain Management for the Adult" Symposium; December, 1995; El Paso, TX.

26. Webster LR. Risk management for anesthesiologists. Presented: April 15, 2000; Snowbird, UT.

27. Webster LR. Opioid management of chronic pain and addiction liability: focus on pain management. Presented: August 24, 2000; Salt Lake City, UT.

28. Webster LR. Study medication efficacy in patients with chronic intractable pain of malignant origin: efficacy as a function of patient characteristics. Presented at: The American Society of Clinical Oncology's (ASCO) 2001 Annual Virtual Meeting; 2001.

29. Webster LR. Symposium on the application of advanced technology in complex pain syndromes. Presented: July 21, 2001; Palo Alto, CA.

30. Webster LR. Anesthesia risk management. Presented at: UMIA Risk Management Workshop; 2002-2004; Salt Lake City, UT.

31. Webster LR. Botulinum toxin treatment for dystonia. Presented: January 17, 2002; Salt Lake City, UT.

32. Webster LR. Interventional pain management. Presented: March 6, 2002; Salt Lake City, UT.

33. Webster LR. Predicting aberrant drug related behavior in chronic pain patients. Presented at: 2002 Interventional Conference on Pain & Chemical Dependency; June 6, 2002; New York City, NY.

34. Webster LR. Abuse, addiction, diversion: issues and concerns. Presented: February 14-16, 2003; Sundance, UT.

35. Webster LR. Anesthesia risk management. Presented at: UMIA Risk Management Workshop; March 2003; Salt Lake City, UT.

36. Webster LR. Abuse, addiction, diversion: issues and concerns. Presented at: Actiq Consultant's Meting; April 26, 2003; Carlsbad, CA.

37. Webster LR. Abuse, addiction, diversion: issues and concerns. Presented: August 5, 2003; Salt Lake City, UT.

38. Webster LR. Abuse, addiction, diversion: issues and concerns. Presented: August 7, 2003; Seattle, WA.

39. Webster LR. Abuse, addiction, diversion: issues and concerns. Presented: August 9, 2003; Aspen, CO.

40. Webster LR, Walker M. Safety and efficacy of prolonged outpatient ketamine infusions for neuropathic pain. Presented at: 2003 Neuropathic Pain Conference; September 2003; Rochester, NY.

41. Webster LR. Pre-clinical pharmacology of Provigil. Presented: September 12-13, 2003; Omaha, NE.

42. Webster LR. Disclosure of unanticipated outcomes. Presented at: UMIA Risk Management Workshop; September 27, 2003; Bozeman, MT.

43. Webster LR. Anesthesia risk management. Presented at: UMIA Risk Management Workshop; September 27, 2003; Bozeman, MT.

44. Webster LR. Anesthesia risk management. Presented at: UMIA Risk Management Workshop; October 18, 2003; Salt Lake City, UT.

45. Webster LR. Disclosure of unanticipated outcomes. Presented at: UMIA Risk Management Workshop; October 18, 2003; Salt Lake City, UT.

46. Webster LR. Provigil: clinical profile: issues and concerns. Presented at: Medical Education Program; October 20-21, 2003; Raleigh, NC.

47. Webster LR. Abuse, addiction, diversion: issues and concerns. Presented: November 13, 2003; Colorado Springs, CO.

48. Webster LR. The art of investigation prescription fraud and understanding pain management. Presented at: Colorado Prescription Drug Abuse Taskforce Conference; November 14, 2003; Colorado Springs, CO.

49. Webster LR. Levorphanol pharmacologic profile: levorphanol in neuropathic pain. Presented at: Pain Management Advisory Panel; January 16-19, 2004; Miami, FL.

50. Webster LR. Levorphanol pharmacologic profile: levorphanol in neuropathic pain. Presented at: Pain Management Advisory Panel; January 23-25, 2004; New Orleans, LA.

51. Webster LR. Recognizing and treating addiction. Presented at: Pain, Addiction, and the Law; February 7, 2004; University of North Carolina; Chapel Hills, NC.

52. Webster LR. Anesthesiology; pain and addiction medicine. Presented at: UMIA Risk Management Workshop; February 21, 2004; Salt Lake City, UT.

53. Webster LR. Levorphanol pharmacologic profile: levorphanol in neuropathic pain. Presented at: Pain Management Advisory Council; February 27-29, 2004; San Diego, CA.

54. Webster LR. Levorphanol pharmacologic profile: levorphanol in neuropathic pain. Presented at: Pain Management Advisory Council; March 12-15, 2004; Las Vegas, NV.

55. Webster LR. Abuse, addiction, diversion. Presented: April 16, 2004; University of Utah; Salt Lake City, UT.

56. Webster LR. Disclosure of unanticipated outcomes. Presented at: UMIA Risk Management Workshop; April 17, 2004; Salt Lake City, UT.

57. Webster LR. Effective opioid therapies across the spectrum of chronic pain. Presented at: Continuing Medical Education activity; May 15, 2004; Scottsdale, AZ.

58. Webster LR. Pain and substance abuse: recognizing the potential for misuse and diversion. Presented: June 14, 2004; Salt Lake City, UT.

59. Webster LR. Pain and substance abuse: recognizing the potential for misuse and diversion. Presented at: Continuing Medical Education activity; July 10, 2004; Universal City, CA.

60. Webster LR. Buprenorphine: detox and maintenance therapy for opioid dependence. Presented at: 26th Annual Utah Fall Conference on Substance Abuse; September 23, 2004; St. George, UT.

61. Webster LR. Detecting abuse and addiction in chronic pain patients. Presented at: Medical/Surgical Nursing Workshop; September 24, 2004; Salt Lake City, UT.

62. Webster LR. Pain and substance abuse: recognizing the potential for misuse and diversion. Presented at: Continuing Medical Education activity; September 29, 2004; Lafayette, LA.

63. Webster LR. Pain and substance abuse: recognizing the potential for misuse and diversion. Presented at: Continuing Medical Education activity; October 6-8, 2004; Hattiesburg, MS.

64. Webster LR. Assessment and treatment of breakthrough cancer pain. Presented: December 6, 2004; Idaho Falls, ID.

65. Webster LR. Assessment and treatment of breakthrough cancer pain. Presented: December 8, 2004; Great Falls, MT.

66. Webster LR. Assessment and treatment of breakthrough cancer pain. Presented: December 9, 2004; Billings, MT.

67. Webster LR. Assessment and treatment of breakthrough cancer pain. Presented: December 15, 2004; Salt Lake City, UT.

68. Webster LR, Jansen JP, Peppin J, et al. A randomized, double blind, placebo controlled multicenter phase IIb study to evaluate the efficacy and safety of multiple alvimopan dosage regimens for the treatment of constipation associated with opioid use in subjects with persistent non-cancer pain. Presented at: 2006 AAPM Conference; November 2006; San Diego, CA.

69. Webster LR, Hale M, Peppin J, et al. Alvimopan dosage regimens for the treatment of opioid-induced gastrointestinal side effects in subjects with persistent non-cancer pain. Presented at: 5th Congress of the European Federation of ISAP Chapters; September 13-16, 2006; Istanbul, Turkey.

70. Webster LR. Legal guidance when prescribing narcotics. Presented: January 6, 2005; Vernal, UT.

71. Webster LR. Actiq pharmacology. Presented: January 26, 2005; Denver, CO.

72. Webster LR. Pharmacologic management of pain. Presented: February 23, 2005; Rigby, ID.

73. Webster LR. Treating pain in the addicted patient. Presented at: Continuing Medical Education activity; February 19, 2005; University of North Carolina School of Medicine; Chapel Hill, NC.

74. Webster LR. Assessment: abuse and addiction: discussion for tools predicting abuse when treating patients in opioids. Presented at: 24th Annual Meeting of the American Pain Society; March 31, 2005; Boston, MA.

75. Webtser LR. Actiq pharmacology. Presented: April 12, 2005; Helena, MT.

76. Webster LR. Clinical experts in pain. Presented at: Continuing Medical Education dinner; April 12, 2005; Helena, MT.

77. Webster LR. Assessment and treatment of breakthrough pain. Presented at: Continuing Medical Education activity; April 20, 2005; Reno, NV.

78. Webster LR. Pharmacologic management of pain. Presented at: Continuing Medical Education activity; April 20, 2005; Reno, NV.

79. Webster LR. Assessment and treatment of breakthrough pain. Presented: June 2, 2005; St. Louis Park, MN.

80. Webster LR. Substance abuse. Presented at: Continuing Medical Education dinner; June 2, 2005; Minneapolis, MN.

81. Webster LR. Treatment advocate training program. Presented: June 3-4, 2005; San Francisco, CA.

82. Webster LR. Actiq pharmacology. Presented: June 9, 2005; University of Colorado; Boulder, CO.

83. Webster LR. Actiq pharmacology. Presented at: Medical Education Program; June 29, 2005; Salt Lake City, UT.

84. Webster LR. Actiq pharmacology. Presented: July 15, 2005; Twin Falls, ID.

85. Webster LR. Suboxone pharmacology. Presented: July 29, 2005; Salt Lake City, UT.

86. Webster LR. Actiq pharmacology. Presented: August 30, 2005; Salt Lake City, UT.

87. Webster LR. Actiq pharmacology. Presented at: Continuing Medical Education dinner; August 31, 2005; Boise, ID.

88. Webster LR. Chronic pain. Presented at: Continuing Medical Education dinner; September 8, 2005; St. Paul, MN.

89. Webster LR. Actiq pharmacology. Presented at: Continuing Medical Education dinner; September 20, 2005; Wichita, KS.

90. Webster LR. Actiq pharmacology. Presented: September 21, 2005; Wichita, KS.

91. Webster LR. Actiq pharmacolohy. Presented: September 29, 2005; Grand Junction, CO.

92. Webster LR. Opioid pain management: the good, the bad, the facts. Presented at: Conference by the Utah Chapter of the American Pain Academy; October 1, 2005; Salt Lake City, UT.

93. Webster LR. Pain management in Utah: making it safe and available. Presented at: Conference by the Utah Chapter of the American Pain Academy; October 1, 2005; Salt Lake City, UT.

94. Webster LR. Evidence based use of methadone to manage pain safely and effectively. Presented at: Conference by the Utah Chapter of the American Pain Academy; October 1, 2005; Salt Lake City, UT.

95. Webster LR. Pain and substance abuse: recognizing the potential for misuse and diversion. Presented at: Continuing Medical Education dinner; October 5, 2005; Duluth, MN.

96. Webster LR. Assessment and treatment of breakthrough cancer pain. Presented: October 6, 2005; La Crosse, WI.

97. Webster, LR. Pain and addiction. Presented at: Continuing Medical Education dinner; October 12, 2005; Great Falls, MT.

98. Webster, LR. Pain and addiction. Presented at: Continuing Medical Education dinner; October 13, 2005; Missoula, MT.

99. Webster LR. The management of noncancerous breakthrough pain treatment. Presented: October 20, 2005; Idaho Falls, ID.

100. Webster LR. Definition of addiction, dependency and risk factors. Presented: October 27, 2005; Wichita, KS.

101. Webster LR. Opioid addiction. Presented: October 28, 2005; Lehi, UT.

102. Webster LR. Pharmacologic management of cancer pain. Presented at: Continuing Medical Education dinner; December 1, 2005; Portland, OR.

103. Webster LR. Advanced bionics. Presented at: SCS Physicians Workshop; January 14, 2006; Henderson, NV.

104. Webster LR. Workshop on respironics. Presented: January 17-18, 2006; Pittsburg, IL.

105. Webster LR. Emerging solutions in pain. Presented: January 19-20, 2006; Las Vegas, NV.

106. Webster LR. Pain management. Presented: UEN Educational TV; February 1, 2006; Salt Lake City, UT.

107. Webster LR. Pain and substance abuse. Presented at: Continuing Medical Education breakfast; February 10, 2006; Helena, MT.

108. Webster LR. Emerging solutions in pain and clinical advisors. Presented at: AAPM Annual Meeting; February 22-25, 2006; San Diego, CA.

109. Webster LR. Pain complexities of treatment. Presented: March 29, 2006; Salt Lake City, UT.

110. Webster LR. Advances in neuromodulation. Presented at: Utah Academy of Pain meeting; March 30, 2006; Salt Lake City, UT.

111. Webster LR. Pain: the complexities of treatment. Presented: April 7, 2006; Salt Lake City, UT.

112. Webster LR. Emerging therapies. Presented at: American Pain Conference; April 8, 2006; New York, NY.

113. Webster LR. Pain: the complexities of treatment. Presented at: Governor's Brown Bag Series; April 14, 2006; Salt Lake City, UT.

114. Webster LR. Emerging solutions in pain. Presented at: APS Annual Conference; May 5-6, 2006; San Antonio, TX.

115. Webster LR. Ziconotide. Presented: May 11, 2006; Salt Lake City, UT.

116. Webster LR. Pain: the complexities of treatment. Presented at: Michigan Pain Specialists meeting; May 17-18, 2006; Detroit, MI.

117. Webster LR, Ling W, Passik S. Opioid analgesia: risk management strategies and emerging therapies. Presented at: King Pharmaceuticals Advisory Board meeting; May 2006; New York, NY.

118. Webster LR. The complexities of treatment. Presented: June 7, 2006; Omaha, NE.

119. Webster LR. Pain in America: a chronic problem. Presented: June 15, 2006; Vernal, UT.

120. Webster LR. The complexities of treatment. Presented: June 18-19, 2006; Kansas City, MO.

121. Webster LR. Pain in America: a chronic problem. Presented: August 8, 2006; Salt Lake City, UT.

122. Webster LR. Pain in America: a chronic problem. Presented at: Utah Medical Association Board Meeting; September 6, 2006; Salt Lake City, UT.

123. Webster LR. The management of breakthrough pain with rapid onset: opioids. Presented at: Continuing Medical Education telecast; September 7, 2006; Salt Lake City, UT.

124. Webster LR. Pain in America: a chronic problem. Presented at: Utah Medical Association Annual Meeting; September 15, 2006; Salt Lake City, UT.

125. Webster LR. Pain in America: a chronic problem. Presented at: Greater Philadelphia Pain Society meeting; September 20, 2006; Philadelphian, PA.

126. Webster LR. Pain in America: a chronic problem. Presented: October 5, 2006; St. George, UT.

127. Webster LR. Pain in America: a chronic problem. Presented at: Continuing Medical Education lunch; October 6, 2006; St. George, UT.

128. Webster LR. An open-label, long-term, multicenter study of Ziconotide administered intrathecally (study 351). Presented at: 10th Annual North American Neuromodulation Society

Meeting; December 7-10, 2006; Las Vegas, NV.

129. Webster LR. Pain in America: a chronic problem. Presented: January 4, 2007; Salt Lake City, UT.

130. Webster LR. Persistent and breakthrough pain management: individualizing therapy and optimizing functions. Presented at: Continuing Medical Education event; January 26-27, 2007; San Francisco, CA.

131. Webster LR. Today's best practice patient management strategies for minimizing risk of opioid misuse, abuse and diversion. Presented at: The 23rd Annual Meeting of the American Academy of Pain Medicine; February 7–10, 2007; New Orleans, LA

132. Webster LR. Improving the care of patients with persistent and breakthrough pain. Continuing Medical Education teleconference. Presented: Salt Lake City, UT; 2007.

133. Webster LR. Naltrexone and alcohol. *Emerging Solutions in Pain*. May 7, 2007. http://www.emergingsolutionsinpain.com/knowledge-center/ask-the-experts/204-askexperts2007-05-07webster

134. Webster LR. Avoiding opioid abuse while managing chronic pain. Presented: June 7, 2007; Colorado Springs, CO.

135. Webster LR. Avoiding opioid abuse while managing chronic pain. Presented: Colorado Pain Consortium; June 7, 2007; Colorado Springs, CO.

136. Webster LR. Acute pain management: new challenges. Presented: June 14, 2007; Salt Lake City, UT.

137. Webster LR. Methadone: a unique profile, a cautious approach. *Emerging Solutions in Pain*. June 15, 2007. http://www.emergingsolutionsinpain.com/knowledge-center/expert-commentary/181-commentary2007-06-15webster

138. Webster LR. Sleep disordered breathing with chronic opioid therapy. Presented at: Memorial Sloan-Kettering Cancer Center; June 22, 2007; New York City, NY.

139. Webster LR. Opioid therapy in chronic pain with breakthrough episodes: therapeutic advances and their impact on risk. Presented at: 7th International Conference on Pain and Chemical Dependency; June 22, 2007; New York City, NY.

140. Webster LR. Structuring opioid therapy to minimize risk. Presented at: 7th International Conference on Pan and Chemical Dependency; June 24, 2007; New York City, NY.

141. Webster LR. A new guide to foster clinician confidence in pain treatment. *Emerging Solutions in Pain*. July 27, 2007. http://www.emergingsolutionsinpain.com/knowledge-center/expert-commentary/301-commentary2007-07-27webster

142. Webster LR. How do we suggest making a transition from methadone to buprenorphine treatment in chemically dependent pain patients? *Emerging Solutions in Pain*. July 30, 2007. http://www.emergingsolutionsinpain.com/knowledge-center/ask-the-experts/183-how-do-we-suggest-making-a-transition-from-methadone-to-buprenorphine-treatment-in-chemically-dependent-pain-patients

143. Webster LR. Opioid abuse and addiction. Presented at: Utah Society of Health's Symposium of Pharmacists; September 8, 2007; Salt Lake City, UT.

144. Webster LR. Emerging solutions for avoiding opioid abuse while managing pain. Presented at: 2007 AAPM Annual Meeting; September 28, 2007; Las Vegas, NV (via satellite symposium from Salt Lake City).

145. Webster LR. Scope, burden and critical drivers of prescription opioid abuse and emerging solutions for risk management. Presented: September 28, 2007; Deer Valley, UT.

146. Webster LR. Understanding the multidimensional experience of pain and addiction, synergy of pain and addiction. Presented at: AAPM Annual Meeting; September 30, 2007; Las Vegas, NV.

147. Webster LR. Advances in opioid analgesia: evolving strategies for patient management. Presented: October 11, 2007; Salt Lake City, UT.

148. Webster LR. Restarting a patient on an opioid. *Emerging Solutions in Pain.* October 19, 2007. http://www.emergingsolutionsinpain.com/knowledge-center/ask-the-experts/226-askexperts2007-10-19webster

149. Webster LR. Understanding the multidimensional experience of pain and addiction, synergy of pain and addiction. Presented at: Midwest Pain Society meeting; October 27, 2007; Chicago, IL.

150. Webster LR. Emerging therapies in pain management. Presented at: The American Academy of Pain Medicine's 24th Annual Meeting; February 15, 2008; Orlando, FL.

151. Webster LR, Heit H. Your questions about opioid abuse answered. *Emerging Solutions in Pain*. February 21, 2008. http://www.emergingsolutionsinpain.com/pain-101-q-a/279-your-questions-about-opioid-abuse-answered

152. Webster LR. Spectrum of abuse potential with various opioids. *Emerging Solutions in Pain.* March 21, 2008. http://www.emergingsolutionsinpain.com/knowledge-center/ask-the-experts/304-askexperts2008-03-21webster

153. Webster LR. Sources of diverted prescription opioids. Presented at: Tufts Health Care Institute; March 27-28, 2008; Providence, RI.

154. Webster LR. Chronic opioid therapy: understanding risk while maximizing analgesia. Presented at: National Initiative on Pain Control Dinner Dialogue Series; April 9, 2008; Portland, OR.

155. Webster LR. Recognizing addiction and methadone: avoiding the death trap. Presented: April 19, 2008; Chapel Hill, NC.

156. Webster LR. Chronic opioid therapy: understanding risk while maximizing analgesia. Presented at: National Initiative on Pain Control Dinner Dialogue Series; May 28, 2008; St. Louis, MO.

157. Webster LR. Diffuse trunk radicular pain in a patient. *Emerging Solutions in Pain*. June 6, 2008. http://www.emergingsolutionsinpain.com/state-your-case/326-diffuse-trunk-radicular-pain-in-a-patient

158. Webster LR. Cortex pharmacy key opinion. Presented: June 11, 2008; Cumberlain, RI.

159. Webster LR. Advances in Opioid Therapy. Presented at: Rehabilitation Institute of Chicago; July 18, 2008; Chicago, IL.

160. Webster LR. Methadone: friend or foe? Presented at: Rehabilitation Institute of Chicago; July 18, 2008; Chicago, IL.

161. Webster LR. Prialt: how it works. Presented: July 31, 2008; Kansas City, MO.

162. Webster LR. Prescribing the right way. Presented at: Severe Valley Medical Center; August 7, 2008; Richfield, UT.

163. Webster LR. The right patient, the right therapy, the right outcomes. Presented at: AAPM 19th Annual Clinical Meeting; September 9, 2008; Nashville, TN.

164. Webster LR. Easing the strain of chronic pain: optimizing analgesia and minimizing risk. Presented at: AAPM 19th Annual Clinical Meeting; September 10, 2008; Nashville, TN.

165. Webster LR. Pain management and overdosing. Presented: September 17, 2008; Salt Lake City, UT.

166. Webster LR. Pain, opioids and sleep. *Emerging Solutions in Pain*. October 17, 2008. http://www.emergingsolutionsinpain.com/knowledge-center/expert-commentary/378-commentary2008-10-17webster

167. Webster LR. Long term opioid therapy and sleep dysfunction. Presented at: 8th International Conference on Pain and Chemical Dependency; October 30, 2008; Philadelphia, PA.

168. Webster LR. Treatment strategies for patients with chronic pain: prescribing methadone for pain. Presented at: National Association of Drug Diversion Investigators Annual Convention; November 13, 2008; Nashville, TN.

169. Webster LR. Helping clinicians manage pain safely: an update on clinical strategies that avoid medication abuse. Presented at: Meeting of the Connecticut Chapter of the American Society for Pain Management Nursing; November 14, 2008; Middlebury, CT.

170. Webster LR. Treating chronic pain using methadone as an option. Presented at: Norwalk Hospital; November 14, 2008; Stanford, CT.

171. Webster LR. Trend of methadone deaths. Presented at: Utah Pharmacists Association Annual Meeting; November 23, 2008; Sandy, UT.

172. Webster LR. Chronic pain management issues in the chronic pain patient. Presented: December 12, 2008; New York City, NY.

173. Webster LR. Chronic pain management issues in the chronic pain patient. Presented at: Lakeview Hospital; January 15, 2009; Bountiful, UT.

174. Webster LR. Do you use point-of-care (POC) urine drug test kits? *Emerging Solutions in Pain*. January 16, 2009. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/412-knowledgelib2009-01-16webster

175. Webster LR. Unappreciated risks of opioids, endocrine effects, sleep disordered breathing and hyperglasia. Presented at: AAPM 25th Annual Meeting; January 27-31, 2009; Honolulu, HI.

176. Webster LR. The role of urine and alternative biofluid drug testing in patient care. Presented at: AAPM 25th Annual Meeting; January 27-31, 2009; Honolulu, HI.

177. Webster LR. Current treatment landscape and emerging management options in breakthrough pain. Presented at: AAPM 25th Annual Meeting; January 27-31, 2009; Honolulu, HI.

178. Webster LR. Effective clinician-patient communication. *Emerging Solutions in Pain*. February 13, 2009. http://www.emergingsolutionsinpain.com/knowledge-center/expert-commentary/422-commentary2009-02-13webster

179. Webster LR. Chronic opioid therapy: minimize the risk and maximize the therapy. Presented: March 3-4, 2009; Price, UT.

180. Webster LR. How to identify offenders in the pain clinic. Presented at: World Institute of Pain; March 13, 2009; New York, NY.

181. Webster LR. Treating pain but avoiding opioid abuse. Presented at: 25th Annual Rheumatology on the Beach; April 2, 2009; Destin, FL.

182. Webster LR. Emerging technologies in chronic pain. Presented: April 16, 2009; Orlando, FL.

183. Webster LR. Science in Pain Management: overcoming controversies wit new methods and new medications. Presented: May 1, 2009; Miami, FL.

184. Webster LR. Considering pain as a chronic disease. Presented: May 1, 2009; Miami, FL.

185. Webster LR. When do you obtain a prescription monitoring report? *Emerging Solutions in Pain*. May 22, 2009. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/490-when-do-you-obtain-a-prescription-monitoring-report

186. Webster LR. TUFTS: what are the core elements of safe opioid prescribing? Presented: July 23, 2009; Boston, MA.

187. Webster LR. How can I safely treat pain in a patient who has substance abuse if I have no one in my community trained in addiction medicine? *Emerging Solutions in Pain*. August 28, 2009. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/548-how-can-i-safely-treat-pain-in-a-patient-who-has-substance-abuse-if-i-have-no-one-in-my-

community-trained-in-addiction-medicine

188. Webster LR. New opioid formulation: will they deter abuse? Presented at: Pain Therapeutics Summit meeting; September 25, 2009; Summit, NJ.

189. Webster LR. How often do you order urine drug tests? *Emerging Solutions in Pain*. November 20, 2009. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/595-how-often-do-you-order-urine-drug-tests

190. Webster LR. Will you discharge a patient who has marijuana (tetrahydrocannabinol, THC) or cocaine in their urine? *Emerging Solutions in Pain*. March 26, 2010. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/630-will-you-discharge-a-patient-who-has-marijuana-tetrahydrocannabinol-thc-or-cocaine-in-their-urine

191. Webster LR. Presentation to the Federal Drug Administration Advisory Committee as the Principal Investigator of the Acurox 22-451 Tablets on behalf of Acura Pharmaceuticals, Inc. April 22, 2010; Washington, DC.

192. Webster LR. Prescription medication: dangers and causes of overdose, prescribing practices and identification of patients with problems (and how to respond). Presented at: Castle View Hospital; August 26, 2010; Price, UT.

193. Webster LR. Dual opioid therapy: changing the paradigm. Presented at: QRxPharma Breakfast Symposium at the 13th Annual World Congress on Pain; August 31, 2010; Montreal, Quebec, Canada.

194. Webster LR. Pain management. Presented to: Covidien Medical Science Liaisons team at the 13th Annual World Congress on Pain; August 31, 2010; Montreal, Quebec, Canada.

195. Webster LR. Risk stratification and monitoring of opioid therapy. Presented at: 13th Annual World Congress on Pain; September 2, 1010; Montreal, Quebec, Canada.

196. Webster LR. Spinal cord efficacy. Presented at: Boston Scientific Conference; September 25, 2010; Salt Lake City, UT.

197. Webster LR. American Pain Foundation (APF) presents: Safe prescribing of opioids. Presented: November 3-4, 2010; Salt Lake City, UT (3 webinars).

198. Webster LR. Economic issues in intrathecal delivery. Presented at: North American Neuromodulation Society's 2010 Annual Meeting; December 4, 2010; Las Vegas, NV.

199. Webster LR. Personalized opioid therapy: role of pharmacogenetics and abuse deterrent formulations. Presented at: LDS Hospital Sleep Grand Rounds; December 8, 2010; Salt Lake City, UT.

200. Webster LR. New abuse-deterrent medication technology. Presented at: New York State Anesthesiologists Postgraduate Assembly; December 12, 2010; New York City, NY.

201. Webster LR, Gudin J. Responsible prescribing and safe use of EXALGO® (hydromorphone HCI) extended-release tablets, C11. Presented: December 14-15, 2011; Salt Lake City, UT (2 Webinars).

202. Burke J, Webster LR, Lipinski M. Community Rx crisis: balance and perspective on prescription drug abuse. Presented at: Community Anti-Drug Coalitions of America 2011 Annual Forum; February 10, 2011; Washington, DC.

203. Webster LR, Morelli A, Brushwood D. C.A.R.E.S. Alliance Presentation and Q&A. Presented at: Covidien National Sales Meeting; March 9, 2011; St. Louis, MO.

204. Webster LR. Responsible opioid prescribing in the era of REMS. Presented at: American Pain Foundation–National Initiative on Pain Control Dinner Dialogue Series; March 10, 2011; Houston, TX.

205. Webster LR. Practitioner's Edge: Strategies to ensure the safe use of opioid therapy for patients with chronic pain. Presented at: The American Academy of Pain Medicine's 2011 Annual Meeting; March 25, 2011; Washington, DC.

206. Fine PG, Webster LR, Kirsh K. Challenging case studies in chronic pain. Presented at: The American Academy of Pain Medicine's 2011 Annual Meeting; March 26, 2011; Washington, DC.

207. Burke J, Webster LR, Lipinski M. Community Rx crisis: the road from adolescent drug abuse to recovery. Presented: April 11, 2011; Reading, PA.

208. Webster LR. Pain and sleep: addiction. Presented at: The American Academy of Sleep Medicine's 42nd Annual Medical-Scientific Conference; April 14, 2011; Washington, DC.

209. Webster LR, Vargas M. The safe use of implantable pain therapies: dialogue between a health care provider and a person with pain. Presented: April 21, 2011; Salt Lake City, UT (webinar).

210. Webster LR. Do pain patients prescribed abuse-deterrent opioid formulations still require risk assessment? *Emerging Solutions in Pain*. April 27, 2011. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/728-do-pain-patients-prescribed-abuse-deterrent-opioid-formulations-still-require-risk-assessment

211. Webster LR, New J, Yancey-Wrona J, Seikel S, Barna S, Panchal S, Peppin JF, Driver L. Opioid induced constipation: OIC treatments. Presented: May 2, 2011; Salt Lake City, UT (webinar).

212. Webster LR. Should only high-risk pain patients receive abuse-deterrent/tamper-resistant opioid formulations? *Emerging Solutions in Pain*. May 13, 2011. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/732-should-only-high-risk-pain-patients-receive-abuse-deterrenttamper-resistant-opioid-formulations

213. Webster LR. Practical considerations for peripheral opioid receptor antagonist drug development. Presented at: 11th Annual Pain Therapeutics Clinical Studies in Pain Meeting; June 1, 2011; London, UK.

214. Webster LR. Human Abuse Liability Assessment and Drug Regulation: Clinical Proof of Concept Studies for Abuse-Deterrent Formulations. Presented at: 11th Annual Pain Therapeutics Clinical Studies in Pain Meeting; June 2, 2011; London, UK.

215. Webster LR, Barthwell A. Assessing and monitoring risk for prescription opioid abuse across diverse populations. Presented at: The 73rd Annual Meeting of the College on Problems of Drug Dependence; June 19, 2011; Hollywood, FL.

216. Webster LR. Transforming pain management in the war against pain (keynote address). Presented at: The 7th Annual South Central VA Pain Symposium; June 24, 2011; Jackson, MS.

217. Webster LR. Risk stratification in clinical practice. Presented at: The Substance Abuse and Mental Health Services Administration's Open Dialogue Meeting IV—Non-Therapeutic Use of Prescription Medications; September 7, 2011; Washington, DC.

218. Webster LR. Responsible opioid prescribing in the era of REMS. Presented at: PAINWeek 2011; September 10, 2011; Las Vegas, NV.

219. Webster LR, McCarberg B, Passik S, Heit H, Bolen J, Gourlay D. Changing landscape of opioid therapy. Presented at: The American Academy of Pain Management's 22nd Annual Clinical Meeting; September 20, 2011; Las Vegas, NV.

220. Webster LR, Dhingra L, Declan B. The interface of pain and chemical dependency: From the Clinical Encounter to Emerging Clinical Research. Presented at: The American Academy of Pain Management's 22nd Annual Clinical Meeting; September 21, 2011; Las Vegas, NV.

221. Webster LR, McPherson L, Kirsh K. Treatment Options. Presented at: The American Academy of Pain Management's 22nd Annual Clinical Meeting; September 22, 2011; Las Vegas, NV.

222. Webster LR. Abuse-deterrent and tamper resistant opioid formulations: what is their role in addressing prescription opioid abuse? Presented at: The American Society of Addiction Medicine's 2011 Course on the State of the Art in Addiction Medicine Meeting; October 27–29, 2011; Washington, DC.

223. Webster LR, Hahn KL, Kirsch KL. Managing Patient's Opioid Use: Balancing the Need and the Risk. *Emerging Solutions in Pain*. Available November 1, 2011–November 1, 2012. http://www.emergingsolutionsinpain.com/component/continued/?option=com_continued&view=frontmatter&Itemid=&course=209

224. Webster LR. Managing pain and avoiding misuse. Presented at: The American Medical Association's Educational Session on Prescription Drugs; November 13, 2011; New Orleans, LA.

225. Webster LR. What are the key factors that contribute to fatal and nonfatal opioid overdose? *Emerging Solutions in Pain*. December 2, 2011. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/777-what-are-the-key-factors-that-contribute-to-fatal-and-nonfatal-opioid-overdose

226. Webster LR. Automated Postural Adjustments of SCS. Presented at: The North American Neuromodulation Society's 15th Annual Meeting; December 8–11, 2011; Las Vegas, NV.

227. Webster LR. Presentation to Ambulatory Pain Management Group. Presented at: The University of Pittsburgh Medical Center; December 15, 2011; Pittsburgh, PA.

228. Webster LR. What are the current concepts of pseudoaddiction and how has it changed from the original concept? *Emerging Solutions in Pain*. December 16, 2011. http://www.emergingsolutionsinpain.com/knowledge-center/expert-commentary/783-what-are-the-current-concepts-of-pseudoaddiction-and-how-has-it-changed-from-the-original-concept

229. Webster LR. How do you develop strategies to reduce opioid-related mortality without limiting needed therapies? *Emerging Solutions in Pain*. January 27, 2012. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/786-how-do-

you-develop-strategies-to-reduce-opioid-related-mortality-without-limiting-needed-therapies

230. Webster LR, Passik S. Improving opioid safety: a focus on patient education. Presented at: PriMed CME Activity; February 9, 2012; Ft. Lauderdale, FL.

231. Webster LR. What critical education points should be covered to teach safe use to the patient? *Emerging Solutions in Pain*. February 10, 2012. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/794-what-critical-educational-points-should-be-covered-to-teach-safe-use-to-the-patient

232. Webster LR. Guide to aberrant drug related behaviors. Presented at: The American Academy of Pain Medicine's 28th Annual Meeting; February 22–26, 2012; Palm Springs, CA.

233. Webster LR. Opioids and sleep-disordered breathing. Presented at: The American Academy of Pain Medicine's 28th Annual Meeting; February 22–26, 2012; Palm Springs, CA.

234. Webster LR. Safe opioid prescribing: reversing the trends. Presented at: The American Academy of Pain Medicine's 28th Annual Meeting; February 22–26, 2012; Palm Springs, CA.

235. Webster LR. Unintentional overdose deaths: reversing the trend. Presented at: The American Academy of Pain Medicine's 28th Annual Meeting; February 22–26, 2012; Palm Springs, CA.

236. Webster LR. What can be done to reduce deaths related to prescription medications? *Emerging Solutions in Pain*. March 9, 2012. http://www.emergingsolutionsinpain.com/knowledge-center/knowledge-library/804-what-can-be-done-to-reduce-deaths-related-to-prescription-medications

237. Webster LR. Opioid use and misuse. Presented at: The University of Utah Medical School. March 21, 2012; Salt Lake City, UT.

238. Webster LR. Opioids: clinical considerations. Presented at: The University of Utah Medical School. March 21, 2012; Salt Lake City UT.

239. Webster LR. The future of abuse liability and pain studies. Presented at: The International Society for Clinical Drug Development's Annual Meeting; March 22, 2012; Las Vegas, NV.

240. Webster LR. Chronic pain and addiction. Presented at: The National Rx Drug Abuse Summit; April 10, 2012; Orlando, FL.

241. Webster LR. Abuse liability. Presented at: The 21st Annual Meeting of the Association of Clinical Pharmacology Units; April 27, 2012; Bethesda, MD.

242. Webster LR. Chronic Pain Treatment Options in Patients with Opioid Use Disorder. Presented at: Pain, Addiction and The Law 2012; April 28, 2012; Chapel Hill, NC.

243. Webster LR. Human Abuse Liability: design and execution issues important in controlling experimental conditions; May 2, 2012; St. Louis, MO.

244. Webster LR. Unintentional Overdose Deaths: Causes & Solutions. Presented at: The 73rd Annual Theodor Lang May Day Medical Conference; May 3, 2012; Rockford, IL.

245. Webster LR. Unintentional Overdose Deaths: Causes & Solutions. Presented at: The 73rd Annual Theodor Lang May Day Medical Conference; May 4, 2012; Rockford, IL.

246. Webster LR. Pain Management. Presented at: The 73rd Annual Theodor Lang May Day Medical Conference; May 3, 2012; Rockford, IL.

247. Webster LR, Passik SD, Gauvin D. Pain treatment, abuse, addiction, and psychiatric co-morbidities —latest thinking and future treatment possibilities. Presented at: The 31st Annual Meeting of the American Pain Society; May 17, 2012; Honolulu, HI.

248. Webster LR. Novel Approaches in Opioid Analgesic Development and Use. Presented at: The 7th Annual NIH Pain Consortium Symposium: Advancing Pain Therapies; May 29, 2012; Bethesda, MD.

249. Webster LR. Abuse of synthetic drugs. *Emerging Solutions in Pain*. June 15, 2012. http://emergingsolutionsinpain.com/about-us/clinical-advisors/14-expert-commentary/825-abuse-of-synthetic-drugs

250. Webster LR. Insights on improvements to the collection of death data by the CDC. Presented at: The 2012 C.A.R.E.S. Alliance Summit; June 26, 2012; Washington, DC.

251. Webster LR. Safe Opioid Prescribing and Practice Improvement Continuing Medical Education Initiative Update. Presented at: The 2012 C.A.R.E.S. Alliance Summit; June 27, 2012; Washington, DC.

252. Gudin JA, Webster LR. Individualized approaches to the treatment of breakthrough pain. *Emerging Solutions in Pain*. August 30, 2012.

253. Webster LR, Passik S, Gudin J. Pain, Addiction, Abuse and Psychiatric Co-Morbidities. Presented at: PAINWeek 2012; September 5, 2012; Las Vegas, NV.

254. Webster LR. Interface Between Pain and Chemical Dependency. Presented at: Pain and Addiction: Management of Patients with Chronic Pain; September 15, 2012; Santa Fe, NM.

255. Gudin JA, Webster LR, Brennan MJ. Effective strategies in managing breakthrough pain for nurses. *Emerging Solutions in Pain*. September 28, 2012.

256. Gudin JA, Brennan MJ, Webster LR. Effective strategies in managing breakthrough pain. *Emerging Solutions in Pain*. December 4, 2012.

257. Webster LR. Understanding Intrathecal analgesia for challenges in adherence and abuse. *ReachMD*. January 14, 2013 (CME Activity).

258. Webster LR. Rescheduling Hydrocodone: Patient and Public Health Considerations. Presented at: Meeting of the Drug Safety and Risk Management Committee of the Federal Drug Administration Regarding the Rescheduling of Hydrocodone from Schedule III to Schedule II. January 24, 2013; Silver Spring, MD.

259. Webster LR, Silva C. SCOPE of Pain: Safe and Competent Opioid Prescribing Education. Recorded January 29, 2013; Launch March 1, 2013.

260. Webster LR. Concurrent issues in pain management. Presented at: Ada County Medical Society 2013 Winter Clinics; February 23, 2013; McCall, Idaho.

261. Kerr N, Colling F, Hall R, Webster LR. Pain Management – Panel Discussion. Presented at: Ada County Medical Society 2013 Winter Clinics; February 23, 2013; McCall, Idaho.

262. Webster LR. Case presentations of sleep and pain, addiction and depression. Presented at: National Sleep Foundation's Sleep Health & Safety 2013; March 2, 2013; National Harbor, MD.

263. Webster LR, Shelby G. Highlight of best practices for prescribing prescription drugs. Presented at: The National Governor's Association State Policy Academy on Reducing Prescription Drug Abuse; March 11, 2013; Little Rock, AR.

264. Webster LR. Best Practices: Opioid Prescribing. Presented at: The University of Utah School of Medicine; March 13, 2013; Salt Lake City, UT.

265. Webster LR. Improving safety through opioid rotation: reducing dosing and extending rotation schedule. March 28, 2013.

266. Webster LR. Guide to aberrant drug related behaviors. Presented at: The American Academy of Pain Medicine's 29th Annual Meeting; April 10, 2013; Fort Lauderdale, FL.

267. Webster LR, Gudin J. Opioids in America…navigating a tectonic shift. Presented at: The American Academy of Pain Medicine's 29th Annual Meeting; April 12, 2013; Fort Lauderdale, FL. (400+)

268. Webster LR, Stanos S. Clinical pearls of safe opioid prescribing. Presented at: The American Academy of Pain Medicine's 29th Annual Meeting; April 12, 2013; Fort Lauderdale, FL.

269. Webster LR. Best practices: opioid prescribing. Presented at: New Mexico In-State Policy Workshop: National Governors Association Policy Academy: Reducing Prescription Drug Abuse; April 18, 2013; Santa Fe, NM. (100)

270. Webster LR. Non-interventional approaches to pain. Presented at: The 115th Missouri Osteopathic Annual Convention; April 28, 2013; Lake of the Ozarks, MO. (250)

271. Webster LR. How to use pain therapy the right way. Presented at: The 115th Missouri Osteopathic Annual Convention; April 28, 2013; Lake of the Ozarks, MO. (250)

272. Webster LR. Is Peripheral Opioid Analgesia a Viable Strategy for the Treatment of Neuropathic Pain? Presented at: The 4th International Congress on Neuropathic Pain; May 24, 2013; Toronto, Ontario. (100)

273. Webster LR, Medve M, Henningfield J. Human Abuse Liability Testing in CNS Drug Development. Presented at: The 49th Annual Meeting of the Drug Information Association; June 22-27, 2013; Boston, MA.

274. Webster LR. Improving patient care and treatment options in the traditional pain practice – what interventional options are available to your patients today? Presented at: The West Virginia Society of Interventional Pain Physician's PAIN 2013; July 11-14, 2013; West Palm Beach, FL.

275. Webster LR. Pharmacology and drug interactions – minimizing risk and improving outcomes. Presented at: The West Virginia Society of Interventional Pain Physician's PAIN 2013; July 11-14, 2013; West Palm Beach, FL.

276. Webster LR, McRoberts P. Opioids for chronic, non-cancer pain (pro opioids). Presented at: The West Virginia Society of Interventional Pain Physician's PAIN 2013; July 11-14, 2013; West Palm Beach, FL.

277. Webster LR. Preventing unintentional overdose deaths: eight prescribing guidelines. Presented at: The 2013 Oklahoma Physicians Liability Insurance Company Conference; August 9, 2013; Oklahoma City, OK.

278. Webster LR. Pills, policies and predicaments. Presented to: The RAND Corporation; August 29, 2013; Santa Monica, CA.

279. Webster LR. Best Practices: Opioid Prescribing. Presented at: The 2013 Conference on Dentist Health and Well-Being of the American Dental Association; September 19, 2013; Chicago, IL.

280. Webster LR. Best Practices: Opioid Prescribing. Presented at: Psychiatry Grand Rounds at the University of Missouri; October 2, 2013; Columbia, MO.

281. Webster LR. Best Practices: Opioid Prescribing. Presented at: The 2013 Annual Clinical and Quality Conference of the Missouri Primary Care Association (MPCA); October 5, 2013; Branson, MO.

282. Chey WD, Tack J, **Webster L**, Lappalainen J, Barker PN, Sostek M. Naloxegol symptom responder rates in patients with opioid-induced constipation: results from 2 prospective randomized controlled trials. The 2013 Annual Scientific Meeting of the American College of Gastroenterology (ACG); October 11 – 16, 2013; San Diego, CA.

283. Tack J, Chey WD, **Webster L**, Sostek M, Barker PN, Lappalainen J. Efficacy of Naloxegol in a subpopulation of patients with opioid-induced constipation and an inadequate baseline response to laxatives: results from 2 prospective, randomized, controlled trials. Presentation #OP161; United European Gastroenterology Week's 21st Annual Conference (UEGW); October 12 - 16, 2013; Berlin, Germany.

284. Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Hawkins T, Schwartz H, Rustgi V, Hinestrosa F, Levin JM, Younossi Z, **Webster L**, Eley T, Huang S-P, McPhee F, Grasela D, Gardiner DF. Phase 2b study of the interferon-free and ribavirin-free combination of daclatasvir, asunaprevir, and BMS-791325 for 12 weeks in treatment-naive patients with chronic HCV genotype 1 infection. Presentation #LB-1; The Liver Meeting 2013: The 6^{4th} Annual Meeting of the American Association of the Study of Liver Diseases (AASLD); November 1 – 5, 2013; Washington, DC.

285. Webster LR. Preventing Unintentional Death in Chronic Pain Management. Presented at: *OptumHealth's 7th Annual Medical Director Forum*; November 7, 2013; Austin, TX.

286. Webster LR. Human Abuse Liability: What, Why, When and How? *Japan Tobacco Incorporated's 2013 Scientific Workshop*; November 14, 2013; Geneva, Switzerland.

287. Marshall W, Jumes P, Yeh W, Liu R, Ma J, Mangin E, **Webster LR**, Butterton JR. Lack of PK interaction between the hepatitis C virus non-structural protein 5A inhibitor MK-8742 and methadone in subjects on stable opiate maintenance therapy. HepDart 2013; December 8 – 12, 2013; Big Island, HI.

288. Webster LR. Human Abuse Liability and Human Pain Models. *PRA International 2014 Annual Sales Meeting*; January 21, 2014; Atlanta, GA.

289. Webster LR. Human Abuse Liability Role in NDAs. *15th Annual Phase I & IIa Clinical Trials Conference;* February 26, 2014; London, UK.

290. Webster LR. Guide to Aberrant Drug Behavior. *30th Annual Meeting of the American Academy of Pain Medicine (AAPM)*; March 5, 2014; Phoenix, AZ.

291. Webster LR, Cheatle MD. Best Practices: Safe Opioid Prescribing. *30th Annual Meeting of the American Academy of Pain Medicine (AAPM)*; March 9, 2014; Phoenix, AZ.

292. **Webster LR**. Opioids: The Good, Bad and Ugly. *Taking Control of Your Pain 2014 (U.S. Pain Foundation)*; March 9, 2014; Phoenix, AZ.

293. **Webster LR**. Human Abuse Liability Design & Execution Issues Important in Controlling Experimental Conditions. *Pharmaceutical Business Review: Clinical Trials Dinner;* April 3, 2014; London, UK.

294. Fardipour P, Rodenas E, **Webster L**. Applying innovative trial design to address the challenge of novel analgesic drug development. *The 33rd Annual Scientific Meeting of the American Pain Society (APS)*; April 30 - May 3, 2014; Tampa, FL.

295. **Webster LR**. The State of Pain Medicine 2014. *Pain, Addiction & The Law: Update 2014*; May 3-4, 2014; Chapel Hill, NC.

296. Hassanein T, Everson G, Sims KD, Bennett M, Gitlin N, Lawitz E, Nguyen T, **Webster L**, Younossi Z, Schwartz H, Thuluvath PJ, Zhou H, Rege B, McPhee F, Zhou N, Wind-Rotolo M, Chung E, Griffies A, Grasela D, Gardiner DF. All-oral therapy with Daclatasvir in combination with Asunaprevir and BMS-791325 for treatment-naive patients with chronic HCV genotype 4 infection. Digestive Disease Week (DDW) 2014; May 3 – 6, 2014; Chicago, IL.

297. **Webster LR**. How to Overcome the Challenges in Conducting Pain Trials. *Gruenthal 2014 US Pain Day and Grand Rounds*; May 21, 2014; New York City, NY.

298. **Webster LR**, McPherson ML, Portenoy R. Opioid Rotation. *The 2014 International Conference on Opioids;* June 8 – 10, 2014; Boston, MA.

299. **Webster LR**, McPherson ML. Abuse Deterrent Formulations. *The 2014 International Conference on Opioids*; June 8 – 10, 2014; Boston, MA.

300. Setnik B, Bass A, Sommerville KW, Matschke K, **Webster L**. Abuse potential study of intravenous oxycodone hydrochloride alone or in combination with intravenous naltrexone in non-dependent recreational opioid users. The 76th Annual Meeting of the College on Problems of Drug Dependence (CPDD); June 14 – 19, 2014; San Juan, Puerto Rico.

301. Tack J, Chey WD, Sostek M, Barker PN, **Webster L**. Naloxegol treatment improves symptoms of opioid-induced constipation in noncancer pain patients. The 19th WONCA Europe Conference; July 2 – 5, 2014; Lisbon, Portugal.

302. **Webster L**, Pantaleon C, Shah MS, DiFalco R, Iverson M, Smith MD, Kinzler ER, Aigner S. Intranasal human abuse potential of a novel abuse-deterrent extended-release formulation of morphine. Oral Poster #145; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

303. Argoff C, Nalamachu S, **Webster L**, Gudin J, Young C. SoluMatrix Diclofenac demonstrates sustained opioid-sparing effects in a phase 3 study of patients with acute pain following elective surgery. Oral Poster #155; PAINWeek 2014; September 2 - 6, 2014; Las Vegas, NV.

304. Kraft WK, Freiberger DJ, Sugerman DE, **Webster LR**. An approach to pain management. Part of Opioid Prescribing: Reducing the Risks workshop. The 2014 Annual Meeting of the American College of Clinical Pharmacology (ACCP); September 13, 2014; Atlanta, GA.

305. **Webster LR**, Gudin J, Medve R. Kappa: Myths/Misconceptions, and Moving Beyond Mu. The 25th Annual Meeting of the American Academy of Pain Management; September 20, 2014; Phoenix, AZ.

306. **Webster LR**. Methodological Challenges in Conducting Human Abuse Potential Studies. The 8th Annual Pain & Migraine Therapeutics Summit East; September 25, 2014; Boston, MA.

307. Cheatle M, Tang N, **Webster L**. Pain, Depression and Suicidal Ideation: Risk Assessment and Interventions. Part of Pain, Depression and Suicide: Risk Stratification and Mitigation. The 15th World Congress on Pain; October 6 – 11, 2014; Buenos Aires, Argentina.

308. **Webster LR**. Research Updates: Fibromyalgia & Chronic Pain Conditions. Leaders Against Pain Scholarship Training Conference; October 26, 2014; Salt Lake City, UT.

309. **Webster LR**. Expiring Opioids: First-in-Class Diversion-Resistance Technology. Human Abuse Liability & Abuse-Deterrent Formulations Conference; November 17, 2014; Washington, DC.

310. **Webster LR**. Lessons from a DEA Investigation: A Physician's Experience. The 25th Annual Conference of the National Association of Drug Diversion Investigators (NADDI); November 18, 2014; Cincinnati, OH.

311. **Webster LR**. Addiction. The 2014 Annual Meeting of the Pain Society of the Carolinas; December 5, 2014; Charleston, SC.

312. **Webster LR**. Personalized medicine: incorporating genetic testing to optimize the management of pain. The 16th Annual Early Clinical Development: Phase I&IIa Conference; February 24-25, 2015; London, UK.

313. **Webster LR**. Opioidphobia in the USA. The Pain Society of the Carolinas: Pain for the Practicing Physician and HCP; February 28, 2015; Chapel Hill, NC.

314. **Webster LR.** Opioid risk assessment & mitigation. Reading Health Systems Pain Symposium; March 7, 2015; Reading, PA.

315. **Webster L**, Yamada T, Ferreira JCA, Davidson J. A phase 2 randomized, double-blind, placebo-controlled study to evaluate naldemedine for the treatment of opioid-induced constipation in patients with chronic, non-cancer pain. Presentation #901e; Digestive Disease Week (DDW) 2015; May 16-19, 2015; Washington, DC.

316. **Webster L.** Assessing Suicidal Risk in Patients with Chronic Pain. The 9th Congress of the European Pain Federation; September 4, 2015, Vienna, Austria.

317. **Webster L.** The Painful Truth. The American Society for Pain Management Nursing 25th National Conference; September 18, 2015, Atlanta, GA.

318. **Webster L.** Alternatives to Opioid Medications. Treating and Preventing Chronic Pain Conference; October 9, 2015, Washington, D.C.

319. **Webster L.** Opioids and Suboxone in Pain Medicine. Treating and Preventing Chronic Pain Conference; October 9, 2015, Washington, D.C.

320. **Webster L.** Modify Abuse Liability Trial Designs with Greater Versatility for Generic Drugs. The 2nd Human Abuse Liability & Abuse Deterrent Formulations Conference; November 3, 2015, Washington, D.C.

321. **Webster L.** What is the Pipeline for Acute Pain? The University of Utah Department of Anesthesiology Post-Graduate Meeting; February 11, 2016, Park City, UT.

322. **Webster L.** Methadone: What Physicians Need to Know; The American Academy of Pain Medicine's 32nd Annual Meeting; February 17, 2016, Palm Springs, CA.

323. **Webster L.** Opioid Induced Constipation: A Consensus Definition and Its Clinical Implications; The American Academy of Pain Medicine's 32nd Annual Meeting; February 18, 2016, Palm Springs, CA.

324. **Webster L**. Pharmacotherapy of Sleep Disorders in Patients with Chronic Pain; The American Academy of Pain Medicine's 32nd Annual Meeting; February 19, 2016, Palm Springs, CA.

325. **Webster L.** Chronic Opioid Therapy: Who Needs It, How to Start It, When to Stop it, and How to Stop It; The American Academy of Pain Medicine's 32nd Annual Meeting; February 20, 2016, Palm Springs, CA.

326. Fudin J, **Webster L.** Teaming up for Safer Pain Management Strategies; The American Pharmacists Association Annual Meeting; March 6, 2016, Baltimore, MD.

327. **Webster L.** Pain & Addiction: Common Threads Course XVII, Patient-Centered Approaches for Real World Problems, Case 3: Sleep; The American Society of Addiction Medicine 47th Annual Meeting; April 14, 2016, Baltimore, MD.

328. **Webster L.** Abuse Deterrence: Primer on Trial Design of Drug Liking Studies; The American Pain Society Annual Meeting; May 11, 2016, Austin, TX.

329. **Webster L.** Controversies in Medical Management of Pain; The World Institute of Pain Conference; May 20, 2016, New York, NY.

330. Shram M, Levy-Cooperman N, **Webster L.** No Evidence of increased abuse potential of CL-108, a bi-layered tablet containing hydrocodone/acetaminophen/promethazine, in recreational opioid users; Presentation 324; The College on Problems of Drug Dependence 78th Annual Scientific Meeting; June 14, 2016; Palm Springs, CA.

331. **Webster L.** Legal Considerations in Pain Practice – What is New, What do you Need to Know in 2016 and Beyond; The West Virginia Society of Interventional Pain Physicians Annual

Meeting; July 23, 2016; Nassau, Bahamas.

332. **Webster L**. Addiction, Drug Diversion, Abuse, and Deaths; The West Virginia Society of Interventional Pain Physicians Annual Meeting; July 23, 2016; Nassaua, Bahamas.

333. **Webster L.** Opiate Medications – Overdose, Deaths, and Safe Prescribing; The West Virginia Society of Interventional Pain Physicians Annual Meeting; July 24, 2016; Nassau, Bahamas.

334. **Webster L.** How do the Courts Influence the Practice of Pain Medicine; The West Virginia Society of Interventional Pain Physicians Annual Meeting; July 24, 2016; Nassau, Bahamas.

335. **Webster L.** Pain Policies and Predicaments. The 10th Annual Pain & Migraine Therapeutics Conference; October 19, 2016; Chicago, IL.

336. **Webster L.** Risks and Myths of Opioid Prescribing and Morphine Milligram Equivalents. The Midwest Pain Society's Annual Meeting; October 28, 2016; Chicago, IL.

337. **Webster L.** Gauge the Impact of Inclusion and Exclusion Criteria on HAP Cost and Schedule. 3rd Human Abuse Liability & Abuse-Deterrent Formulations; November 2, 2016; Arlington, VA.

338. **Webster L.** Ask the Experts: Managing Opioid Tapering. The American Pharmacists Association 2017 Annual Meeting; March 25, 2017; San Francisco, CA.

339. **Webster L**. Frontlines of the Opioid Epidemic. Association of University Anesthesiologists/ International Anesthesia Research Society (AUA-IARS) Symposium; May 6, 2017; Washington, DC.

340. Fudin J, **Webster L**. Teaming Up for Safer Pain Management: Strategies for Effective Collaboration. APhA Institute on Alcoholism and Drug Dependence; June 4, 2017; Salt Lake City, UT.

341. **Webster L.** Keynote Session: The Role of ADFs in Curbing Opioid Abuse. The International Conference on Opioids; June 12, 2017; Boston, MA.

342. **Webster L**. Utilizing Precision Medicine Technologies to Avoid and Treat Prescription Opioid Abuse. The International Conference on Opioids; June 12, 2017; Boston, MA.

343. **Webster L**, Gudin J. Managing Opioid Risks & Adverse Effects in a Politically Charged Environment. PAINWeek 2017; September 6, 2017; Las Vegas, NV.

344. **Webster L**, Gudin J. Managing Opioid Risks & Adverse Effects in a Politically Charged Environment. PAINWeek 2017; October 15, 2017; Baltimore, MD.

345. **Webster L**. Configure Studies for Opioid Interactions with Benzos. Human Abuse Liability – Abuse Deterrent Formulations Conference; November 7, 2017; Washington, DC.

346. **Webster L.** The Role of ADFs in Curbing Opioid Abuse. The Colorado Pain Society Annual Meeting; April 6, 2018; Breckenridge, CO.

347. **Webster L.** New and Emerging Pharmacotherapy for Pain. The Colorado Pain Society Annual Meeting; April 7, 2018; Breckenridge, CO.

348. **Webster L.** Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS). PAINWeekend; April 8, 2018; Anaheim, CA.

349. **Webster L.** Extended-Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS). PAINWeekend; April 15, 2018; West Palm Beach, FL.

350. **Webster L**. Keynote: Successful Opioid Prescribing. Patient Safety and Quality Improvement Conference; April 20, 2018; Boise, ID.

351. **Webster L**. Pain, Addiction, & Opioid Therapy: Harm Reduction Strategies. The American Academy of Pain Medicine's 34th Annual Meeting; April 25, 2018; Vancouver, Canada.

352. **Webster L**. Walking the Line in Pain and the Law: Organized Medicine, Pain Physicians, and AAPM's Work to Support Providers and Patients. The American Academy of Pain Medicine's 34th Annual Meeting; April 28, 2018; Vancouver, Canada.

353. **Webster L**. Prescribing Trends in Pain Management and the Response to the Opioid Crisis. The American Geriatrics Society Annual Meeting; May 2, 2018; Orlando, FL.

354. **Webster L.** Extended- Release and Long-Acting Opioid Analgesics: Risk Evaluation and Mitigation Strategy (REMS). Pain Week; September 4, 2018; Las Vegas, NV.

355. **Webster L.** The journey starts with Genetic biomarkers as common denominators for specific pain disorders. Santorini 9th Annual Conference; October 2, 2018; Santorini, Greece.

356. **Webster L.** Statemement made at the Open Public Hearing Session of the Anesthetic and Analgesic Drug Products Advisory Committee. October 12, 2018; Washington, D.C.

357. **Webster L.** Developing an Effective Treatment Plan: Opioid- and Nonopioid-based Treatment Options for Acute and Chronic Pain Management. October 21, 2018; CSU- Long Beach, CA.

358. **Webster L.** Walking the Line in Pain and the Law. International Health Facility Diversion Association Annual Meeting. October 22, 2018; Dallas, TX.

359. **Webster L.** Pain and the Opioid Odyssey. St. Vincent Healthcare Pain Conference; October 23, 2018; Billings, MT.

360. **Webster L.** Developing an Effective Treatment Plan: Opioid- and Nonopioid-based Treatment Options for Acute and Chronic Pain Management. November 18, 2018; The University of North Texas Health Sciences Center, TX.

361. **Webster L.** Virtual Reality Therapy for Pain. Summit on Balanced Pain Management. November 27, 2018; Ronald Reagan Building and International Trade Center, Washington, DC.

362. **Webster L.** Compare IR and ER Opioid Use, Abuse Patterns, and Abuse-Deterrent Approaches. Visiting Professor Program- Daiichi Sankyo. February 27,2019; Basking Ridge, NG.

363. **Webster L.** Opportunities in Evaluating Abuse Deterrence of Opioid Drug Products. American Society for Clinical Pharmacology And Therapeutics. March 15, 2019; Washington, DC.

364. **Webster L.** CognifiSense Case Study Seminar. Yale Innovation 2 Impact Symposium. April 2, 2019; New Haven, CT.

365. **Webster L.** Sana Health Product Development Insights. Yale Innovation 2 Impact Symposium. April 2, 2019; New Haven, CT.

366. **Webster L.** Pain, Addiction & Sleep. Pain & Addiction Common Threads Course-American Society of Addiction Medicine Conference. April 4, 2019; Orlando, FL.

367. **Webster L.** Pain & the Opioid Oyssey, St. Alphonsus Heath Conference. April 26,2019; Boise ID.

368. **Webster L.** Developing an Effective Treatment Plan, St. Alphonsus Heath Conference. April 26,2019; Boise, ID.

369. **Webster L.** Annual Congress of Clinical Rheumatology May 4, 2019; Destin, FL

370. **Webster L.** & Fudin J. The Visible Few: An Imperfect Burden on Patients and Providers. PainWeek 2019. September 6, 2019; Las Vegas, NV.

371. **Webster L**, Rauck R. A Fresh Look at Atypical Opioids as Frontline Analgesics: *Science NOT Misconceptions*. Presented at The American Academy of Pain Medicine's 36th Annual Meeting; February 29, 2020; National Harbor, MD.

372. **Webster L.** 2021 NANS Virtual - Oral Abstract Presentation. January 15-16, 2021; Online.

373. **Webster L.** 2023 Rational Opioid Pain Management: Shifting the Focus to Patients. American Academy of Pain Medicine (AAPM) 39th Annual Meeting; March 25, 2023; Fort Lauderdale Marriott Harbor Beach Resort & Spa.

374. **Webster L.** 2023 Opioid Analgesic Therapy for Chronic Pain: Defining Current Therapeutic Use. A MEDSCAPE Live Event; March 24, 2023; Henry B. Gonzalez Convention Center, San Antonio, Texas

375. **Webster, L.** 2023 Rational Opioid Pain Management: Shifting the Focus to Patients. American Academy of Pain Medicine Annual Meeting, Fort Lauderdale Marriott Harbor Beach Resort & Spa, March 24-26, 2023.

376. **Webster, L.** 2003 Myths of Opioids. Pennsylvania Pain Society Annual meeting, Harrisburg Pennsylvania, May 3-5, 2023.

377. **Webster, L.** 2003 Opioids to Manage Chronic Pain. American Chronic Pain Association, Kansas City, KS, Aug 18-20, 2023.

378. **Webster, L.** A Focus on Buprenorphine: A Unique Atypical Opioid with Favorable Pharmacologic Properties & Safety Advantages. American Chronic Pain Association, Kansas City, KS, Aug 18-20, 2023.

379. **Webster, L.** Opioids to Mange Chronic Pain, Special Guest Lecturer, Tennessee Pain Society, Gaylord Hotel, Nashville TN, September 21-23, 2023.

380. **Webster, L.** Rethinking the Fundamentals of Opioid Prescribing: Rebalancing Benefit-Risk to Improve Patient Outcomes. A CME Lunch Symposium, American Academy of Pain Medicine Annual Meeting, Scottsdale, AZ March 8 2023.

381. **Webster, L.** Human Abuse Potential (HAP) and Withdrawal" Webinar XTalks. Feb 28, 2024.

382. **Webster, L**, 2024 AAPM Rethinking the Fundamentals of Opioid Prescribing. American Academy of Pain Medicine (AAPM) 40th Annual Meeting; March 8, 2024; Westin Kierland Resort & Spa, Scottsdale, AZ.

383. **Webster, L.** Human Abuse Potential (HAP) and Withdrawal" Webinar XTalks. Feb 28, 2024.

384. **Webster L**. Treatment Strategies for Acute and Postoperative Pain Management. VuMedi. June 18, 2025. https://www.vumedi.com/video/treatment-strategies-for-acute-and-postoperative-pain-management/

CLINICAL STUDIES

	Date	Title
1.	2003	An Open-Label, Long-Term Safety and Tolerability Study of Ziconotide Administered lntrathecally to Patients with Chronic, Severe Pain.
2.	2003	An Open-Label, Multicenter Study of the Safety and Efficacy of Combined lntrathecal lnfumorph and lnfumorph in Patients Receiving Study Medication for Severe Chronic Pain
3.	2003	A Randomized, Double-Blind, Placebo-Controlled Study of lntrathecal Ziconotide in Adults with Severe Chronic Pain
4.	2003	An Open-Label,3-Week, with Optional Long-Term Extension Phase, Multi-Center Study of the Safety and Efficacy of lntrathecal Ziconotide for Chronic, Severe Pain When Delivered Via an External Pump
5.	2003	An Open-Label,Long-Term, Multi-Center Study of Ziconotide Administered lntrathecally. (Part 1)
6.	2003	An Open-Label,Long Term,Multi-Center Study of Ziconotide Administered lntrathecally. (Part 2)
7.	2003	An Open-Label, Long-Term, Multi-Center, lntratheca l ZICONOTIDE (PRIALml) Effectiveness and Safety Trial (Zest) in Patients with Chronic Severe Pain
8.	2003	The Effect of Chronic opioids on Respiration During Sleep

9.	2003	Safety and Effectiveness of the Archimedes Implantable Constant-Flow Infusion Pump System
10.	2003	A Pilot Study to Evaluate the Assay Sensitivity of the Lifetree Outpatient Digital Arthrop lasty Pain Model in a Single-Dose, Double-Blind, Placebo-Controlled Comparison of the Analgesic Activity of Ibuprofen 400 mg, and Placebo in Patients with Pain on Postoperative Day 0 Following Digital Arthroplasty
11.	2003	A Pilot Study to Determine If Chronic opioid use for Pain Management Promotes Sleep Disordered Breathing
12.	2003	A Randomized, Double Blind, Controlled Dose Finding Study Of NGX-4010 For The Treatment Of Postherpetic Nueralgia
13.	2003	A 5-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of [S,S)-Reboxetine in Patients with Post herpetic Neuralgia (PHN), who are Gabapentin Treatment Failures
14.	2004	A Phase II, Multi-center, Randomized, Placebo-controlled, Dose-ranging Study of the Safety and Efficacy of Alvimopan Capsules in Doses of 1.0 mg, 3.0 mg, and 8.0 mg Administered Twice Daily for Treatment of Chronic Constipation in Adults
15.	2004	A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase llb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of opioid - Induced Bowel Dysfunction in Subjects with Chronic Pain of Non-Malignant Origin
16.	2004	A Randomized, Double-Blind, Controlled Study of NGX-4010 For The Treatment of Postherpetic Neuralgia
17.	2004	A Randomized, Open-Label Study Of The Tolerability Of Three Local Anesthetic Formulations In Conjunction With NGX-4010 For The Treatment Of Neuropathic Pain
18.	2004	An Open- Label Extension Study of NGX-4010 for the Treatment of Neuropathic Pain
19.	2004	A Multicenter, Double-Blind, Act ive-and Placebo-Contro lled Efficacy and Safety Study of Oxycodone HCL and Low-Dose Naltrexone HCL (PTl-801) in Patients with Low Back Pain

20.	2004	A Single-Center, Randomized, Active-Controlled, Pharmacokinetic, Crossover Study of PTI- 821in Healthy Male Volunteers
21.	2004	A Phase I, Single-Center, Four-Way Crossover, Active-Controlled, Pharmacokinetic Study of PTl-821 in Healthy Male Volunteers
22.	2004	A Phase I, Single-Center, Dose Proportionality Pharmacokinetic Study of PTl-821 in Healthy Male Volunteers
23.	2004	A Phase I,S ingle-Center, Multi-Dose, Pharmacokinetic Study of PTl-821in Healthy Male Volunteers
24.	2004	Multicenter, randomized, placebo-contro lled, Phase Ill,efficacy and safety study of PTl-821 in patients with moderate to severe chronic pain due to osteoarthritis of the hip or knee
25.	2004	A Phase I, Single-Center, Four-Way Crossover, Pharmacokinetic Study to Determine the Absorption of Oxycontin® Following Disruption of the Controlled-Release Mechanism versus Roxicodone™ in Healthy Male Volunteers
26.	2004	Effect of Naltrexone on the Abuse Liability of Hydrocodone in Methadone-Maintained Subjects
27.	2004	A Randomized Placebo-Controlled Crossover Trial Evaluating the Effect of Naltrexone at 1, 3, and 6mg dose levels on the Abuse Potential of 40 mg Oxycodone in Non-dependent, opioid-Abusing Subjects
28.	2004	A Phase I, Randomized, Placebo-Controlled, Double-Blind, Dose-Escalation Study of Safety, Pharmacokinetics and Activity of Single Intravenous Doses of RI624 in Adults with Moderate-to-severe Pain from Osteoarthritis of the Knee
29.	2004	A multicenter, randomized, double blind, placebo controlled, study assessing the safety and efficacy of XP13512 in patients with post herpetic neuralgia
30.	2005	An Open-Label, 12-Month Study to Evaluate the Safety, Tolerability, and Efficacy of Oravescent Fentanyl Citrate for the Management of Breakthrough Pain in opioid-Tolerant Patients with Chronic Noncancer Pain

31.	2005	An Open-Label Study to Evaluate both the Conversion Strategy from Fentanyl Transdermal System (Duragesic®) to the Sufentanil Transdermal Therapeutic System (Sufenta nil TTS) and the Pharmacokinetics, Efficacy and Safety of Repeated SufentanilTTS Applications in Patients with Chronic Pain
32.	2005	A double-blind, placebo-controlled study evaluating the safety and efficacy of Campral in maintaining abstinence in Adolescent patients with alcohol dependence
33.	2005	A randomized, double-blind, placebo-controlled ,multicenter, phase Ill study to evaluate the long-term safety of Alvimopan 0.5 mg once daily and 0.5mg twice daily for 12 weeks for the treatment of opioid-induced bowel dysfunction in adults taking opioid therapy for persistent, non-cancer pain
34.	2005	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Safety And Efficacy Of Lamotrigine 200-400 mg/Day Compared With Placebo In Subjects With Painful Diabetic Neuropathy
35.	2005	A Randomized, Double-Blind, Placebo-Controlled,Multi-Center Phase Ill Study to Evaluate the Efficacy and Safety of Alvimopan 0.5 mg Once Daily and 0.5 mg Twice Daily for 12 Weeks for the Treatment of opioid-Induced Bowel Dysfunction in Adults taking opioids
36.	2005	A Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety and Efficacy of Topical KDS2000 (anandamide) in the Treatment of Pain Associated with Post herpetic Neuralgia
37.	2005	A multicenter, randomized, double blind, placebo controlled,2-period crossover study conducted under in-house blinding conditions to evaluate the safety and efficacy of oral MK-0686 in the treatment of post herpetic neuralgia
38.	2005	A Multicenter, Open-Label, Phase II Study Of NGX-4010 For The Treatment Of Neuropathic Pain In Patients With Painful HIV-Associated Neuropathy (HIV-AN) Or Postherpetic Neuralgia (PHN)

39.	2005	A Long-Term, Open Label, Safety Study of Oxycodone HCI and Low-Dose Naltrexone HCI (PTI 801) In Patients with Moderate to Severe Chronic Low Back Pain or with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee
40.	2005	A Single-Center, Active-Controlled, Pharmacokinetic, Crossover Study of the PTl-801 Active Comparator in Healthy Male Volunteers
41.	2005	A Phase I, Single-Center, Four-Way Crossover, Active-Controlled, Pharmacokinetic Study of PTl-821 in Healthy Male Volunteers
42.	2005	A Phase I, Single-Center, Dose Proportionality Pharmacokinetic Study of PTl-821in Healthy Male Volunteers
43.	2005	A Phase I, Single-Center, Multi-Dose, Pharmacokinetic Study of PTl-821 in Healthy Male Volunteers
44.	2005	A Long-Term, Open-Label, Safety Study of PTl-821in Patients with Moderate to Severe Chronic Low Back Pain or with Moderate to Severe Chronic Pain Due to Osteoarthritis of the Hip or Knee
45.	2005	A Phase I, Single-Center, Crossover, Pharmacokinetic Study of PTl-821 (prepared with micronized oxycodone base) in Healthy Male Volunteers
46.	2005	Double-Blind, Randomized Study of Combination opioid Agonist and Low Dose Antagonist (Oxytrex™) vs. Oxycodone in Patients with Post Herpetic Neuralgia
47.	2005	A Phase lb Randomized, Placebo Controlled, Double-Blind, Crossover Study to Evaluate the Pharmacodynamic Effects of PRX-08066 During Hypoxic Challenge in Healthy Adults
48.	2005	A Phase I/II, Randomized, Placebo-Controlled, Double-Blind, Dose Escalation Study of Safety, Pharmacokinetics and Activity of Single Intravenous Doses of RN624 in Adults With Moderate to Severe Pain from Osteoarthritis of the Knee
49.	2005	Randomized, Double-Blind, Placebo-Controlled Study to Assess the Subjective Response to Treatment with Ramelteon in Adult Subjects with Chronic Insomnia by Utilizing an Interactive Voice Response System (IVRS) for Collecting Diary Data

50.	2005	A Double-Blind, Placebo-Controlled, Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NGX267 in Healthy Elderly Volunteers
51.	2005	A Double-Blind, Placebo-Controlled, Ascending Dose-Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous NGX424 in Healthy Male Volunteers Using an "Up and Down" Design
52.	2005	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Once Daily XP13512 in Patients with Restless Legs Syndrome
53.	2005	A Double-Blind, Placebo-Controlled, Multiple Crossover Proof-of-Concept Study to Evaluate the Efficacy of CHADD™ (Controlled Heat-Assisted Drug Delivery) Applied Over a ZR-02-01 Matrix Transdermal Fentanyl Patch for the Treatment of Breakthrough Pain in Patients With Moderate to Severe Non-malignant Chronic Pain
54.	2006	A long-term, open-label, safety study of Kadian NT (morphine sulfate plus naltrexone hydrochloride extended release) capsules in subjects with chronic moderate to severe nonmalignant pain
55.	2006	An evaluation of a modified immunoassay urinalysis used with a dose compliant algorithm to discriminate between multiple clinically-relevant doses of Hydrocodone in naltrexone- blocked opioid naive healthy volunteers
56.	2006	An Observational Study to Characterize the Burden of Illness Associated with Laxative Use in Subjects Using opioids for the Management of Persistent Pain
57.	2006	A phase Ila study evaluating the efficacy and safety of a unique intravenous iron preparation (VIT-45) in the treatment of Restless leg syndrome (RLS)
58.	2006	A Randomized, Controlled, Open-Label Study to Investigate the Effects of Topical Capsaicin Formulations on Epidermal Nerve Fiber lmmunostaining and Cutaneous Sensory Function in Healthy Volunteers

59.	2006	A Single-Center, Randomized, Bioequivalence, Study of PTI 801in Healthy Male Volunteers
60.	2006	Multicenter, randomized, placebo-controlled, Phase Ill, efficacy and safety study of PTl-821 in patients with moderate to severe chronic pain due to osteoarthritis of the hip or knee
61.	2006	A Phase I, Single-Center, Dose Proportionality Pharmacokinetic Study of PTl-821 in Healthy Male Volunteers
62.	2006	A Phase I, Single-Center ,Four-Way Crossover, Active-Controlled, Pharmacokinetic Study of PTl-821H in Healthy Male Volunteers
63.	2006	A Double-Blind, Placebo-Controlled, Single Dose, Ascending, Sequential Cohort Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Subcutaneous NGX426 In Healthy Male and Female Volunteers, Phase I
64.	2006	A Double-Blind, Placebo-Controlled, Single Dose Ascending, Sequential Cohort Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral NGX426 In Healthy Male And Female Volunteers, Phase I
65.	2006	Safety, Tolerability, And Pharmacokinetics Of Oral NGX426 With Estimation Of The Maximally Tolerated Dose (MTD) In Healthy Male And Female Volunteers Using A Double-Blind, Placebo-Controlled, Single Ascending Dose, Sequential Cohort Study Phase I
66.	2006	A Multiple Dose, Double-Blind, Placebo-Controlled Safety, Tolerance and Pharmacokinetic Study of Oral NGX426 In Healthy Male And Female Volunteers
67.	2006	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of XP13512 In Patients With Restless Leg Syndrome
68.	2006	Application of CHADD™ (Controlled Heat-Assisted Drug Delivery) over a Single Dose of ZR-02-01 Matrix Transdermal Fentanyl Patch
69.	2006	A Study to Evaluate the Pharmacokinetics of a 30cm2 CHADD™ (Controlled Heat-Assisted Drug Delivery) When Applied To 3 Doses Of The ZR-02-01 Matrix Transdermal Fentanyl Patch

70.	2006	An Open-Label Study to Evaluate the Safety and Pharmacokinetics of Repeated Applications Of CHADD™ (Controlled Heat-Assisted Drug Delivery) Units On The ZR-02-01 Matrix Transdermal Fentanyl Patch/Overlay In Healthy Adult Subjects
71.	2007	A randomized, placebo-controlled, double-blind, single-dose,3-way crossover study to determine the relative drug-liking/euphoria effects of intravenous morphine alone or in Combination With Naltrexone In Opioid Experienced, Non-Dependent Male Subjects
72.	2007	An Open-Label Study to Assess the Pharmacokinetic and Pharmacodynamic Effects of Increasing Doses of Naltrexone In Precipitation of a Moderate Withdrawal Syndrome in Subjects With Chronic, Non-Malignant Pain On Extended Release Morphine
73.	2007	A Randomized, Open-Label, Single-Site, Multi-Dose Study To Determine the Correlation of Steady-State Urine Drug Samples With Three Different Doses of Oxycontin
74.	2007	A Phase 111, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of the Sterile Lidocaine Hydrochloride Monohydrate (LHM) Product in Adult Subjects
75.	2007	A 4-Week, Open Label, Study to Evaluate the Effect of Treatment With Fentanyl Buccal tablets on Pain/Anxiety Symptoms When Used For the Management of Breakthrough Pain in opioid-Tolerant Patients With Chronic Pain
76.	2007	A randomized, double-blind, active-controlled crossover study to evaluate the efficacy and safety of Fentanyl Buccal Tablets compared with immediate release Oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain
77.	2007	A Phase I Single Escalating Dose Study to assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males
78.	2007	A Randomized, Double-Blind, Placebo Controlled, Two-Way Cross-Over Study of Analgesic Efficacy of Bupivacaine Transdermal Therapeutic System in Patients with Post-Herpetic Neuralgia

79.	2007	A pilot study to select a dose of Naltrexone hydrochloride that will reduce subjective euphoric effects of Oxycodone hydrochloride in non-dependent opioid-preferring subjects
80.	2007	A Pivotal Study of the Euphoria-Blocking Effects of Naltrexone HCI Co-Administered with Oxycodone HCI in Non-dependent, opioid-Prefer ring Subjects
81.	2007	A Phase Ill, Multi-center, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of the Sterile XXX in Adult Subjects
82.	2007	A Double Blind, Placebo Controlled, Enriched Enrollment, Randomized Withdrawal Study To Evaluate An Optima l Methodology For Conducting Proof Of Concept Trials In Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin As A Test Drug
83.	2007	A Phase Ill,Variable-Dose Titration Followed by a Randomized Double-Blind Study of Controlled-Release OROS* Hydromorphone HCI (NMED-1077) Compared to Placebo in Patients with Chronic Low Back Pain
84.	2007	A Multicenter, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Reduction In Opioid Withdrawal In Subjects Receiving Low-Dose Naltrexone (0.0001 mg BID) While Taking High-Dose Controlled Release Oxycodone For The Treatment Of Chronic Non-Malignant Pain
85.	2007	Randomized, Double-Blind, Placebo-Controlled ,Single Dose Escalation Study Of The Analgesic Efficacy Of Nalbuphine-ER With Patients With Chronic Pain Secondary To Osteoarthritis Of The Knee/Hip
86.	2007	A Phase I, Open-Label Study Of Latanoprost Acid Plasma Concentrations In Pediatric And Adult Glaucoma Patients Treated With Latanoprost 0.005%
87.	2007	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study Of 4 Fixed Oral Doses Of DVS SR In Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

88.	2007	A 9-Month Open-Label Extension Study Of The Long-Term Safety Of DVS SR In Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
89.	2007	A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With An Open-Label Run-In To Assess The Efficacy, Tolerability, And Safety Of BIDS 10 Or BIDS 20 Compared to Placebo In Opioid-Naive Subjects With Moderate To Severe, Chronic Low Back Pain
90.	2007	A Double-Blind, Multi-center Extension Study to Evaluate the Safety and Efficacy of Q8003 in Patients with Acute Moderate to Severe Pain
91.	2007	A Multicenter, Randomized, Placebo-Controlled, Double Blind Study Of The Efficacy And Safety Of Lubiprostone In Patients With Opioid-Induced Bowel Dysfunction
92.	2007	A Phase Ill, Multicenter, Randomized, Placebo-controlled, Double blinded Study of the Efficacy and Safety of Lubiprostone in Patients with opioid-induced Bowel Dysfunction
93.	2007	A Randomized, Double Blinded, Placebo-Controlled Study to Assess Whether the Administration of Ramelteon Could Facilitate the Discontinuation of Zolpidem (Ambien) > 10 mg Therapy in Subjects with Chronic Insomnia
94.	2007	A Multiple Dose, Double-Blind, Placebo-Controlled, Safety, Tolerance and Pharmacokinetic Study of Tezampanel subcutaneous in healthy male and female volunteers
95.	2008	A Single-Center, Randomized, Open-Label, Single-Dose Crossover Study to Assess the Relative Bioavailability of AGN-209323 Oral Capsules Compared with Oral Solution to Examine the Effect of Food on the Bioavailability of AGN-209323 Capsules in Healthy Male and Female Subjects and the Evaluate AG N-209323 Exposure in the Cerebrospinal Fluid
96.	2008	A Single Center, Double-Blind, Placebo-Controlled Study to Evaluate Plasma Naltrexone Exposure and Clinical Opiate Withdrawal Symptoms Following Oral Dosing with Naltrexone HCL in Subjects with Chronic, Non-malignant Pain and Stabilized on Extended Release Morphine Sulfate

97.	2008	A Randomized, Open-Label, Four-Way Crossover Study to Evaluate the Relative Bioavailability of a Pilot AL0-02 Formulation to the Same Formulation Taken Concomitantly with 20% and 40% Ethanol and With a High Fat Meal in Healthy Subjects
98.	2008	A Randomized, Double-Blind, Placebo- and Active-Controlled Parallel Group, Analgesic Efficacy Trial of Oral ARRY 371797 in Subjects Undergoing Third Molar Extraction
99.	2008	A double-blind, randomized, placebo and naproxen controlled study to investigate the analgesic efficacy of a single dose of AZ D1386 in patients undergoing impacted mandibular third molar extraction
100.	2008	A Randomized, Double Blind, Placebo-Controlled Comparison of the Analgesic Efficacy of a Single Dose of AZD1940 in Patients Undergoing Impacted Mandibular Third Molar Extraction
101.	2008	A randomized, crossover study to compare systemic exposure following administration of multiple 200-mg doses of Armodafinil and Modafinilin patients with excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome who are currently using nasal continuous positive airway pressure
102.	2008	A Phase I Open-label Study to assess the Safety and CSF Pharmacokinetics of CTS2 1166 Administered Intravenously in Healthy Adult Males
103.	2008	A Phase I Single Escalating Dose Study to assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously in Healthy Adult Males
104.	2008	An Open-Label Multiple Dose Study to Evaluate the Pharmacokinetics of Sequestered Naltrexone Hydrochloride Pellets in Pain Subjects on Stable Doses of opioids with opioid Induced Constipation
105.	2008	An Exploratory, Randomized, Double-Blind, Placebo-Controlled, Crossover Pilot Study to Explore the Pharmacokinetics and Pharmacodynamic Effects Following Oral Oxycodone in opioid Experienced, Non-Dependent, Recreational Drug Users
106.	2008	A Multicenter, Double Blind, Placebo Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral

		MK-0974 with Placebo for the Acute Treatment of Migraines With or Without Aura
107.	2008	A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose, Dose Escalation Study to Evaluate the Efficacy, Safety and Tolerability of NKTR-118 in Patients with opioid-Induced Constipation
108.	2008	A Randomized, Single Blind Study to Investigate the Tolerability and Effects on Epidermal Nerve Fiber Density of Three Low-Concentrations of Capsaicin Topical Liquid NGX-1998 in Healthy Volunteers
109.	2008	A Phase I, 2-Part, Randomized, Subject and Investigator Blinded, Placebo-Controlled, Cross-Over Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of CE-326,597 in Obese, Adult Subjects with Asymptomatic Cholelithiasis
110.	2008	A Placebo-Controlled, Randomized, Double-Blind Study of the Safety and Efficacy of Q8003 in the Management of Post-Bunionectomy Pain
111.	2008	An Open-Label, Single-Dose, Fasting, Three-Way Crossover, Relative-Bioavailability Study of Q8003 Capsule Compared to Morphine and Oxycodone Solutions in Healthy Volunteers
112.	2008	An Open-Label,Fasting,Single- and Multiple-Dose, Two- Part Crossover Pharmacokinetic Study of Orally Administered Q8003 Morphine Sulfate and Oxycodone HCI Combination Capsules in Healthy Volunteers
113.	2008	Prevalence of Sleep Disordered Breathing in Subjects Taking Pain Medications to Treat Chronic Pain
114.	2008	A multicenter, randomized, observer -blinded, parallel group, single dose, placebo- controlled sequential cohort study of efficacy and safety of Xen2174 in subjects following bunionectomy surgery
115.	2009	A Randomized, Double-blind, Placebo- and Active-Controlled Study to Assess the Relative Abuse Potential of Acurox Tablets in Non-dependent Recreational opioid Users

116.	2009	A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of RDC-1036 Administered as a Single Oral Dose to Healthy Adults
117.	2009	A Phase I Study of the Effect of RDC-1036 on Gastrointestinal Transit Time Following Morphine Administration to Healthy Men
118.	2009	A Placebo-Controlled, Double-Blinded, Pilot Study to Assess the Efficacy of Lidoderm® in Relieving Allodynia
119.	2009	Randomized, double blind, placebo controlled single ascending dose (25-400 mg) study to characterize the safety and pharmacokinetics of Celecoxib for injectable suspension (CEP 33222) in Healthy subjects
120.	2009	A Randomized, Open-label, Four-Way Crossover Study to Evaluate the Relative Bioavailability of Oxycodone DETERx™ 40 mg Taken Concomitantly with 0%, 4%, 20% or 40% Ethanol
121.	2009	A Follow-up Safety Evaluation for Subjects that Participated in the Phase I Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males
122.	2009	A randomized, placebo-controlled trial of Duloxetine added to nonsteroidal anti- inflammatory drugs in patients with knee pain due to osteoarthritis who have had suboptimal response to nonsteroidal anti-inflammatory drug treatment
123.	2009	A Phase IIb, Randomized, Double-Blind, Two-Arm, Multicenter, Placebo-Controlled Study to Assess the Efficacy and Safety of EN3324 (Axomadol) in Subjects with Moderate to Severe Chronic Low Back Pain
124.	2009	A randomized, double-blind, placebo- and active controlled study of the safety and efficacy of RGH 896 in patients with diabetic peripheral neuropathic pain
125.	2009	A Single-Center, Single-Dose, Open-Label, 2-Period, 1-Way Crossover Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Risperidone Patch (16 mg/20 cm2) as Compared to Risperdal® (2 mg Tablet) in Healthy Male Subjects

126.	2009	A Randomized, Double-Blind, Triple-Dummy, Placebo and Active-Controlled, Six-Way Crossover Study to Determine the Relative Abuse Potential of Remoxy Compared to Immediate and Extended-Release Oxycodone, Administered Whole and/or Crushed/Chewed in Non-Dependent, Recreational opioid Users, under Fed and Fasted Conditions
127.	2009	A Pilot Study of the Cold Pressor Test as an Experimental Model of Pain in Healthy Volunteers
128.	2009	A Randomized, Double-blind, Double-dummy Evaluation of the Single Dose Pharmacokinetics, Pharmacological Effects, and Safety of Fentanyl Buccal Soluble Film Compared to Morphine Immediate-Release Tablets in Healthy Male Volunteers
129.	2009	A Randomized, Double- Blind, Placebo-Controlled, Parallel Dose Response Study of Gabapentin Injection for lntrathecal Administration in Subjects with Chronic, Intractable Pain
130.	2009	A multicenter, randomized, double blind, placebo and active controlled, crossover study to evaluate the safety and efficacy of MK-0974 in the treatment of acute migraine in patients with stable vascular disease
131.	2009	A Phase I, Open-Label Study to Assess the Effects of UGT Modulation on the Pharmacokinetic Parameters of Single-Dose MPC-4326 in Healthy Subjects
132.	2009	A Phase II Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache without Aura
133.	2009	An Open-Label Study of the Use of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream as Pre-Treatment for NGX-4010 in Subjects with Post herpetic Neuralgia (PHN)
134.	2009	A Randomized, Double-blind, Multicenter, Repeat-dose Comparison of the Analgesic Efficacy and Safety of Q8003 with Oxycodone and Morphine for the Management of Acute Moderate to Severe Postoperative Pain Following Bunionectomy Surgery

135.	2009	A Repeat-Dose, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Flurbiprofen 8.75 mg Lozenge compared to its Vehicle Control Lozenge in Patients with Painful Pharyngitis
136.	2009	A Phase lb, Double-Blind, Placebo Controlled, Three-Period, Evaluation of the Safety, Efficacy, and Pharmacokinetics of Sublingual Dexmedetomi dine (DEX-SL.01) in Chronic
137.	2009	A randomized, double-blind, placebo-controlled ,parallel group, repeat dose study of the safety and efficacy of REGN475 in patients with osteoarthritis of the knee
138.	2009	Pilot Study to Investigate the Effects of R04917838 on Brain Magnetic Resonance Spectroscopy (MRS) Measures
139.	2009	Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Subcutaneous MOA-728 to Treat Opioid-Induced Constipation
140.	2009	Randomized, double blind, placebo-controlled study to evaluate the safety and tolerability of X P19986 in subjects with acute back spasms
141.	2010	A Phase I, Double-Blind, Placebo-controlled, Multiple-dose, 2-Part Study Evaluating the Safety, Tolerability, Pharmacokinetics and Clinical Effect of ADL5945 in Subjects With opioid-induced Constipation
142.	2010	A Randomized, Double-Blind, Placebo-Controlled, Five-Way Crossover Study to Assess the Safety, Pharmacokinetics, Effect on Analgesia and Effect on Gastrointestinal Motility of AIK0-150, Administered Intravenously to Healthy Male Adults
143.	2010	A Phase II study of the Effects of RDC-1036 Administered to Subjects with opioid-induced Constipation during Treatment with opioids for Chronic Pain
144.	2010	A Single-Center, Single blind, randomized placebo-controlled comparative biodistribution and memory study of SANCTURA X R (60 mg once daily) vs. Immediate Release Oxybutynin (5 mg three times daily) in Patients with Overactive Bladder and Age-associated Memory

		Impairment
145.	2010	A Single-center, Randomized, Double-blind, 2-way Crossover Study to Evaluate whether a Single-Dose Administration of Crushed and Whole EMBEDA induces Clinical Opiate Withdraw al Signs and Symptoms in opioid Dependent Patients with Chronic, Non-Cancer Pain who are Stabilized on EMBEDA
146.	2010	A Multi-Center, Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single, Oral Dose of a Fast Release Aspirin 1000 mg in Postsurgical Dental Pain
147.	2010	A Multicenter, Prospective, Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Occipital Nerve Stimulation (ONS) Using a Precision Implantable Neurostimulator Device for Migraine
148.	2010	An Assessment of the Safety and Pharmacokinetics of Single Dose Administration of Four Formulations of Oxycodone DETERx™ Compared with Oxycontin
149.	2010	An Assessment of the Pharmacokinetics and Safety of Single Dose Administration of Oxycodone DETERX 40 mg in the Fasted State, with a High Fat, High-Calorie Meal, and with a Low-Fat, Low-Calorie Meal
150.	2010	A Phase lb, Dose-Escalating, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Subcutaneous ELND002 in Patients with Relapsing Forms of Multiple Sclerosis
151.	2010	A Randomized, Single-Dose, Double-Blind, Double-Dummy, Four-Period Crossover Study to Evaluate the Relative Bioavailability and Subjective Effects of EN3288 40 mg Administered Intact and After Mastication Compared with Opana® ER 40 mg Administered After Mastication and with Opana® 40 mg (4x10mg) Administered Intact in Healthy Non-Dependent Recreational Oral Prescription Opioid Users Experienced in Mastication of Extended-Release Opioid Formulations

152.	2010	RestoreSensor Study
153.	2010	A Randomized, Double-blind, Three-period Crossover Study Evaluating of the Impact of Varying Doses of Oxycodone (15 and 30mg) Compared to Placebo on the Ventilatory Response to Hypercapnia and the Cold Pressor Test in Male Volunteers
154.	2010	A Multicenter Randomized, Double-Blind, Controlled Study to Evaluate Safety, Tolerability and Preliminary Efficacy of Two Capsaicin Concentration Variations of NGX-1998 (10% or 20% w/w) in Subjects with Postherpetic Neuralgia (PHN)
155.	2010	A Phase I, Double-Masked, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetcs, Pharmcodynamics, and Immunogenicity of Single, Escalating Doses of RN6G in Patients with Dry, Age-Related Macular Degeneration (AMD)
156.	2010	A Randomized Phase IIa, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of CP-601,927 Augmentation of Antidepressant Therapy in Major Depression
157.	2010	A Randomized, Double-blind, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Efficacy of S-297995 for the Treatment of opioid-Induced Bowel Dysfunction In Subjects with Chronic Pain
158.	2010	A Phase I Single-Center Dose-Ranging Study of Kovacaine Mist (Tetracaine Hydrochloride with Oxymetazoline Hydrochloride) for Anesthetizing Maxillary Teeth in Healthy Subjects
159.	2010	A phase I/II randomized, double blind,multiple ascending dose study to assess the safety, pharmacokinetics and effect on opioid analgesia ofTD-1211 administered orally to healthy volunteers and to assess the safety, pharmacokinetics and effect on bowel movements in subjects with opioid-induced constipation
160.	2010	An Open Label Study to Evaluate the Long-Term Safety of Subcutaneous MOA-728 for the Treatment of Opioid-Induced Constipation in Subjects with Non-Malignant Pain
161.	2010	A Randomized, Multiple Dose, Double Blind, Placebo-Controlled Study of Sequential, Ascending Dose Levels to Assess the Safety, Tolerability and Electrocardiograph Effects of Propoxyphene

		Napsylate Capsules (and its Metabolite Norpropoxyphene) When Administered Orally to Healthy Adult Subjects
162.	2011	A Phase II, Randomized, Double Blind, Placebo Controlled Repeat-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ALKS37 in Subjects with Opioid Induced Constipation
163.	2011	A Randomized, Double-Blind, Placebo- and Active-Co ntrolled,3-Way Crossover Study to Determine the Abuse Potential of Oral Administration of crushed EMBEDA Relative to Crushed Controlled-Release Morphine Sulfate and Placebo in Non-dependent Recreational Opioid Users
164.	2011	A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NKTR-118 in Patients with Non-Cancer Related Pain and Opioid Induced Constipation
165.	2011	An open-label,52-week study to assess the long-term safety of NKTR-118 in opioid induced constipation (OIC) in patients with non-cancer related pain
166.	2011	A Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Safety and Tolerability Trial of Naproxen Sodium/Diphenhydramine Combination in an OTC Population
167.	2011	A Multicenter, Randomized, Double-Blind, Parallel Group Trial Assessing the Efficacy and Safety of Naproxen Sodium/Diphenhydramine Combination in Postsurgical Dental Pain with Phase Advanced Sleep (Phase Ill)
168.	2011	A 12-week, placebo controlled, double blind, randomized, withdrawal study to evaluate the efficacy and safety of BEMA buprenorphine in subjects with moderate to severe chronic low back pain
169.	2011	A 52 Week, Open-Label, Long-Term Treatment Evaluation of the Safety and Efficacy of BEMA buprenorphine in Subjects with Moderate to Severe Chronic Pain
170.	2011	An open-label, long-term treatment evaluation of the safety and efficacy of BEMA buprenorphine in subjects with moderate to severe chronic low back pain

171.	2011	Double blind, placebo controlled, 4-treatment ,4-period crossover study to determine the lowest dose of Naloxone that will produce a withdrawal response when administered with buprenorphine in opioid dependent subjects
172.	2011	A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients with Osteoarthritis or low back pain who require opioid treatment for an extended period of time
173.	2011	A 12-Month, Open-Label Study to Evaluate the Long-Term Safety of Hydrocodone C33237/3080 Bitartrate Extended-Release Tablets (CEP33237) at 15 to 90 mg Every 12 Hours in Patients Who Require opioid Treatment for an Extended Period of Time
174.	2011	A Phase IV, Double-Blind, Placebo-Controlled, Single-Center, Crossover Study Investigating the Effects of EXALGO® Time of Dosing on Sleep at Steady-State Dose Levels in Patients with Low Back Pain
175.	2011	A Randomized, Double-blind, Placebo-controlled, Combined Single Ascending Dose and Multiple Ascending Dose Study to Assess Safety, Tolerability, lmmunogenicity, Pharmacodynamic Response and Pharmacokinetics of Intravenous Infusions of BAN2401 in Subjects With Mild to Moderate Alzheimer's disease
176.	2011	A phase I, double-blind, randomized, placebo-controlled multiple-dose ranging study evaluating the safety, tolerability and pharmacokinetics and antiviralactivity of GS6620 in treatment naïve subjects with chronic Hepatitis C virus infection
177.	2011	A Randomized, Double-Blind, Dose Escalation, Fusion, First Time In Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Single and Repeat Doses of XXX in Chronica lly Infected Hepatitis C Subjects
178.	2011	STD Test Collection Kit Validation Study
179.	2011	Study of Pain Improvement with Novel Electrotherapy (SPINE Trial), a Prospective, Randomized, double-blind, sham controlled, multi-

		center study of the safety and effectiveness of Cutaneous field stimulation as a treatment for chronic lumbar and/or thoracic back pain
180.	2011	An Open-Label, One-Period Study in Patients Receiving Methadone or Buprenorphine/Naloxone Maintenance Therapy to Evaluate the Effect of SCH 503034 (Boceprevir) on Either Methadone or Buprenorphine/Naloxone Plasma Concentrations
181.	2011	A Phase II, Double-Blind, Placebo-Controlled Single Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NKTR-181Solution Administered Orally to Healthy Volunteers
182.	2011	A phase I, double blind, randomized, placebo-controlled ascending multiple dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of NKTR-181 solution administered orally in healthy male volunteers
183.	2011	A Randomized, Single-Blind Study to Investigate the Effects of Capsaicin Topical Liquid Formulations on Epidermal Nerve Fiber Density in Healthy Volunteers
184.	2011	A two-part study to assess the effect of alisporivir on the pharmacokinetics, safety, and tolerability of methadone in healthy subjects and subjects on stable methadone maintenance therapy
185.	2011	Pilot Randomized, Single Oral Dose, Two way Crossover Relative Bioavailability Study of Tranexamic Acid from Lysteda Oral Solution Compared with Lysteda Tablets in Healthy Adult Women
186.	2011	A Phase lb, Randomized, Double-Blind, Placebo-Controlled, Three Period Crossover Evaluation of the Efficacy, Safety, and Pharmacokinetics of Intranasal Dexmedetomidine in Chronic Pain Patients
187.	2011	Human abuse liability study in recreational drug users to investigate the abuse liability potential of R049 17838
188.	2011	A Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study of Medication in Subjects with Moderate to Severe Pain Following Surgical Removal of Impacted Third Molar Teeth

189.	2011	A multicenter, randomized, placebo-controlled, double blind study of the efficacy and safety of Lubiprostone in subjects with opioid-induced bowel dysfunction
190.	2011	Phase 11, Randomized, Double-blind, Placebo-controlled ,dose escalation study to assess the safety, tolerability and clinical activity ofTD-1211in subjects with opioid-induced constipation
191.	2011	A Phase I, Open-Label,Single-Sequence Study to Examine the Effect of Telaprevir on the Pharmacokinetics of Buprenorphine In Subjects on Stable Buprenorphine/Naloxone Maintenance Therapy
192.	2012	A Multicenter, 12-Month,Open-Label,Single-Arm, Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain
193.	2012	Open label study to assess the safety and tolerability of BEMA buprenorphine in opioid dependent subjects
194.	2012	Effect of multiple dosing with Bl 201335 on the safety,pharmacok inetics and pharmcodynamics of steady-state methadone and buprenorphine/naloxone in subjects on stable addiction management therapy
195.	2012	A Randomized, Double-Blind, Placebo- and Comparator -Controlled Study of BMS-820836 in Recreational Polydrug User Healthy Subjects
196.	2012	A randomized, double blind, placebo-controlled, ascending dose study to evaluate the safety and efficacy of CEP-37247 administered at single doses of 0.5, 1,3, 6 ,12,20 or 30 mg by the transforaminal epidural route of the treatment of patients with lumbosacral radicular pain associated with disk herniation
197.	2012	A Phase Ill, Multi-Center, Randomized, Double-blind, Placebo-Controlled, Safety, Tolerability , and Efficacy Study of Oxycodone DETERx™ vs Placebo in opioid-Experienced and opioid-Naive Subjects with Moderate-to-Severe Chronic Low Back Pain
198.	2012	A Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled Study to Assess the Relative Abuse Potential of COV795 (Oxycodone HCl/Acetaminophen) vs. Immediate-Release Oxycodone

		HCl/Acetaminophen Tablets in Non-Dependent, Recreational opioid Users
199.	2012	A Randomized, Double-blind, Placebo-controlled, Escalating Multiple Oral Dose Study of the Safety, Tolerability, and Pharmacokinetics of GRT6005 in Patients with Chronic Low Back Pain Without a Neuropathic Component
200.	2012	A double-blind, randomized, placebo-controlled single and multiple-dose ranging study evaluating the safety, tolerability and pharmacokinetic s and antiviral activity of GS9620 in treatment naive subjects with chronic Hepatitis C virus infection
201.	2012	A phase II, randomized, open-label study of GS5885 administered concomitantly with GS9451,Tegobuvir and Ribavirin (RBV) to treatment naive subjects with chronic genotype 1HCV infection
202.	2012	A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infection
203.	2012	A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead-Sponsored Trials in Subjects with Chronic Hepatitis C Infect ion
204.	2012	A phase I/Ila study assessing single and multiple doses of HCV NS5A Inhibitor IDX719 in Healthy and HCV-infected subjects
205.	2012	A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Single-Dose, Four-Way Crossover Study to Determine the Relative Bioavailability, Abuse Potential and Safety of Equivalent Doses of Crushed and Intact IDT-001 compared with Crushed MS CONTIN® and Placebo in opioid Experienced, Non-Dependent Subjects, Following Intranasal Administration
206.	2012	A 4-Way Cross-Over Study to Evaluate the Relative Bioavailability of Oxycodone ARIR 30 Mg Tablets, Oxycodone ARIR-C 30 mg Tablets, and Roxicodone 30 Mg Tablets Administered Under Fasted Conditions and Oxycodone ARIR 30 Mg Tablets Administered Under Fed Conditions

207.	2012	Crossover Study to Determine the Relative Bioavailability, Abuse Potential, and Safety of Equivalent Doses of Crushed and Intact Oxycodone ARIR compared with Crushed Roxicodone and Placebo in opioid Experienced, Non-Dependent Subjects Following
208.	2012	Open-Label Evaluation of the Pharmacokinetic Profile and Safety of Tapentado l Oral Solution for the Treatment of Postsurgical Dental Pain in Children and Adolescents Aged From 6 to Less Than 18 Years
209.	2012	Pilot Study to Evaluate the Blood Pressure and Heart Rate Response to Cold Stress in Volunteer Subjects
210.	2012	A Study to Evaluate the Effect of MK-5172 on the Pharmacokinetics of Methadone and Buprenorphine/Naloxone
211.	2012	An open label, randomized, single dose, 4 treatment, 4 period, crossover study to determine the bioavailability of NKTR-181tablets relative to NKTR-181oral solution and to investigate the effect of the administration with food on NKTR-181pharmacokinetics
212.	2012	A phase I exploratory study evaluating the pharmacokinetics of single ascending oral doses of NKTR-192 in healthy male volunteers under Naltrexone blockade
213.	2012	A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects with Moderate-to-Severe Chronic Pain Due to Osteoarthritis of the Knee
214.	2012	Extension Pilot Single Oral Dose Relative Bioavailability Study of Tranexamic Acid of Modified Lysteda Oral Solution to be Compared with Lysteda Tablets Relative Bioavailability from Lysteda 106 PK Pilot results in Healthy Adult Women
215.	2012	A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of S-297995 for the Treatment of opioid-induced Constipation (DIC) in Subjects with Non-malignant Chronic Pain Receiving opioid Therapy
216.	2012	A Pilot, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects

217.	2012	A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Electrocardiographic Effects of Lofexidine When Administered Orally to Methadone Maintained Adult Subjects
218.	2013	A single center, randomized, double-blind active- and placebo-controlled, 5-way crossover study assessing the abuse potential of intranasally administered XXXX tablets in non-dependent recreational opioid users
219.	2013	A phase II, randomized, multicenter, safety, tolerability and dose-ranging study of Samidorphan, a component of XXXX, in adults with Schizophrenia treated with XXXX
220.	2013	A Study to Evaluate the Cardiovascular Reactivity and Cold Pain Tolerance of Healthy Volunteers with or without Specific Single Nucleotide Polymorphisms in the XXXX Gene to the Cold Pressor Test
221.	2013	A randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmcodynamics of XXX XXX in healthy subjects and subjects with migraines
222.	2013	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of XXX XXX in Migraine Prevention
223.	2013	Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of XXXX Administered to Healthy Adult Subjects
224.	2013	A multicenter, randomized, double blinded, placebo-controlled study using a Bayesian adaptive design to assess the efficacy, safety, tolerability and serum exposure of multiple doses of XX00010 (XXXX) in subjects with painful lumbar radiculopathy
225.	2013	A long-term, follow-up study of subjects who participated in a clinical trial in which XXXX (XXX-XXXX) and/or XXXX (XXX-XXXX) were administered for the treatment of chronic hepatitis C

226.	2013	A phase I, open label, drug-drug interaction study between XXXX and XXXX, and between XXXX/XXXX and XXXX
227.	2013	A multicenter, open label, parallel group trial to evaluate the pharmacokinetic interactions between XX XXXX (600 mg t.i.d. or 600 mg b.i.d.) and XX XXXX (120 mg q.d.) given in combination with XXXX for 24 weeks, and their combined effect on the pharmacokinetics of XXXX, XXXX, caffeine (the probe drug substrate for CYP1A2), XXXX (the probe drug substrate for CYP2C9) and XXXX (the probe drug substrate for CYP3A4) in treatment naïve patients and prior treatment relapse or partial responder patients with genotype 1 chronic hepatitis C infection
228.	2013	Assessment of the Relative Human Abuse Potential of Intranasal XXXX XXXX
229.	2013	A Randomized, Double-Blind, Double-Dummy, Active- and Placebo-Controlled Study to Assess the Relative Abuse Potential of XXXXXX (XXXX/XXXX XXXX) vs. Immediate-Release XXXX XXXX/XXXX Tablets in Non-Dependent, Recreational opioid Users
230.	2013	A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study To Evaluate The Efficacy And Safety Of XX-XXXX For The Treatment Of opioid-Induced Constipation In Adults Taking opioid Therapy For Chronic Non-Cancer Pain
231.	2013	A phase II assessment of Safety, Tolerability, and Pharmacodynamic Effects of XXXX in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer’s Disease
232.	2013	A safety, pharmacokinetic and pharmacodynamic study of XXXX in healthy subjects and patients diagnosed with Alzheimer's Disease
233.	2013	A single-dose and multiple-dose, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of XXXX in patients with mild cognitive impairment due to Alzheimer's disease or mild to moderate Alzheimer's disease
234.	2013	AN EVALUATION OF THE TOLERABILITY OF SWITCHING SUBJECTS ON CHRONIC AROUND-THE-CLOCK (ATC) OPIOID THERAPY TO XXXX XXXX

235.	2013	A Randomized, Double-Blind placebo- and active controlled study to evaluate the safety and efficacy of XXX-XXXX in patients with moderate to severe chronic pain due to Osteoarthritis of the Knee
236.	2013	3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of XXXX Anti-HCV, Direct Acting Antivirals
237.	2013	A Randomized, Multiple-Dose, Two-Treatment, Two-Period Crossover Study to Evaluate the Comparative Bioavailability of XXXX XXXX (XXXX XXXX XXXX ER) and XX XXXX® in Healthy Volunteers
238.	2013	A double-blind, randomized, placebo-controlled, parallel group, dose frequency study of XXXX in subjects with treatment-resistant depression
239.	2013	A randomized, multicenter, double-blind, relapse prevention study of XXXX XXXX 3-month formulation for the treatment of subjects with Schizophrenia
240.	2013	A Randomized Crossover Study to Evaluate the Bioavailability and Bioequivalence of XXXX® versus XXXX® Prepared with a Flavored Diluent Solution in Healthy Subjects
241.	2013	A Randomized, Double-Blind, Crossover Taste Testing Study in Healthy, Subjects Comparing XXXX® (sodium oxybate) Oral Solution and XXXX Placebo Oral Solution Prepared with Flavored Diluents
242.	2013	Interventional, open-label, flexible-dose, exploratory study of XXXX as adjunctive treatment of sleep disturbances in patients with major depressive disorder
243.	2013	A multiple dose study to evaluate the safety and pharmacokinetics of XX-XXXX and opiates in subjects receiving opiate maintenance therapy
244.	2013	A Seamless Phase IIa/IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial to Evaluate the Efficacy and

		Safety of XX-XXXX as an Adjunctive Therapy to XXXX for Symptomatic Treatment in Subjects with Alzheimer's Disease
245.	2013	A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of XXXX in subjects With Bipolar I Disorder Experiencing an Acute Manic or Mixed Episode (Protocol XXXX [Formerly XXXX])
246.	2013	A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to XXXX in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. XXXX)
247.	2013	Efficacy and Safety of 3-Week Fixed-Dose XXXX Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. XXXX)
248.	2013	A randomized, double blind, active- and placebo-controlled, 5-period crossover study to assess the relative abuse potential and safety of XXXX-XXX at 3 doses compared with placebo and XXXX in non-dependent recreational opioid users
249.	2013	A Phase I double-blind, randomized, placebo-controlled, ascending multiple dose study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of oral doses of XXXX-XXX in healthy male volunteers.
250.	2013	A PHASE 1, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF XXXX-XXX IN HEALTHY ADULT MALE VOLUNTEERS
251.	2013	A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate prevention of relapse in patients with schizophrenia receiving either flexible dose XXXX or placebo in long-term use (up to 26 weeks) followed by up to 52 weeks of open-label extension
252.	2013	A multicenter, open-label, sequential-cohort, dose escalation, 14-day study to explore the tolerability and pharmacokinetics of XXXX (XXXX®) 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day) in adolescent patients (aged 12 to 17 years)

253.	2013	Induction, stabilization, adherence and retention trial (ISTART) - A randomized, non-inferiority, multicenter study to assess early treatment efficacy of XXXX vs XXXX film and to explore switching between treatments
254.	2013	A randomized, blinded, active-controlled non-inferiority study for the efficacy and safety of XXXX for the induction of treatment of opioid dependence.
255.	2013	A multi-center, open-label, 24-week, follow-up study to assess safety, efficacy and treatment adherence for maintenance treatment of opioid dependence with XXXX
256.	2013	A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXX (XXX-XXXX) as Maintenance Treatment in Patients with Bipolar I Disorder
257.	2013	A 52-week, Multicenter, Open-label Study to Evaluate the Effectiveness of an Intramuscular Depot Formulation of XXXX (XXX-XXXX) as Maintenance Treatment in Patients with Bipolar I Disorder
258.	2013	A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Flexible-Dose Once-Weekly Oral XXXX in Children and Adolescents with Tourette's Disorder
259.	2013	A 12-week, Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXXX Intramuscular Depot (XXX-XXXX, XX XXXX) in the Acute Treatment of Adults With Schizophrenia
260.	2013	An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral XXXX in Children and Adolescents with Tourette's Disorder
261.	2013	A blood based diagnostic study to distinguish healthy volunteers from Patients with Alzheimer's
262.	2013	A 12-WEEK , RANDOMIZED, PHASE I, DOUBLE-BLIND, PARALLEL-GROUP STUDY OF TWO DOSE LEVELS OF XX-

		XXXX COMPARED TO PLACEBO IN THE ADJUNCTIVE TREATMENT OF OUTPATIENTS WITH SUBOPTIMALLY CONTROLLED SYMPTOMS OF SCHIZOPHRENIA
263.	2013	A Randomized, Double-Blind, Triple-Dummy, Placebo Controlled, Single-Dose, 4-Way Crossover Study to Determine The Relative Abuse Potential of XX-XXXX (XXXX ER Capsules) Compared to Immediate-Release XXXX and Placebo When Administered Orally Whole and/or Chewed to Non Dependent, Recreational opioid Users Under Fasted Conditions
264.	2013	A Randomized, Single-Dose, Placebo-Controlled, Double-Blind, 3-Way Crossover Study to Determine the Relative Abuse Potential of Intravenous XXXX XXX Alone or in Combination with Intravenous XXXX XXX in opioid Experienced Non-Dependent Subjects
265.	2013	Development and Validation of an Instrument to Identify Individuals at Risk of Abusing Certain Substances for Utilization in Human Abuse Liability Studies
266.	2013	Multicenter cognition assessment for healthy subjects to collect reference data for comparison to patients with depression
267.	2013	A randomized, double blind, placebo-controlled, parallel group, multicenter, Phase III study to evaluate the long-term safety of XXXX for the treatment of opioid-induced constipation in subjects with non-malignant chronic pain receiving opioid therapy
268.	2013	A randomized, double blind, placebo-controlled, multicenter study of the pharmacodynamics, pharmacokinetics and tolerability of a liquid form of XXXX in adult subjects with chronic idiopathic constipation
269.	2013	A 104-WEEK, FLEXIBLE-DOSE, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFECTIVENESS OF XXXX IN PEDIATRIC SUBJECTS WITH SCHIZOPHRENIA AND SUBJECTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
270.	2013	A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF

		XXXX IN CHILDREN AND ADOLESCENT SUBJECTS WITH IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
271.	2013	A randomized, double blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics and effects of food on absorption of XX-XXXX administered orally to healthy male volunteers
272.	2013	A double blind, randomized, placebo-controlled, parallel group study to simultaneously qualify a biomarker algorithm for prognosis of risk in developing mild cognitive impairment due to Alzheimer's disease (MCI due to AD) and to test the safety and efficacy of XXXX (XX-XXXX SR 0.8 mg QD) to delay the onset of MCI due to AD in cognitively normal subjects
273.	2013	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 18-Month Safety and Efficacy Study of XXXX-XXXX XXX (XXXX) in Subjects with Mild Alzheimer’s Disease
274.	2013	A Double-Blind, Placebo-Controlled, Randomized, Parallel Group, 12-Month Safety and Efficacy Trial of XXXX-XXXX XXX (XXXX) in Subjects with Behavioral Variant Frontotemporal Dementia (bvFTD)
275.	2013	A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of XXXX XXXX ER Tablets (XXX-XXXXX) at 30 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain
276.	2013	A 6-month, open label extension study to evaluate the safety XXXX XXXX ER Tablets (XXX-XXXXX) at 15-90 mg every 12 hours for relief of moderate to severe pain in patients with chronic low back pain who require opioid treatment for an extended period of time
277.	2013	A multinational, multicenter, randomized, parallel-group study performed in subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to assess the efficacy, safety and tolerability of XXXX XXXX (XX) injection 40 mg administered three times a week compared to placebo in a double-blind design
278.	2013	A Randomized, Six-way, Crossover, Open-Label Study to Compare the Pharmacokinetics of Two Different Formulations of XXXX XXXX/XXXX Tablets (10 mg/325 mg) (XX-XXXXX) when

		Administered Intranasally and XXXX® (10 mg/325 mg) Administered Intranasally and Orally in Nondependent, Recreational Drug Users
279.	2013	A 12-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Once-Weekly Intra-Muscular Injections of XX-XXXX (150 mg/week or 300 mg/week) as Treatment for Facilitation of Abstinence in Cocaine-Dependent Subjects
280.	2013	A phase II, multicenter, randomized, double blind, parallel group, placebo-controlled study of XX-XXXX in subjects with Fibromyalgia (FM)
281.	2013	A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Explore the Pharmacokinetics and Pharmacodynamics of XXX-XXX, XXXX, and Placebo in Healthy Adult Male Subjects
282.	2013	A randomized, double-blind, placebo-controlled, multiple ascending dose study to assess the safety, tolerability, and electrocardiographic effects of XXXX when administered orally to XXXX maintained adult subjects.
283.	2013	A Phase III, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety and Dose-Response Study of XXXX in the Treatment of opioid Withdrawal (Days 1-7) Followed by Open-Label, Variable Dose XXXX Treatment (Days 8-14)
284.	2013	An Open-Label, Sequentially Staggered, Single Center, Parallel Group, Two Part, Phase I Study to Evaluate the Safety and Tolerability of VXXX-XXXXX Injection in Healthy Volunteers
285.	2014	Pharmacokinetic and Pharmacodynamic Study of XXXX XXXX in Elderly Subjects with Geographic Atrophy Associated with Dry Age-Related Macular Degeneration
286.	2014	Phase I, Randomized, Double-Blind, Placebo-Controlled, Ascending MultipleDose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Subjects and Migraine Patients.

287.	2014	A 6-Month, Multicenter, Randomized, Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of XXXX in Adolescents with Tourette's Disorder
288.	2014	A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of XXXX in Subjects with Mild to Moderate Alzheimer's Disease
289.	2014	A Phase 1, Open-Label, Drug-Drug Interaction Study between XXXX and XXXX/XXXX/XXX-XXXX 3 DAA FDC + 75 mg XXX-XXXX and between XXXX/XXXX And XXXX/XXXX/XXX-XXXX 3 DAA FDC + 75 mg XXX-XXXX
290.	2014	A Phase 3 Evaluation of XXXX and XXXX in Treatment Naïve and Treatment Experienced Subjects with Genotype 3 Chronic Hepatitis C Infection
291.	2014	A Randomized, Single-Dose, Double-Blind, Active- and Placebo-Controlled, 5-Way Crossover Study to Assess the Relative Abuse Potential of Intravenous XXXX in Healthy, Non-dependent Recreational Opioid Users
292.	2014	A PHASE 1 SINGLE DESCENDING DOSE AND DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF XXX-XXX SOLUTION ADMINISTERED ORALLY TO HEALTHY VOLUNTEERS
293.	2014	Assessment of the Oral Human Abuse Potential of XXXX XXXX®
294.	2014	A PHASE 2, RANDOMIZED, MULTICENTER, DOUBLEBLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY COMPARING XX-XXXX WITH PLACEBO IN SUBJECTS WITH AGE-ASSOCIATED MEMORY IMPAIRMENT (AAMI)
295.	2014	A Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Four-Way Crossover Study Comparing the Abuse Potential of Manipulated and Intact XXXX® XX XXXX Tablets versus Manipulated XX XXXX following Oral Administration in Nondependent Recreational Opioid Users

296.	2014	A Randomized, Double-Blind, Double-Dummy, Active and Placebo-Controlled, Five-Way Crossover Study Comparing the Abuse Potential of Manipulated and Ground XXXXXX® PR XXXX Tablets versus Manipulated XXMXXXXXX following Intranasal Administration in Nondependent Recreational Opioid Users
297.	2014	A PLACEBO-CONTROLLED STUDY OF THE ANALGESIC EFFECT OF XXXX USING EXPERIMENTAL PAIN MODELS IN HEALTHY VOLUNTEERS
298.	2014	A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Dose Ranging Study to Assess the Analgesic Efficacy, Tolerability, Safety and Pharmacokinetic/Pharmacodynamic Properties of a Sublingual Wafer Formulation of XXXX Following Third Molar Extraction
299.	2014	Interventional, randomised, double-blind, parallel-group, placebo-controlled, flexible-dose study of XXXX as adjunctive treatment to XXXX or XXXX in adult patients suffering from post-traumatic stress disorder (PTSD)
300.	2014	A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Abuse Potential of Crushed XXXX (XXXX XXXX/XXXX Bilayer ER Tablets) with Crushed XX XXXX XXXX/XXXXX Administered Intranasally to Nondependent Recreational Opioid Users
301.	2014	A Randomized, Double-Blind, Double-Dummy, Crossover Study Comparing the Abuse Potential of Crushed XXXX (XXXX XXXX/XXXX Multilayer ER Tablets) With Crushed XX XXXX/XXXX Administered Intranasally to Nondependent Recreational Opioid Users
302.	2014	Open Label Extension for Subjects with Inadequate/Partial Response to Antidepressants during the Current Episode of Major Depressive Disorder Previously Treated with GLYX-13 (Extension of GLYX13-C-202, NCT01684163)
303.	2014	Phase 2, Randomized, Double-Blind, Multiple-Dose Level, Placebo-Controlled, Single Intravenous Dose, Parallel Efficacy and Safety Study of XXX-XXXX in Subjects with Major Depressive Disorder

304.	2014	A PHASE 1, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF XXXX-XXX IN HEALTHY VOLUNTEERS
305.	2014	Pharmacokinetics of Flibanserin in Relation to CYP2C19 and CYP2C9 Genotypes
306.	2014	A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, TRIPLE CROSS-OVER STUDY INVESTIGATING THE SAFETY, ORAL STEADY-STATE PHARMACOKINETICS, AND CLINICAL ACTIVITY OF 20 MG XXXX AND 50 MG XXXX IN NORMAL HUMAN SUBJECTS
307.	2014	A Single-Dose, Double-Blind, Randomized Crossover Study to Assess the Intranasal Pharmacokinetics, Abuse Potential and Safety of XXX-XXXX in Healthy, Nondependent, Recreational Opioid Users
308.	2014	A Two-Part, Randomized, Double-Blind, Placebo-Controlled, Adaptive, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous XXXX in Healthy Adults
309.	2015	A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX-XXX in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
310.	2015	A Randomized, Double-Blind, Placebo- and Active-Controlled, Crossover Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of XX-XXX Tablets Administered via the Oral and Intranasal Routes
311.	2015	An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of XXX® XXXX XXXX Tablet, XXX®-002, in Patients with Moderate-to-Severe Chronic Noncancer Pain
312.	2015	Single-Ascending Dose, Safety, Tolerability, Pharmacokinetic, and Cytochrome P450 Interaction Study of XXXX in Healthy Subjects
313.	2015	A PHASE I, RANDOMIZED, SINGLE AND MULTIPLE ASCENDING DOSE, PLACEBO-CONTROLLED, DOUBLE-

		BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF XXX-XXX IN HEALTHY VOLUNTEERS
314.	2015	A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Seven-Way Crossover Study to Determine the Relative Bioavailability, Abuse Potential, and Safety of Equivalent Oral Doses of XXXX Compared with XXXX in Opioid Experienced, Nondependent Subjects
315.	2015	A Double-Blind, Randomized, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of XXXX in Recreational Drug Users
316.	2015	A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of XXXX (XXXXXX) Administered Intravenously to Subjects with Neuropathic Pain
317.	2015	A Randomized, Placebo-Controlled, Double-Blind, Two-Part, Cross-over Study in Healthy Adult Male Subjects to Compare the Reduction in Pain Intensity After Single-Dose Administration of Intravenous or Oral XXXX and Intravenous XXXX by Using UVB Burn and Intradermal Capsaicin Experimental Pain Models
318.	2015	Open-label, fixed-sequence, multiple-dose trial in subjects on a stable oral methadone maintenance program to evaluate the pharmacokinetics of methadone administered alone and with XX-XXXX.
319.	2015	A Study to Evaluate the Abuse Potential of XX-XXXX (XXX XXXXXX)
320.	2015	A Study to Assess Potential Physical Dependence and Withdrawal Effects after Discontinuation of XX-XXXX in Healthy, Non-Dependent Subjects.
321.	2015	A phase 1 study to evaluate the safety, tolerabiltiy, pharmacokinetics and pharmacodynamics of multiple-dose subcutaneous and intranvenous administration of XXXXXX in healthy subjects

322.	2015	A Double-Blind, Randomized Crossover Study to Assess the Subjective Abuse Potential of Intravenous XXXX Compared to XXXX and Placebo in Recreational CNS Depressant Users
323.	2015	A ramondomized, open-label, single-dose, 2-way crossover study to compare the relative bioavailability of orally administered XXXX to an intravenous forumlation in healthy volunteers
324.	2015	A Randomized, Double-Blind, Two-Way Crossover Study to Determine the Relative Bioavailability, Abuse Potential, and Safety of Equivalent Doses of Ground XXXX/XXXX 10/300 mg Tablets (Abuse Deterrent) versus Ground XXXX/XXXX 10/300 mg Tablets in Opioid Experienced, Nondependent Recreational Users Following Intranasal Administration
325.	2015	A Randomized, Double-Blind, Placebo and Active-Controlled, Single-Dose, Crossover Study to Assess the Abuse Potential, Safety, and Pharmacokinetics of XX-XXXXX Following Oral Administration of Multiple Intact Tablets to Healthy, Nondependent, Recreational Opioid Users
326.	2015	A Randomized, Double-Blind, Active-Controlled, Single-Dose Crossover Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Increasing Doses of XX-XXXX (XXXX XXXX/XXX 10 mg/325 mg) Compared with XXXX Following Intranasal Insufflation by Healthy, Nondependent, Recreational Opioid Users
327.	2015	A Randomized, Double-Blind, Placebo- and Active-Controlled, Single-Dose Crossover Study to Assess the Abuse Potential, Safety, and Pharmacokinetics of XXXX Following Intranasal Administration by Healthy, Nondependent, Recreational Opioid Users
328.	2016	A RANDOMIZED, DOUBLE-BLIND, SINGLE-DUMMY, ACTIVE AND PLACEBOCONTROLLED, CROSSOVER STUDY COMPARING THE ABUSE POTENTIAL OF MANIPULATED XXXX® PROLONGED RELEASE XXXX TABLETS VERSUS MANIPULATED IMMEDIATE RELEASE XXXX AND XXXX FOLLOWING INTRANASAL ADMINISTRATION IN NONDEPENDENT RECREATIONAL OPIOID USERS

329.	2016	A Single-Center, Single-Dose, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized Crossover Study to Evaluate the Abuse Potential of Intranasal XXXX Compared to Racemic Intravenous XXXX in Nondependent, Recreational Users of Perception-Altering Drugs
330.	2016	AN OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO INVESTIGATE THE BIOEQUIVALENCE OF XXXX IN HEALTHY SUBJECTS FOLLOWING SUBCUTANEOUS ADMINISTRATION VIA AN AUTOINJECTOR (AI 1000 G2) VS. PRE-FILLED SYRINGE
331.	2017	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOUBLE-DUMMY, SINGLE-DOSE, 4-WAY CROSSOVER STUDY WITH EXPLORATORY FIFTH TREATMENT TO DETERMINE THE RELATIVE NASAL ABUSE POTENTIAL OF PTI-821 (OXYCODONE EXTENDED-RELEASE CAPSULES) COMPARED TO OXYCODONE IR AND PLACEBO IN NONDEPENDENT, RECREATIONAL OPIOID USERS UNDER FASTED CONDITIONS
332.	2017	A Phase 1, Double-Blind, Single-Dose, 3-Treatment, 3-Period, Randomized, Crossover, Dose-Finding Study Based on Drug-Liking after Nasal Insufflation of d-Methylphenidate in Healthy Nondependent Recreational CNS Stimulant Users
333.	2017	A Phase 1, Single-Dose, Double-Blind, Randomized, Placebo- and Active-Controlled, 6-Period, 6-Sequence Crossover Study to Evaluate the Abuse Potential of Tirasemtiv in Healthy Recreational Polydrug Users
334.	2017	A Randomized, Double-blind, Three-Way Crossover (Group 1) or Two-Way Crossover (Group 2) Study Evaluating both the Impact of Two Doses of Oxycodone (30mg) (Group1) and a Single Dose of Oxycodone (30mg) (Group 2) Compared to Placebo to Determine the Ventilatory Response to Hypercapnia in Normal Healthy Volunteers
335.	2017	A Randomized, Double-Blind, 3-Period, Placebo-Controlled, Single-Dose, Crossover Pilot Study to Explore the Ventilatory Response to Hypercapnia (VRH) of Oral Doses of KP201/APAP, Norco®, and Placebo in Non-Dependent Recreational Opioid Users

336.	2017	Title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AMG 334 in Migraine Prevention
337.	2017	Single-Dose and Multiple-Dose, Dose-Escalation Study with LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients with Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
338.	2017	A Single- and Multiple-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Intravenous Doses of LY3002813 in Patients with Mild Cognitive Impairment due to Alzheimer's Disease or Mild to Moderate Alzheimer's Disease
339.	2017	A PHASE I, RANDOMIZED, SINGLE AND MULTIPLE ASCENDING DOSE, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF GDC-0310 IN HEALTHY VOLUNTEERS
340.	2017	A randomized, double-blind, three-way crossover study to compare the pharmacokinetics, pharmacodynamics and safety of a single 6 mg subcutaneous administration of the proposed biosimilar product LA-EP2006, Neulasta® US and Neulasta® EU in healthy subjects
341.	2017	A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Single-Dose, 4-Way Crossover Study with Exploratory Fifth Treatment to Determine the Relative Nasal Abuse Potential of PTI-821 (Oxycodone Extended-Release Capsules) Compared to Oxycodone IR and Placebo in Nondependent, Recreational Opioid Users Under Fasted Conditions
342	2017	A Randomized, Double-blind, Comparative, Placebo-controlled Nine-period Crossover, Dose-Escalation Study on the Safety, Pharmacokinetics, Bioavailability, and Pharmacodynamics of Remimazolam Administered Intranasally as Powder and as Solution in Healthy Subjects and Compared to an Intravenous Control
343.	2017	A Double-Blind, Double-Dummy, Randomized, Crossover Study to Assess the Abuse Potential of Subcutaneous Bremelanotide Compared to Phentermine and Placebo in Recreational Stimulant Users

344.	2017	A Randomized, Double-blind, Three-Way Crossover (Group 1) or Two-Way Crossover (Group 2) Study Evaluating both the Impact of Two Doses of Oxycodone (30mg) (Group 1) and a Single Dose of Oxycodone (30mg) (Group 2) Compared to Placebo to Determine the Ventilatory Response to Hypercapnia in Normal Healthy Volunteers
345.	2017	A Randomized, Two-Way Crossover Study to Demonstrate Bioequivalence of 85 mg PRC-063 Capsules Manufactured in the USE (Test) Versus 85 mg PRC-063 Capsules Manufactured in Canada (Reference) in Healthy Adults Under Fasting Conditions
346.	2017	A Phase 1, Randomized, Open-Label, Single-Center, Single-Dose, Two-Period Two-Part Crossover Study in Healthy Subjects to Compare the Bioavailability of Dexlansoprazole from Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda GmbH Plant Oranienburg Relative to Dexlansoprazole Delayed-Release Capsules 30 mg and 60 mg Manufactured by Takeda Pharmaceutical Company Limited Osaka Plant
347.	2017	A Randomized, Double-Blind, Placebo- and Active-Controlled, Single-Dose Crossover Study to Assess the Relative Abuse Potential of Laquinimod in Healthy Non-Dependent Recreational Polydrug Users with a History of Cannabinoid Drug Use
348.	2017	Open-label, Single dose, Randomized, Parallel, Bioequivalence Study to Compare the Pharmacokinetics of TEV-48125 Administered Subcutaneously Using a Device Referenced to a Prefilled Syringe Configuration
349.	2018	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Five-Way Crossover Study to Determine the Abuse Potential and Pharmacokinetics of 120 and 240 mg KP415 Prodrug in Capsules Compared with 80 mg of Focalin XR and 60 mg Phentermine after Oral Administration in Healthy, Nondependent, Recreational Stimulant Users
350.	2018	STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy
351.	2018	An Open-Label, Fixed-Sequence Study in Healthy Subjects to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of XXXX

352.	2018	A Randomized, Balanced, 4-Period, Placebo-controlled Crossover Study in Healthy Participants to Evaluate the Effects of Morphine on Cutaneous Hyperalgesia Induced by Topical Heat and Capsaicin Treatment
353.	2019	A Randomized, Double-Blind, Sham-Controlled Crossover Study Evaluating the Efficacy of the Sana Device for Withdrawal Management in Methadone- Maintained, Opioid-Dependent Adults.
354.	2019	A Randomized, Double-Blind, Double-Dummy, 6-Period, Placebo-Controlled, Crossover Study to Explore and Compare The Ventilatory Response to Hypercapnia (VRH), or Belbuca, Oxycodone Hydrochloride, And Placebo In Recreational Opioid Users.
355.	2019	A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of XXXX in Healthy Adults
356.	2020	A Randomized, Double-Blind, Double-Dummy, 6-Period, Placebo-Controlled, Crossover Study, to Explore and Compare the Ventilatory Response to Hypercapnia (VRH), of Belbuca, Oxycodone Hydrochloride, and Placebo in Recreation Opioid Users.
357.	2020	A Phase 1, Randomized, Double-blind, Placebo-controlled, Single- and Multiple-dose Escalation Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of VX-961 in Healthy Adults
358.	2020	A Randomized, Triple-Blind, Placebo-Controlled Phase Ia Study of Single and Multiple Ascending Doses of NVG-291 in Healthy Subjects
359.	2020	STAMPOUT: Study of Antibody for Methamphetamine Outpatient Therapy
360.	2020	A Clinical Trial to Study the Effect of a Single Dose of Islatravir (MK-8591) on the Pharmacokinetics of Methadone

361.	2020	A Two-Part Open-Label Study of the Pharmacodynamic Effects of Intranasal Nalmefene, Compared to Intranasal, Naloxone In Healthy Volunteers Under Steady-State Opioid Agonism
362.	2020	A Randomized, Double-Blind, Double-Dummy, Placebo-and Active-Controlled, 4-Period, 4-Way Crossover Study to Evaluate the Abuse Potential of Manipulated, Abuse-Deterrent Dextroamphetamine Sulfate Immediate-Release (Adair) Formulation Compared to Dextroamphetamine Sulfate Immediate-Release When Administered Intranasally to Nondependent, Recreational Stimulant Users.
363.	2021	A Phase 4, Randomized, Double-Blind, Double-Dummy, Placebo – and Active-Controlled, Single-Dose, Five-Way Crossover Study Evaluating the Abuse Potential of Three Doses of NEURONTIN® Taken Orally in Healthy Non-Drug Dependent Participants with Sedative Drug Abuse Experience.

AWARDS

1. "Distinguished Service Award"
    - Awarded by the Utah Medical Association
    - September 15, 2006
    - *"For his initiative in treating pain and reducing unintentional deaths from drug overdoses of prescription pain medication*."
        —Catherine J. Wheeler, M.D., President

2. "Patient Access Advocacy Hero Award"
    - Awarded by Medtronic Neuromodulation
    - December 5, 2008
    - Presented at the NANS Convention, Las Vegas, NV
    - *"This honor goes to select individuals who have worked collaboratively on public policy issues to protect and grow appropriate patient access to neuromodulation therapies. Through your direct collaboration with Medtronic Neuromodulation and others, your efforts have yielded successes throughout the country."*
        —N. William Fehrenbach, Director, Reimbursement

3. "Physicians Dedicated to Relieving Pain" Presidential Commendation
    - Awarded by the American Academy of Pain Medicine

- February 10, 2010
- Presented at the American Academy of Pain Medicine's Annual Meeting in San Antonio, TX
- *"Recognition of years of tireless advocacy to promote the safe use of opioids, and for the successful creation of the local pain initiatives effort."*

4. "Mayday Fellowship"
    - Awarded by the Mayday Fund
    - August 2010

5. "Presidential Excellence Award for Education"
    - The American Academy of Pain Medicine–Inaugural Award
    - February 25, 2012
    - Presented at the American Academy of Pain Medicine's Annual Meeting in Palm Springs, CA
    - *"In recognition of this individual's tireless efforts on the first ever "Safe Opioid Prescribing Course"* (offered at the AAPM 2012 Annual Meeting).

6. "Health Care Heroes Community Outreach Award"
    - Awarded by Utah Business Magazine
    - October 10, 2012
    - Presented at the Health Care Heroes Luncheon
    - This award *"acknowledges excellence and innovation within the health care system and contributes to continuously improving the standard of care that Utah's organizations provide."*

7. 2019 Silver Pen Writing Contest
    - First place for personal story title, "A Story I Never Told"
    - October 10, 2019

8. Top Abstract Award, *The Business of Pain: The Next Big Thing* (Vagus Nerve Society), Eden Roc Miami Beach, Miami, FL, Oct 23–26, 2025. Abstract: "Improving Engagement and Outcomes in Chronic Pain Management: Multi-Specialty Real-World Evidence from a Remote Therapeutic Monitoring Platform." Authors: Webster LR, Cashon S, Huynh J, Cohen D. Award presented Saturday evening, Oct 25, 2025.

9. *Medical Illiteracy Contributes to the Opioid Crisis* was designated as one of *The Hill*'s Top Five Health Stories of 2016.